Conjugated polyethyleneimine compounds and compositions, and uses thereof for the treatment of atherosclerosis, cardiovascular, and lung disease

Lipid conjugated polyethyleneimine compounds facilitate targeted delivery of therapeutic agents to endothelial cells, overcoming the limitations of existing nanoparticle technologies and providing effective treatment for cardiovascular and lung diseases by specifically reducing TGFβR1 expression.

WO2024220742A9PCT designated stage expired Publication Date: 2024-11-21VASORX INC
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
PCT/US2024/025314
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-04-20
Filing Date
2024-04-19
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Current lipid nanoparticles face challenges in effectively targeting and delivering agents to non-liver cell populations, particularly endothelial cells, which are crucial in addressing diseases like atherosclerosis and pulmonary hypertension, due to limitations in biodistribution and cellular uptake.

Method used

Development of lipid conjugated polyethyleneimine (PEI) compounds to form delivery systems such as lipid nanoparticles that can specifically target and deliver agents, like siRNA directed to transforming growth factor beta receptors, to endothelial cells, enhancing the treatment of various cardiovascular and lung diseases.

Benefits of technology

The use of lipid conjugated PEI compounds enables efficient delivery of therapeutic agents to endothelial cells, effectively treating conditions like atherosclerosis, pulmonary hypertension, and lung diseases by specifically targeting and reducing TGFβR1 expression, thereby improving treatment outcomes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2024025314_21112024_PF_FP_ABST
    Figure US2024025314_21112024_PF_FP_ABST
Patent Text Reader

Abstract

Provided herein are lipid conjugated polyethyleneimine (PEI) compounds of Formula (I), which are useful to form delivery systems, such as lipid nanoparticles, for delivery of agents (e.g., nucleic acid molecules) to cells (e.g., endothelial cells). Also provided herein are methods for treating atherosclerosis, a cardiovascular disease, a pulmonary hypertension (e.g, pulmonary arterial hypertension or secondary pulmonary hypertension), a lung cancer, a lung metastasis, chronic obstructive pulmonary disease (COPD), bronchiolitis obliterans, bronchiolitis obliterans organizing pneumonia (BOOP), pulmonary fibrosis, or a fibrotic lung disease, comprising administering to a subject a pharmaceutical composition comprising lipid conjugated polyethyleneimine (PEI) compounds of Formula (I), an agent, and a pharmaceutically acceptable excipient.
Need to check novelty before this filing date? Find Prior Art

Description

CONJUGATED POLYETHYLENEIMINE COMPOUNDS AND COMPOSITIONS, AND USES THEREOF FOR THE TREATMENT OF ATHEROSCLEROSIS, CARDIOVASCULAR, AND LUNG DISEASE 1. PRIORITY

[0001] This application claims the benefit of priority to U.S. Serial No.63 / 497,336 filed April 20, 2023, U.S. Serial No.63 / 497,341 filed April 20, 2023, and U.S. Serial No.63 / 497,345 filed April 20, 2023, each of which is incorporated herein by reference in its entirety. 2. SEQUENCE LISTING

[0002] This application contains a computer readable Sequence Listing which has been submitted in XML file format with this application, the entire content of which is incorporated by reference herein in its entirety. The Sequence Listing XML file submitted with this application is entitled “14766-001-228_SEQLISTING.xml”, was created on April 18, 2024, and is 55,462 bytes in size. 3. FIELD

[0003] Provided herein are lipid conjugated polyethyleneimine (PEI) compounds of Formula (I), which are useful to form delivery systems, such as lipid nanoparticles, for delivery of agents (e.g., nucleic acid molecules) to cells (e.g., endothelial cells). Also provided herein are methods for treating atherosclerosis, a cardiovascular disease, pulmonary hypertension (e.g., pulmonary arterial hypertension or secondary pulmonary hypertension), a lung cancer, a lung metastasis, chronic obstructive pulmonary disease (COPD), bronchiolitis obliterans, bronchiolitis obliterans organizing pneumonia (BOOP), pulmonary fibrosis, or a fibrotic lung disease, comprising administering to a subject a pharmaceutical composition comprising lipid conjugated polyethyleneimine (PEI) compounds of Formula (I), an agent, and a pharmaceutically acceptable excipient. In a specific aspect, the agent is an siRNA directed to transforming growth factor beta receptor 1 (TGFβR1) or transforming growth factor beta receptor 2 (TGFβR2). 4. BACKGROUND

[0004] Lipid nanoparticles (LNPs) are one of the most clinically advanced non-viral delivery vehicles to carry RNA therapeutic agents. While it is common to find nanoparticles that can be taken up in Reticuloendothelial System (RES) organs like the liver and spleen, targeting non-phagocytic cells potently and safely, such as hepatocytes in the liver, was a long-standing challenge that was addressed by ONPATTRO®as well as other LNPs utilizing similar scientific principles. See, e.g., Jadhav, V. et al. Nature Biotechnology, 2024, 42, 394-405. While these advances have paved a pathway to deliver nucleic acids both potently and safely systemically to liver hepatocytes and locally via the intramuscular route to muscle and immune cells, the targeting of non-liver cell populations with siRNA LNPs remains challenging, especially outside RES organs. Overcoming this limitation in biodistribution is paramount to the eventual clinical translation of siRNA-based therapeutics for non-liver cell populations.

[0005] Recent studies have highlighted the importance of endothelial cells in pathogenesis of disease associate with chronic inflammation such as atherosclerosis and pulmonary hypertension (PH). See, e.g., Chen, P.Y. et al. Nat Metab 1, 912-926 (2019), Thus, there is a need for LNPs that can deliver agents to endothelial cells. 5. SUMMARY

[0006] In one aspect, provided herein is a compound of Formula (I):(I), or a salt thereof, wherein R1and R2are as defined herein or elsewhere.

[0007] In one embodiment, provided herein is a compound of Formula (I), or a salt thereof, wherein: each R1is independently hydrogen or a group of formula (i):each R2is independently hydrogen or a group of formula (i); and R3is independently substituted or unsubstituted alkyl; substituted or unsubstituted alkenyl; substituted or unsubstituted alkynyl; substituted or unsubstituted heteroalkyl; substituted or unsubstituted heteroalkenyl; substituted or unsubstituted heteroalkynyl; substituted or unsubstituted carbocyclyl; substituted or unsubstituted heterocyclyl; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; or a hydrophilic polymer; provided that at least one R1or at least one R2is a group of formula (i).

[0008] In some embodiments, 4 to 12 of R1and R2are a group of formula (i). In some embodiments, 9 of R1and R2are a group of formula (i). In some embodiments, 6 of R1and 3 of R2are a group of formula (i). In some embodiments, 8 of R1and R2are a group of formula (i). In some embodiments, 6 of R1and 2 of R2are a group of formula (i). In some embodiments, 7 of R1and R2are a group of formula (i). In some embodiments, 6 of R1and 1 of R2are a group of formula (i). In some embodiments, 6 of R1and R2are a group of formula (i). In some embodiments, 6 of R1are a group of formula (i). In some embodiments, 5 of R1and R2are a group of formula (i). In some embodiments, 5 of R1a group of formula (i). In some embodiments, 4 of R1and R2are a group of formula (i). In some embodiments, 4 of R1are a group of formula (i). In some embodiments, the group of formula (i) is a group of formula (i-a):

[0009] In some embodiments, each instance of R3is independently substituted or unsubstituted alkyl; substituted or unsubstituted alkenyl; substituted or unsubstituted heteroalkyl. In some embodiments, each instance of R3is independently substituted or unsubstituted alkyl. In some embodiments, each instance of R3is independently substituted or unsubstituted C8-C50alkyl. In some embodiments, each instance of R3is independently substituted or unsubstituted C10-C18 alkyl. In some embodiments, each instance of R3is independently substituted or unsubstituted C13alkyl. In some embodiments, each instance of R3is unsubstituted. In some embodiments, each instance of R3is independently -(CH2)nCH3, and n is an integer from 10 to 18. In some embodiments, each instance of R3is independently -(CH2)12CH3.

[0010] In some embodiments, the compound is a compound in Table 3. In some embodiments, the compound is:.

[0011] In some embodiments, the compound is:.

[0012] In some embodiments, the compound has a purity of about 99%, about 95%, about 90%, about 85%, about 80%, about 75%, about 70%, about 65%, about 60%, about 55%,or about 50%. In some embodiments, the compound has a purity of about 99%, about 95%, about 90%, or about 85%.

[0013] In another aspect, provided herein is a pharmaceutical composition comprising a compound of the disclosure, and a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition comprises about 20 weight percent, about 25 weight percent, about 30 weight percent, about 35 weight percent, about 40 weight percent, about 45 weight percent, about 50 weight percent, about 55 weight percent, about 60 weight percent, about 65 weight percent, about 70 weight percent, about 75 weight percent, about 80 weight percent, of a compound described herein. In some embodiments, the pharmaceutical composition comprises about 70 weight percent, about 80 weight percent, or about 90 weight percent of a compound described herein.

[0014] In some embodiments, the compound is in the form of a particle. In some embodiments, the particle is a nanoparticle or a microparticle. In some embodiments, the particle is a micelle, liposome, or lipoplex. In some embodiments, the particle encapsulates an agent. In some embodiments, the nanoparticle further comprises a lipid poly(ethylene glycol). In some embodiments, mass ratio of the compound : lipid poly(ethylene glycol) : nucleic acid is about 7: 1.2 : 1.5.

[0015] In one embodiment, the pharmaceutical composition further comprises an agent. In one embodiment, the agent is an organic molecule, an inorganic molecule, a nucleic acid, a protein, a polypeptide, a polynucleotide, a targeting agent, an isotopically labeled chemical compound, a vaccine, or an immunological agent. In one embodiment, the agent is a polynucleotide, comprising DNA or RNA. In one embodiment, the RNA is a coding RNA. In one embodiment, the RNA is a non-coding RNA. In one embodiment, the RNA is mRNA, RNAi, ssRNA, dsRNA, siRNA, shRNA, miRNA, or antisense RNA. In some embodiments, the polynucleotide and the compound are not covalently attached. In one embodiment, the polynucleotide and the compound are associated together (e.g., by ionic, hydrophobic, hydrogen bonding, electrostatic, van der Waals, or other interactions). In some embodiments, the pharmaceutical composition comprises an agent described in Section 7.5.2, or the Example section (e.g., Example 3 or Example 8).In some embodiments the agent comprises an antibody or antigen-binding fragment thereof that binds to transforming growth factor beta receptor 1(TGFβR1) or transforming growth factor beta receptor 2 (TGFβR2). In some embodiments, the agent comprises a polynucleotide encoding an antibody or antigen-binding fragment thereof that binds to TGFβR1 or TGFβR2. In some embodiments, the agent comprises a TGFβR1 decoy. In some embodiments, the agent comprises a TGFβR2 decoy. In some embodiments, the agent comprises a polynucleotide encoding a TGFβR1 decoy. In some embodiments, the agent comprises a polynucleotide encoding a TGFβR2 decoy. In some embodiments, the agent comprises an siRNA or another inhibitory RNA that targets TGFβR1 or TGFβR2. In some embodiments, the agent comprises a lung cancer antigen. In some embodiments, the agent comprises an siRNA or another inhibitory RNA targeting TGFβR1 or TGFβR2. In some embodiments, the siRNA is a transforming growth factor beta receptor 1 (“TGFβR1") siRNA. In some embodiments, the TGFβR1 siRNA comprises SEQ ID NOS:7 and 8. In some embodiments, the inhibitory RNA is mRNA, RNAi, shRNA, or antisense RNA. In some embodiments, the polynucleotide comprises DNA or RNA.

[0016] In some embodiments, the polynucleotide, siRNA, or another inhibitory RNA and the compound are not covalently attached.

[0017] In some embodiments, provided herein is a nanoparticle comprising a compound of the disclosure, and a nucleic acid, a protein, or a polypeptide. In one embodiment, the nucleic acid is DNA or RNA. In one embodiment, the RNA is mRNA, RNAi, ssRNA, dsRNA, siRNA, shRNA, miRNA, or antisense RNA. In one embodiment, the nanoparticle further comprises a lipid poly(ethylene glycol). In one embodiment, the mass ratio of the compound : lipid poly(ethylene glycol) : nucleic acid is about 7 : 1.2 : 1.5.

[0018] In another aspect, provided herein is a method for delivering an agent to a cell, tissue, or organ of a subject comprising contacting the cell, tissue, or organ of the subject with the pharmaceutical composition described herein, or the nanoparticle described herein. In one embodiment, the cell is an endothelial cell. In one embodiment, the tissue or organ comprises endothelial cells. In a specific embodiment, provided herein is a method for delivering an agent to an endothelial cell comprising administering to a subject the pharmaceutical composition of the disclosure, or the nanoparticle described herein. In specific embodiments, the composition or nanoparticle is administered to the subject intravenously.

[0019] In another aspect, provided herein is a method for treating an endothelial-dependent disorder, comprising administering to a subject (e.g., a human) in need thereof (i) pharmaceutical composition comprising a compound of Formula (I):, or a salt thereof, an agent, and a pharmaceutically acceptable excipient, or (ii) a nanoparticle comprising a compound of Formula (I), or a salt thereof, and an agent. In specific embodiments, the method comprises administering the pharmaceutical composition or nanoparticle intravenously (i.v.) to the subject.

[0020] In another aspect, provided herein is a method for treating atherosclerosis, a cardiovascular disease, pulmonary hypertension (e.g., pulmonary arterial hypertension or secondary pulmonary hypertension), a lung cancer, a lung metastasis, chronic obstructive pulmonary disease (COPD), bronchiolitis obliterans, bronchiolitis obliterans organizing pneumonia (BOOP), pulmonary fibrosis, or a fibrotic lung disease, comprising administering to a subject (e.g., a human) in need thereof (i) pharmaceutical composition comprising a compound of Formula (I):or a salt thereof, an agent, and a pharmaceutically acceptable excipient, or (ii) a nanoparticle comprising a compound of Formula (I), or a salt thereof, and an agent. In specific embodiments,the method comprises administering the pharmaceutical composition or nanoparticle intravenously (i.v.) to the subject.

[0021] In some embodiments the agent comprises an antibody or antigen-binding fragment thereof that binds to transforming growth factor beta receptor 1 (TGFβR1) or transforming growth factor beta receptor 2 (TGFβR2). In some embodiments, the agent comprises a polynucleotide encoding an antibody or antigen-binding fragment thereof that binds to TGFβR1 or TGFβR2. In some embodiments, the agent comprises a TGFβR1 decoy. In some embodiments, the agent comprises a TGFβR2 decoy. In some embodiments, the agent comprises a polynucleotide encoding a TGFβR1 decoy. In some embodiments, the agent comprises a polynucleotide encoding a TGFβR2 decoy. In some embodiments, the agent comprises an siRNA or another inhibitory RNA that targets TGFβR1 or TGFβR2. In some embodiments, the agent comprises a lung cancer antigen. In some embodiments, the agent comprises an siRNA or another inhibitory RNA targeting TGFβR1 or TGFβR2. In some embodiments, the siRNA is a transforming growth factor beta receptor 1 (“TGFβR1") siRNA. In some embodiments, the TGFβR1 siRNA comprises SEQ ID NOS:7 and 8. In some embodiments, the inhibitory RNA is mRNA, RNAi, shRNA, or antisense RNA. In some embodiments, the polynucleotide comprises DNA or RNA.

[0022] In some embodiments, the polynucleotide, siRNA, or another inhibitory RNA and the compound are not covalently attached.

[0023] In some embodiments, the method is for treating pulmonary hypertension (e.g., pulmonary arterial hypertension or secondary pulmonary hypertension). In some embodiments, the pulmonary hypertension is pulmonary arterial hypertension. In some embodiments, the pulmonary hypertension is secondary pulmonary hypertension.

[0024] In some embodiments, the method is for treating a lung cancer. In some embodiments, the lung cancer is a bronchogenic carcinoma, non-small cell lung cancer (NSCLC), adenocarcinoma, squamous cell carcinoma, large cell carcinoma, small cell lung cancer (SCLC), lung carcinoid tumor, adenoid cystic carcinoma, lymphoma, or sarcoma.

[0025] In some embodiments, the method is for treating a lung metastasis. In some embodiments, the lung metastasis is a metastasis of a breast cancer, colon cancer, rectal cancer, head cancer, neck cancer, kidney cancer, testicular cancer, uterine cancer, or a lymphoma.

[0026] In some embodiments, the method is for treating COPD. In some embodiments, the method is for treating bronchiolitis obliterans. In some embodiments, the method is for treating bronchiolitis obliterans organizing pneumonia (BOOP). In some embodiments, the method is for treating pulmonary fibrosis. In some embodiments, the method is for treating a fibrotic lung disease.

[0027] In some embodiments, the method is for treating atherosclerosis. In some embodiments, the method is for treating a cardiovascular disease. In some embodiments, the cardiovascular disease is coronary artery disease, stroke, heart failure, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, abnormal heart rhythm, congenital heart disease, valvular heart disease, carditis, aortic aneurysm, peripheral artery disease, thromboembolic disease, or venous thrombosis.

[0028] In another aspect, provided herein is a double-stranded RNA (dsRNA) oligonucleotide or double-strand RNA-like (dsRNA-like) oligonucleotide directed to transforming growth factor beta receptor 1 (TGFβR1), wherein the double-stranded RNA oligonucleotide or double-stranded RNA-like oligonucleotide comprises an antisense strand and a sense strand. In some embodiments, provided herein is a double-stranded RNA oligonucleotide or double-strand RNA-like oligonucleotide directed to transforming growth factor beta receptor 1 (TGFβR1), wherein the double-stranded RNA oligonucleotide or double- stranded RNA-like oligonucleotide comprises an antisense strand and a sense strand, and wherein the sense strand comprises the nucleotide sequence of SEQ ID NO:7. In some embodiments, provided herein is a double-stranded RNA oligonucleotide or double-strand RNA- like oligonucleotide directed to transforming growth factor beta receptor 1 (TGFβR1), wherein the double-stranded RNA oligonucleotide or double-stranded RNA-like oligonucleotide comprises an antisense strand and a sense strand, and wherein the antisense strand comprises the nucleotide sequence of SEQ ID NO:8.

[0029] The sense strand and the antisense strand of the dsRNA or dsRNA-like (e.g., chemically modified RNA) oligonucleotide may be the same length or different lengths. The sense strand and the antisense strand of the dsRNA or dsRNA-like (e.g., chemically modified RNA) oligonucleotide can each be 19 to 30 nucleotides in length. In specific embodiments, the sense strand and the antisense strand of the dsRNA or dsRNA-like oligonucleotide are each nomore than 30 nucleotides in length. In some embodiments, the sense strand and the antisense strand of the dsRNA or dsRNA-like oligonucleotide are each independently 19 to 30 nucleotides in length. In some embodiments, the sense strand and the antisense strand of the dsRNA or dsRNA-like oligonucleotide are each independently 19 to 25 nucleotides in length. In some embodiments, the sense strand and the antisense strand of the dsRNA or dsRNA-like oligonucleotide are each independently 20 to 25 nucleotides in length. In certain embodiments, the sense strand and the antisense strand of the dsRNA or dsRNA-like oligonucleotide are each independently 19 to 21 nucleotides in length.

[0030] The double stranded region formed by hybridization of the antisense strand and the sense strand of the dsRNA or dsRNA-like oligonucleotide may be the entire length of both strands. For example, the antisense strand of the dsRNA or dsRNA-like oligonucleotide may be 19 nucleotides in length, the sense strand of the dsRNA or dsRNA-like oligonucleotide may be 19 nucleotides in length, and the double strand region formed by hybridization of the strands is 19 nucleotides. In a specific embodiment, the double-strand region of the dsRNA or dsRNA-like oligonucleotide is long enough to serve as a substrate for the Dicer enzyme. In some embodiments, the double strand region of the dsRNA or dsRNA-like oligonucleotide is 15 to 30 base pairs in length. For example, the double strand region of a dsRNA or dsRNA-like oligonucleotide may be 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18- 20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24, 20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21- 25, 21-24, 21-23, or 21-22 base pairs in length. Ranges and lengths intermediate to the above recited ranges and lengths are also contemplated to be part of the disclosure. In some embodiments, the dsRNA or dsRNA-like oligonucleotide comprises a double stranded region greater than 30 base pairs length and is processed to a functional duplex of, e.g., 15 to 30 base pairs, that targets TGFβR1 for cleavage. In some embodiments, the dsRNA or dsRNA-like oligonucleotide does not comprise a double stranded region of greater than 30 base pairs that is cleaved or otherwise processed to produce a functional duplex of, e.g., 15 to 30 base pairs, that targets TGFβR1 for cleavage. In some embodiments, the dsRNA or dRNA-like oligonucleotide is an siRNA. In some embodiments, the dsRNA or dsRNA-like oligonucleotide is blunt ended. In some embodiments, the sense strand or the antisense strand of the dsRNA or dsRNA-likeoligonucleotide comprises an overhang. The overhang may be at the 5’ end, the 3’ end, or both the 5’ and 3’ end of either the sense strand or antisense strand of the dsRNA or dsRNA-like oligonucleotide. In some embodiments, the sense strand and the antisense strand of the dsRNA or dsRNA-like oligonucleotide comprise an overhang. The overhang of the sense strand may be at the 5’ end of the sense strand, and the overhang of the antisense strand may be at the 3’ end of the antisense strand. Alternatively, the overhang of the sense strand may be at the 3’ end of the sense strand, and the overhang of the antisense strand may be at the 5’ end of the antisense strand. In certain embodiments, the overhang of a strand of the dsRNA or dsRNA-like oligonucleotide comprises 1 to 5 nucleotides, 1 to 4 nucleotides, 1 to 3 nucleotides, or 1 to 2 nucleotides. In some embodiments, the overhang of a strand of the dsRNA or dsRNA-like oligonucleotide comprises 2 to 5 nucleotides, 2 to 4 nucleotides, 2 to 3 nucleotides, 3 to 4 nucleotides, 3 to 4 nucleotides, or 4 to 5 nucleotides.

[0031] In some embodiments, provided herein is a double-stranded RNA oligonucleotide or double-strand RNA-like oligonucleotide directed to transforming growth factor beta receptor 1 (TGFβR1), wherein the double-stranded RNA oligonucleotide or double-stranded RNA-like oligonucleotide comprises an antisense strand and a sense strand, and wherein the sense strand comprises the nucleotide sequence of SEQ ID NO: 7, and the antisense strand comprises the nucleotide sequence of SEQ ID NO:8.

[0032] In some embodiments, provided herein is an siRNA directed to transforming growth factor beta receptor 1 (TGFβR1), wherein the siRNA comprises an antisense strand and a sense strand, and wherein the sense strand comprises the nucleotide sequence of SEQ ID NO:7. In some embodiments, provided herein is an siRNA directed to transforming growth factor beta receptor 1 (TGFβR1), wherein the siRNA comprises an antisense strand and a sense strand, and wherein the antisense strand comprises the nucleotide sequence of SEQ ID NO:8.

[0033] The sense strand and the antisense strand of the siRNA may be the same length or different lengths. The sense strand and the antisense strand of the siRNA can each be 19 to 30 nucleotides in length. In specific embodiments, the sense strand and the antisense strand of the siRNA are each no more than 30 nucleotides in length. In some embodiments, the sense strand and the antisense strand of the siRNA are each independently 19 to 30 nucleotides in length. In some embodiments, the sense strand and the antisense strand of the siRNA are eachindependently 19 to 25 nucleotides in length. In some embodiments, the sense strand and the antisense strand of the siRNA are each independently 20 to 25 nucleotides in length. In some embodiments, the sense strand and the antisense strand of the siRNA are each independently 19 to 21 nucleotides in length.

[0034] The double stranded region formed by hybridization of the antisense strand and the sense strand of the siRNA may be the entire length of both strands. For example, the antisense strand of the siRNA may be 19 nucleotides in length, the sense strand of the siRNA may be 19 nucleotides in length, and the double strand region formed by hybridization of the strands is 19 nucleotides. In a specific embodiment, the double-strand region of the siRNA is long enough to serve as a substrate for the Dicer enzyme. In some embodiments, the siRNA is 15 to 30 base pairs in length. For example, the double strand region of siRNA may be 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18- 27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24, 20-23, 20- 22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 base pairs in length. Ranges and lengths intermediate to the above recited ranges and lengths are also contemplated to be part of the disclosure. In some embodiments, the siRNA comprises a double stranded region greater than 30 base pairs length and is processed to a functional duplex of, e.g., 15 to 30 base pairs, that targets TGFβR1 for cleavage. In some embodiments, the siRNA does not comprise a double stranded region of greater than 30 base pairs that is cleaved or otherwise processed to produce a functional duplex of, e.g., 15 to 30 base pairs, that targets the target sequence for cleavage. In some embodiments, the siRNA is blunt ended. In some embodiments, the sense strand or the antisense strand of the siRNA comprises an overhang. The overhang may be at the 5’ end, the 3’ end, or both the 5’ and 3’ end of either the sense strand or antisense strand of the siRNA. In some embodiments, the sense strand and the antisense strand of the siRNA comprise an overhang. The overhang of the sense strand may be at the 5’ end of the sense strand, and the overhang of the antisense strand may be at the 3’ end of the antisense strand. Alternatively, the overhang of the sense strand may be at the 3’ end of the sense strand, the overhang of the antisense strand may be at the 5’ end of the antisense strand. In certain embodiments, the overhang of a strand of the siRNA comprises 1 to 5 nucleotides, 1 to 4 nucleotides, 1 to 3 nucleotides, or 1 to 2 nucleotides. In some embodiments, the overhang of a strand of the siRNAcomprises 2 to 5 nucleotides, 2 to 4 nucleotides, 2 to 3 nucleotides, 3 to 4 nucleotides, 3 to 4 nucleotides, or 4 to 5 nucleotides.

[0035] In some embodiments, provided herein is an siRNA directed to transforming growth factor beta receptor 1 (TGFβR1), wherein the siRNA comprises an antisense strand and a sense strand, and wherein the sense strand comprises the nucleotide sequence of SEQ ID NO: 7, and the antisense strand comprises the nucleotide sequence of SEQ ID NO:8. In some embodiments, provided herein is an siRNA described in Example 3 or Example 8, infra.

[0036] In another aspect, provided herein are compositions comprising a dsRNA or dsRNA- like oligonucleotide described herein. In some embodiments, provided herein is a composition (e.g., a pharmaceutical composition) comprising a dsRNA or dsRNA-like oligonucleotide described herein. In some embodiments, provided herein is a composition (e.g., a pharmaceutical composition) comprising an siRNA described herein. In some embodiments, the composition is a pharmaceutical composition and comprises a pharmaceutically acceptable carrier, diluent or excipient. In some embodiments, the carrier is a lipid nanoparticle or liposome.

[0037] A dsRNA or dsRNA-like oligonucleotide described herein, or a composition described herein comprising such an oligonucleotide may be used in vitro or ex vivo to regulate the expression of TGFβR1. For example, the dsRNA or dsRNA-like oligonucleotide may be used to modulate (e.g., downregulate) TGFβR1 RNA and / or TGFβR1 protein. An siRNA described herein may be used in vitro or ex vivo to regulate the expression of TGFβR1. For example, the siRNA may be used to modulate (e.g., downregulate) TGFβR1 RNA and / or TGFβR1 protein. In some embodiments, provided herein is a method of downregulating TGFβR1 expression in a cell in cell culture or a tissue sample in culture, comprising contacting the cell or tissue sample with a composition described herein. In some embodiments, TGFβR1 expression is downregulated at the RNA level. In some embodiments, TGFβR1 expression is downregulated at the RNA and protein levels. TGFβR1 expression at the RNA level may be assessed by RT-PCR or Northern Blot. TGFβR1 expression at the protein level may be assessed by an immunoassay, such as an ELISA, Western Blot, or FACS analysis.

[0038] In some embodiments, contacting a cell (e.g., endothelial cell) or tissue sample (e.g., heart and / or lung sample) with a composition disclosed herein (e.g., a composition comprisingTGFβR1 siRNA or a nanoparticle described herein encapsulating TGFβR1 siRNA) reduces TGFβR1 (e.g., human TGFβR1) gene expression by at least 50%, at least 55%, or at least 60% relative to a control (e.g., a negative control). In some embodiments, contacting a cell (e.g., endothelial cell) or tissue sample (e.g., heart and / or lung sample) with a composition disclosed herein (e.g., a composition comprising TGFβR1 siRNA or a nanoparticle described herein encapsulating TGFβR1 siRNA) reduces TGFβR1 (e.g., human TGFβR1) gene expression by at least 65%, at least 70%, or at least 75% relative to a control (e.g., a negative control). In some embodiments, contacting a cell (e.g., endothelial cell) or tissue sample (e.g., heart and / or lung sample) with a composition disclosed herein (e.g., a composition comprising TGFβR1 siRNA or a nanoparticle described herein encapsulating TGFβR1 siRNA) reduces TGFβR1 (e.g., human TGFβR1) gene expression by at least 80% or at least 85% relative to a control (e.g., a negative control). In some embodiments, contacting a cell (e.g., endothelial cell) or tissue sample (e.g., heart and / or lung sample) with a composition disclosed herein (e.g., a composition comprising TGFβR1 siRNA or a nanoparticle described herein encapsulating TGFβR1 siRNA) reduces TGFβR1 (e.g., human TGFβR1) gene expression by at least 90% or at least 95% relative to a control (e.g., a negative control). In some embodiments, the control is a negative control, which is, e.g., a buffer or an siRNA that does not modulate TGFβR1 gene expression or activity, contacted with the same type of cell (e.g., endothelial cell) or tissue sample as a composition disclosed herein (e.g., a composition comprising TGFβR1 siRNA or a nanoparticle described herein encapsulating TGFβR1 siRNA). In some embodiments, the control is the same type of cell (e.g., endothelial cell) or tissue sample prior to contact with a composition disclosed herein (e.g., a composition comprising TGFβR1 siRNA or a nanoparticle described herein encapsulating TGFβR1 siRNA).

[0039] In another aspect, provided herein is a method for treating an endothelial-dependent disorder, comprising administering a subject (e.g., a human) in need thereof a composition described herein comprising dsRNA oligonucleotide or dsRNA-like oligonucleotide. In some embodiments, provided herein a method for treating an endothelial-dependent disorder, comprising administering a subject (e.g., a human) in need thereof a composition described herein comprising an siRNA described herein.

[0100] In some embodiments, provided herein is a TGFβR1 siRNA comprising the nucleotide sequences set forth in SEQ ID NOs: 7 and 8. In some embodiments, provided hereinis a pharmaceutical composition comprising the TGFβR1 siRNA, and a pharmaceutically acceptable carrier, diluent or excipient. In some embodiments, provided herein is a method for reducing TGFβR1 RNA in a cell, comprising contacting the cell with the TGFβR1 siRNA, or the pharmaceutical composition comprising the TGFβR1 siRNA. In some embodiments, the cell is an endothelial cell. In some embodiments, provided herein is a method for reducing TGFβR1 RNA in cells, a tissue, or an organ in a subject, the method comprising intravenously administering to the subject the TGFβR1 siRNA, or the pharmaceutical composition comprising the TGFβR1 siRNA. In some embodiments, the subject is a human. In some embodiments, provide herein is use of the TGFβR1 siRNA, or the pharmaceutical composition in the manufacture of a medicament for reducing TGFβR1 RNA in cells, a tissue or an organ. In some embodiments, the TGFβR1 siRNA, or the pharmaceutical composition for use in a method for reducing TGFβR1 RNA in cells, a tissue or an organ, the method comprising administering to a subject the TGFβR1 siRNA or the pharmaceutical composition to a subject. In some embodiments, the subject is a human.

[0040] In another aspect, provided herein is a method for treating atherosclerosis, a cardiovascular disease, pulmonary hypertension (e.g., pulmonary arterial hypertension or secondary pulmonary hypertension), a lung cancer, a lung metastasis, chronic obstructive pulmonary disease (COPD), bronchiolitis obliterans, bronchiolitis obliterans organizing pneumonia (BOOP), pulmonary fibrosis, or a fibrotic lung disease, comprising administering a subject (e.g., a human) in need thereof a composition described herein comprising dsRNA oligonucleotide or dsRNA-like oligonucleotide. In some embodiments, provided herein a method for treating atherosclerosis, a cardiovascular disease, pulmonary hypertension (e.g., pulmonary arterial hypertension or secondary pulmonary hypertension), a lung cancer, a lung metastasis, chronic obstructive pulmonary disease (COPD), bronchiolitis obliterans, bronchiolitis obliterans organizing pneumonia (BOOP), pulmonary fibrosis, or a fibrotic lung disease, comprising administering a subject (e.g., a human) in need thereof a composition described herein comprising an siRNA described herein.

[0041] In some embodiments, a method for treating pulmonary hypertension (e.g., pulmonary arterial hypertension or secondary pulmonary hypertension), comprising administering a subject (e.g., a human) in need thereof a composition described herein comprising dsRNA oligonucleotide or dsRNA-like oligonucleotide. In some embodiments,provided herein is a method for treating pulmonary hypertension (e.g., pulmonary arterial hypertension or secondary pulmonary hypertension), comprising administering a subject (e.g., a human) in need thereof a composition described herein comprising an siRNA described herein. In some embodiments, the pulmonary hypertension is pulmonary arterial hypertension. In some embodiments, the pulmonary hypertension is secondary pulmonary hypertension.

[0042] In some embodiments, provided herein is a method for treating atherosclerosis, comprising administering a subject (e.g., a human) in need thereof a composition described herein comprising dsRNA oligonucleotide or dsRNA-like oligonucleotide. In some embodiments, provided herein is a method for treating atherosclerosis, comprising administering a subject (e.g., a human) in need thereof a composition described herein comprising an siRNA described herein.

[0043] In some embodiments, provided herein is a method for treating a cardiovascular, comprising administering a subject (e.g., a human) in need thereof a composition described herein comprising dsRNA oligonucleotide or dsRNA-like oligonucleotide. In some embodiments, provided herein is a method for treating a cardiovascular disease, comprising administering a subject (e.g., a human) in need thereof a composition described herein comprising an siRNA described herein. In some embodiments, the cardiovascular disease is coronary artery disease, stroke, heart failure, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, abnormal heart rhythm, congenital heart disease, valvular heart disease, carditis, aortic aneurysm, peripheral artery disease, thromboembolic disease, or venous thrombosis.

[0044] In some embodiments, provided herein is a method for treating a lung cancer, comprising administering a subject (e.g., a human) in need thereof a composition described herein comprising dsRNA oligonucleotide or dsRNA-like oligonucleotide. In some embodiments, provided herein is a method for treating a lung cancer, comprising administering a subject (e.g., a human) in need thereof a composition described herein comprising an siRNA described herein.

[0045] In some embodiments, the lung cancer is a bronchogenic carcinoma, non-small cell lung cancer (NSCLC), adenocarcinoma, squamous cell carcinoma, large cell carcinoma, smallcell lung cancer (SCLC), lung carcinoid tumor, adenoid cystic carcinoma, lymphoma, or sarcoma.

[0046] In some embodiments, provided herein is a method for treating a lung metastasis, comprising administering a subject (e.g., a human) in need thereof a composition described herein comprising dsRNA oligonucleotide or dsRNA-like oligonucleotide. In some embodiments, provided herein is a method for treating a lung metastasis, comprising administering a subject (e.g., a human) in need thereof a composition described herein comprising an siRNA described herein. In some embodiments, the lung metastasis is a metastasis of a breast cancer, colon cancer, rectal cancer, head cancer, neck cancer, kidney cancer, testicular cancer, uterine cancer, or a lymphoma.

[0047] In some embodiments, provided herein is a method for treating COPD, comprising administering a subject (e.g., a human) in need thereof a composition described herein comprising dsRNA oligonucleotide or dsRNA-like oligonucleotide. In some embodiments, provided herein is a method for treating COPD, comprising administering a subject (e.g., a human) in need thereof a composition described herein comprising an siRNA described herein.

[0048] In some embodiments, provided herein is a method for treating bronchiolitis obliterans, comprising administering a subject (e.g., a human) in need thereof a composition described herein comprising dsRNA oligonucleotide or dsRNA-like oligonucleotide. In some embodiments, provided herein is a method for treating bronchiolitis obliterans, comprising administering a subject (e.g., a human) in need thereof a composition described herein comprising an siRNA described herein.

[0049] In some embodiments, provided herein is a method for treating bronchiolitis obliterans organizing pneumonia (BOOP), comprising administering a subject (e.g., a human) in need thereof a composition described herein comprising dsRNA oligonucleotide or dsRNA-like oligonucleotide. In some embodiments, provided herein is a method for treating bronchiolitis obliterans organizing pneumonia (BOOP), comprising administering a subject (e.g., a human) in need thereof a composition described herein comprising an siRNA described herein.

[0050] In some embodiments, provided herein is a method for treating pulmonary fibrosis, comprising administering a subject (e.g., a human) in need thereof a composition described herein comprising dsRNA oligonucleotide or dsRNA-like oligonucleotide. In someembodiments, provided herein is a method for treating pulmonary fibrosis, comprising administering a subject (e.g., a human) in need thereof a composition described herein comprising an siRNA described herein.

[0051] In some embodiments, provided herein is a method for treating a fibrotic lung disease, comprising administering a subject (e.g., a human) in need thereof a composition described herein comprising dsRNA oligonucleotide or dsRNA-like oligonucleotide. In some embodiments, provided herein is a method for treating a fibrotic lung disease, comprising administering a subject (e.g., a human) in need thereof a composition described herein comprising an siRNA described herein.

[0052] In another aspect, provided herein is a method of preparing the compound of the disclosure, comprising reacting a compound of Formula (II):with an epoxide of formula (III):in the presence of a solvent.

[0053] In one embodiment, provided herein are methods of use of the nanoparticles provided herein for delivery of a nucleic acid, protein, or polypeptide to cells (e.g., endothelial cells). In one embodiment, provided herein are methods of use of the nanoparticles provided herein for delivery of an RNA molecule (e.g., siRNA) to cells (e.g., endothelial cells). 6. BRIEF DESCRIPTION OF THE FIGURES

[0054] FIG.1 shows TLC plates of fractions from the purification of Compound 1.

[0055] FIG.2 shows a representative1H NMR of Compound 1.

[0056] FIGs.3A-3B. FIG.3A shows 7C1 synthesis scheme; FIG.3B shows thin layer chromatography (TLC) of 7C1; and FIG.3C shows mass spectroscopy of 7C1.

[0057] FIG.4A shows psiCHECK2-IRES-let-78X structure. psiCheck2 plasmids contains let-7 seed sequence 8 times in tandem and linked to the Renilla Luciferase sequence. Firefly luciferase was used as an internal control. When let-7 activity is increased, the renilla luminescence will be decreased.

[0058] FIG.4B shows luciferase activities from 293T cell line transfected with let-7 miRNA nanoparticles formulated with different fractions from the preparation of Compound 1.

[0059] FIGs.5A-5B. FIG.5A shows endothelial cell isolation scheme of the in vivo cellular uptake experiment by qRT-PCR. FIG.5B shows transforming growth factor beta receptor 1 (“TGFβR1” or “Tgfbr1”) mRNA levels in isolated mouse heart and lung endothelial cells 48 hr after i.v. injected with 0.5 mg / kg dose of Compound 9, Compound 1, and reference 7C1 (BP = from branched PEI); β-actin was used for sample loading normalization.

[0060] FIGs.6A-6B. FIG.6A shows the schematic of the experimental design of Compound 9-siTgfbr1 treatment of ameliorates hypoxia-induced pulmonary hypertension. FIG. 6B shows summary plots of RVBP (right ventricular blood pressure) in hypoxia, and hypoxia plus Compound 9-siTgfbr1 treated mice.

[0061] FIGs.7A-7B. FIG.7A shows a representative1H NMR of Compound 9. FIG.7B shows mass spectroscopy of Compound 9.

[0062] FIGs.8A-8B. FIG.8A shows a representative1H NMR of Compound 8. FIG.8B shows mass spectroscopy of Compound 8.

[0063] FIGs.9A-9B. FIG.9A shows a representative1H NMR of Compound 7. FIG.9B shows mass spectroscopy of Compound 7.

[0064] FIGs.10A-10B shows the synthesis and chemical structure of tertiary amine cationic lipids (FIG.10A) and illustrates the components of corresponding LNPs (FIG.10B). Hydrodynamic size distribution of LNPs assessed by DLS, represented as percent volume.

[0065] FIGs.11A-11D. FIG.11A shows characterization data for LNP formulations comprising the indicated compounds. FIG.11B shows Tgfbr1 mRNA levels in bEnd3.1 cells 48 hr after treatment with various doses of Lipid-siTgfbr1. β-actin was used for sample loading normalization. Data shown from left to right for: Compound 5, Compound 6, Compound 7, Compound 8, Compound 9, and Compound 1. FIG.11C shows TGFβR1 protein levels in bEnd3.1 cells 96 hr after treatment with various doses of Lipid-siTgfbr1. HSP90 was used for sample loading normalization. FIG.11D shows Western blot showing time-dependent effects of lipid treatment on TGFβ1-mediated p-Smad2 and p-Smad3 activity in cultured bEnd3.1 cells.

[0066] FIGs.12A-12B show the analysis of Compound 1 LNP biofate in different mouse organs. Endothelial cell reporter mice were used in this study. Following tamoxifen administration at 6 week old to Cdh5-CreERT2;mT / mG adult mice, endothelial cells can be visualized by GFP fluorescence and non-endothelial cells can be visualized by RFP fluorescence. FIG.12 A shows quantification of organ biodistribution of LNP containing siLuciferase Alexa647. Mean fluorescence intensity was utilized to reflect the amount of nanoparticle uptake on a per cell basis. Histogram bars represent the mean Alexa647 signal intensity above threshold ± standard error of measurement (SEM). Higher signal intensities were indicative of a higher uptake of the respective Alexa647-labelled Compound 1 LNP by the given organ. Bars from left to right for each given organ are: background control, endothelial cell (EC), and non-EC. FIG. 12B shows quantification of the transfection percentages of GFP+ endothelial cells and RFP+ non-endothelial cells post Compound 1 / Alexa647 LNP iv injection. Bars from left to right for each given organ are: EC and non-EC.

[0067] FIGs.13A-13D. FIG.13A shows the experimental procedure for evaluation of Compound 1 LNP in vivo lung endothelial cell targeting. FIG.13B shows the FACS gating strategy. FIG.13C shows qRT-PCR analysis of Tgfbr1 gene expression in FACS sorted GFP+ lung endothelial cells. FIG.13D shows western blot analysis of TGFβR1 protein expression in FACS sorted GFP+ lung endothelial cells.

[0068] FIGs.14A-14B. FIG.14A shows experimental setup for evaluation of in vivo siRNA delivery of control to hypoxic pulmonary endothelial cells (left) and qRT-PCR analysis of Tgfbr1 gene expression in FACS sorted GFP+ lung endothelial cells (right). Control animals were exposed to normoxia (20% oxygen). FIG.14B shows experimental setup for LNP ivinjection for evaluation of in vivo siRNA delivery of Compound / siTgfbr1 LNPs to hypoxic pulmonary endothelial cells (left), qRT-PCR analysis of Tgfbr1 gene expression in FACS sorted GFP+ lung endothelial cells (middle), and Western blot analysis of TGFβR1 protein expression in FACS sorted GFP+ lung endothelial cells. Control animals were exposed to hypoxia (10% oxygen).

[0069] FIG.15 shows the design of the Compound 1 / siTgfbr1 prevention and therapy study.

[0070] FIGs.16A-16D show the analyses of Compound 1 / Tgfbr1 LNP in hypoxia-induced mouse hypertension model. FIG.16A shows a representative right ventricular blood pressure measurement in normoxia, hypoxia, and hypoxia plus Compound 1-siTgfbr1 LNP treated mice. FIG.16B shows quantitative analysis of right ventricular hypertrophy. FIG 16C shows absolute numbers of fully muscularized pulmonary arterioles (< 50 μm in diameter). FIG.16D shows histological analysis of lungs with p-Smad2.

[0071] FIGs.17A-17C. FIG.17A shows the effect of TGFβR1 siRNA LNP on IL-4 levels. FIG.17B shows the effect of TGFβR1 siRNA LNP on IL-6 levels. FIG.17C shows the effect of TGFβR1 siRNA LNP on IL-1β levels. Bars for FIGS.17A-C from left to right in each panel are: vehicle, 0.0625 mg / kg, 0.125 mg / kg, 0.25 mg / kg, 0.5 mg / kg, and 1 mg / kg. Animals injected with vehicle or test Compound 1 / TGFβR1 siRNA LNP were analyzed for the presence of IL-4, IL-6, and IL-1β in plasma. Samples were obtained pre-dosing, 15 min, 6 hr, Day 1, Day 2, Day 7, and Day 14. BDL: Below detection limit.

[0072] FIGs.18A-18B show Day 2 and day 14 in vivo assessment of siTGFβR1. FIG.18A shows TGFBR1 mRNA levels in lung endothelial cells 2 days after treatment with increasing doses of Compound 1 / TGFβR1 siRNA LNP. FIG.18B shows TGFBR1 mRNA levels in lung endothelial cells 14 days after treatment with increasing doses of Compound 1 / TGFβR1 siRNA LNP. ACTB and CDH5 were used for sample loading normalization. All data shown as mean ± SEM. 7. DETAILED DESCRIPTION 7.1 General Techniques

[0073] Techniques and procedures described or referenced herein include those that are generally well understood and / or commonly employed using conventional methodology by thoseskilled in the art, such as, for example, the widely utilized methodologies described in Sambrook et al., Molecular Cloning: A Laboratory Manual (3d ed.2001); Current Protocols in Molecular Biology (Ausubel et al. eds., 2003). 7.2 Terminology

[0074] Unless described otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art. For purposes of interpreting this specification, the following description of terms will apply and whenever appropriate, terms used in the singular will also include the plural and vice versa. All patents, applications, published applications, and other publications are incorporated by reference in their entirety. In the event that any description of terms set forth conflicts with any document incorporated herein by reference, the description of term set forth below shall control.

[0075] As used herein and unless otherwise specified, the term “lipid” refers to a group of organic compounds that include, but are not limited to, esters of fatty acids and are generally characterized by being poorly soluble in water, but soluble in many nonpolar organic solvents. While lipids generally have poor solubility in water, there are certain categories of lipids (e.g., lipids modified by polar groups, e.g., DMG-PEG2000) that have limited aqueous solubility and can dissolve in water under certain conditions. Known types of lipids include biological molecules such as fatty acids, waxes, sterols, fat-soluble vitamins, monoglycerides, diglycerides, triglycerides, and phospholipids. Lipids can be divided into at least three classes: (1) “simple lipids,” which include fats and oils as well as waxes; (2) “compound lipids,” which include phospholipids and glycolipids (e.g., DMPE-PEG2000); and (3) “derived lipids” such as steroids. Further, as used herein, lipids also encompass lipidoid compounds. The term “lipidoid compound,” also simply “lipidoid”, refers to a lipid-like compound (e.g. an amphiphilic compound with lipid-like physical properties).

[0076] The term “lipid nanoparticle” or “LNP” refers to a particle having at least one dimension on the order of nanometers (nm) (e.g., 1 to 100 nm), which contains one or more types of lipid molecules. The LNP provided herein can further contain at least one non-lipid payload molecule (e.g., one or more nucleic acid molecules). In some embodiments, the LNP comprises a non-lipid payload molecule either partially or completely encapsulated inside a lipid shell. Particularly, in some embodiments, wherein the payload is a negatively charged molecule(e.g., mRNA), and the lipid components of the LNP comprise at least one cationic lipid. Without being bound by the theory, it is contemplated that the cationic lipids can interact with the negatively charged payload molecules and facilitates incorporation and / or encapsulation of the payload into the LNP during LNP formation. Other lipids that can form part of a LNP as provided herein include, but are not limited to, neutral lipids and charged lipids, such as steroids, polymer conjugated lipids, and various zwitterionic lipids. In certain embodiments, a LNP provided herein comprises one or more compounds of Formula (I) as described herein.

[0077] The term “cationic lipid” refers to a lipid that is either positively charged at any pH value or hydrogen ion activity of its environment, or capable of being positively charged in response to the pH value or hydrogen ion activity of its environment (e.g., the environment of its intended use). Thus, the term “cationic” encompasses both “permanently cationic” and “cationisable.” In certain embodiments, the positive charge in a cationic lipid results from the presence of a quaternary nitrogen atom. In certain embodiments, the cationic lipid comprises a zwitterionic lipid that assumes a positive charge in the environment of its intended use (e.g., at physiological pH). In certain embodiments, the cationic lipid is one or more lipids of Formula (I) as described herein.

[0078] The term “polymer conjugated lipid” refers to a molecule comprising both a lipid portion and a polymer portion. An example of a polymer conjugated lipid is a pegylated lipid (PEG-lipid), in which the polymer portion comprises a polyethylene glycol.

[0079] The term “neutral lipid” encompasses any lipid molecules existing in uncharged forms or neutral zwitterionic forms at a selected pH value or within a selected pH range. In some embodiments, the selected useful pH value or range corresponds to the pH condition in an environment of the intended uses of the lipids, such as the physiological pH. As non-limiting examples, neutral lipids that can be used in connection with the present disclosure include, but are not limited to, phosphotidylcholines such as 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-dimyristoyl-sn-glycero-3- phosphocholine (DMPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2- dioleoyl-sn-glycero-3-phosphocholine (DOPC), phophatidylethanolamines such as 1,2-dioleoyl- sn-glycero-3-phosphoethanolamine (DOPE), 2-((2,3- bis(oleoyloxy)propyl)dimethylammonio)ethyl hydrogen phosphate (DOCP), sphingomyelins(SM), ceramides, steroids such as sterols and their derivatives. Neutral lipids as provided herein may be synthetic or derived (isolated or modified) from a natural source or compound.

[0080] As used herein, and unless otherwise specified, the term “alkyl” refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, which is saturated. In one embodiment, the alkyl group has, for example, from one to fifty carbon atoms (C1-C50alkyl), eight to fifty carbon atoms (C8-C50alkyl), eight to twenty carbon atoms (C8- C20alkyl), ten to eighteen carbon atoms (C10-C18alkyl), ten to fifteen carbon atoms (C10- C15 alkyl), or thirteen carbon atoms (C13 alkyl) and which is attached to the rest of the molecule by a single bond. Examples of alkyl groups include, but are not limited to, methyl, ethyl, n- propyl, 1-methylethyl (isopropyl), n-butyl, n-pentyl, 1,1-dimethylethyl (t-butyl), 3-methylhexyl, 2-methylhexyl, and the like. Unless otherwise specified, an alkyl group is optionally substituted.

[0081] As used herein, and unless otherwise specified, the term “alkenyl” refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, which contains one or more carbon-carbon double bonds. The term “alkenyl” also embraces radicals having “cis” and “trans” configurations, or alternatively, “E” and “Z” configurations, as appreciated by those of ordinary skill in the art. In one embodiment, the alkenyl group has, for example, from two to fifty carbon atoms (C2-C50alkenyl), two to forty carbon atoms (C2- C40 alkenyl), two to thirty carbon atoms (C2-C30 alkenyl), two to twenty carbon atoms (C2- C20alkenyl), four to twenty carbon atoms (C4-C20alkenyl), eight to twenty carbon atoms (C8- C20alkenyl), eight to sixteen carbon atoms (C8-C16alkenyl), six to twenty carbon atoms (C6- C20 alkenyl), six to sixteen carbon atoms (C6-C16 alkenyl) and which is attached to the rest of the molecule by a single bond. Examples of alkenyl groups include, but are not limited to, ethenyl, prop-1-enyl, but-1-enyl, pent-1-enyl, penta-1,4-dienyl, and the like. Unless otherwise specified, an alkenyl group is optionally substituted.

[0082] As used herein, and unless otherwise specified, the term “alkynyl” refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, which contains one or more carbon-carbon triple bonds. In one embodiment, the alkynyl group has, for example, from two to fifty carbon atoms (C2-C50 alkynyl), two to forty carbon atoms (C2- C40alkynyl), two to thirty carbon atoms (C2-C30alkynyl), two to twenty carbon atoms (C2- C20alkynyl), two to twenty-four carbon atoms (C2-C24alkynyl), four to twenty carbon atoms(C4-C20 alkynyl), eight to twenty carbon atoms (C8-C20 alkynyl), eight to sixteen carbon atoms (C8-C16 alkynyl), six to twenty carbon atoms (C6-C20 alkynyl), six to sixteen carbon atoms (C6- C16alkynyl) and which is attached to the rest of the molecule by a single bond. Examples of alkynyl groups include, but are not limited to, ethynyl, propynyl, butynyl, pentynyl, and the like. Unless otherwise specified, an alkynyl group is optionally substituted.

[0083] As used herein, and unless otherwise specified, the term “heteroalkenyl,” as used herein, refers to an alkenyl group, as defined herein, which further comprises 1 or more (e.g., 1 to 25) heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus) included in the parent chain. In certain embodiments, the heteroalkenyl group is an unsubstituted C2-50heteroalkenyl. In certain embodiments, the heteroalkenyl group is a substituted C2-50heteroalkenyl.

[0084] As used herein, and unless otherwise specified, the term “heteroalkynyl,” as used herein, refers to an alkynyl group, as defined herein, which further comprises 1 or more (e.g., 1 to 25) heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus) included in the parent chain. In certain embodiments, the heteroalkynyl group is an unsubstituted C2-50 heteroalkynyl. In certain embodiments, the heteroalkynyl group is a substituted C2-50heteroalkynyl.

[0085] As used herein, and unless otherwise specified, the term “carbocyclyl” refers to a radical of a non-aromatic cyclic hydrocarbon group having from 3 to 10 ring carbon atoms (“C3-10carbocyclyl”) and zero heteroatoms in the non-aromatic ring system. In some embodiments, a carbocyclyl group has 3 to 8 ring carbon atoms (“C3-8 carbocyclyl”). In some embodiments, a carbocyclyl group has 3 to 6 ring carbon atoms (“C3-6carbocyclyl”). In some embodiments, a carbocyclyl group has 5 to 10 ring carbon atoms (“C5-10carbocyclyl”). Exemplary C3-6carbocyclyl groups include, without limitation, cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl (C4), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (C6), cyclohexenyl (C6), cyclohexadienyl (C6), and the like. Exemplary C3-8carbocyclyl groups include, without limitation, the aforementioned C3-6 carbocyclyl groups as well as cycloheptyl (C7 ), cycloheptenyl (C7 ), cycloheptadienyl (C7 ), cycloheptatrienyl (C7 ), cyclooctyl (C8), cyclooctenyl (C8), bicyclo[2.2. l]heptanyl (C7), bicyclo[2.2.2]octanyl (C8), and the like. Exemplary C3-10carbocyclyl groups include, without limitation, the aforementioned C3-8carbocyclyl groups as well as cyclononyl (C9), cyclononenyl (C9), cyclodecyl (C10), cyclodecenyl (C10), octahydro-lH-indenyl (C9), decahydronaphthalenyl (C10), spiro[ 4.5]decanyl (C10), and the like. As the foregoing examples illustrate, in certain embodiments, the carbocyclyl group is either monocyclic (“monocyclic carbocyclyl”) or polycyclic (e.g., containing a fused, bridged or spiro ring system such as a bicyclic system (“bicyclic carbocyclyl”) or tricyclic system (“tricyclic carbocyclyl”)) and can be saturated or can contain one or more carbon-carbon double or triple bonds. “Carbocyclyl” also includes ring systems wherein the carbocyclyl ring, as defined above, is fused with one or more aryl or heteroaryl groups wherein the point of attachment is on the carbocyclyl ring, and in such instances, the number of carbons continue to designate the number of carbons in the carbocyclic ring system. Unless otherwise specified, each instance of a carbocyclyl group is independently unsubstituted ( an “unsubstituted carbocyclyl”) or substituted ( a “substituted carbocyclyl”) with one or more substituents. In certain embodiments, the carbocyclyl group is an unsubstituted C3-10carbocyclyl. In certain embodiments, the carbocyclyl group is a substituted C3-10carbocyclyl.

[0086] In some embodiments, “carbocyclyl” is a monocyclic, saturated carbocyclyl group having from 3 to 10 ring carbon atoms (“C3-10cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 8 ring carbon atoms (“C3-8cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 6 ring carbon atoms (“C3-6 cycloalkyl”). In some embodiments, a cycloalkyl group has 5 to 6 ring carbon atoms (“C5-6cycloalkyl”). In some embodiments, a cycloalkyl group has 5 to 10 ring carbon atoms (“C5-10cycloalkyl”). Examples of C5-6cycloalkyl groups include cyclopentyl (C5) and cyclohexyl (C6). Examples of C3-8 cycloalkyl groups include the aforementioned C3-6cycloalkyl groups as well as cyclopropyl (C3) and cyclobutyl (C4). Examples of C3-8cycloalkyl groups include the aforementioned C3-6cycloalkyl groups as well as cycloheptyl (C7) and cyclooctyl (C8). Unless otherwise specified, each instance of a cycloalkyl group is independently unsubstituted (an “unsubstituted cycloalkyl”) or substituted (a “substituted cycloalkyl”) with one or more substituents. In certain embodiments, the cycloalkyl group is an unsubstituted C3-10cycloalkyl. In certain embodiments, the cycloalkyl group is a substituted C3-10cycloalkyl.

[0087] As used herein, and unless otherwise specified, the term “heterocyclyl” refers to a non-aromatic radical monocyclic or polycyclic moiety that contains one or more (e.g., one, one or two, one to three, or one to four) heteroatoms independently selected from nitrogen, oxygen, phosphorous, and sulfur. The heterocyclyl may be attached to the main structure at anyheteroatom or carbon atom. A heterocyclyl group can be a monocyclic, bicyclic, tricyclic, tetracyclic, or other polycyclic ring system, wherein the polycyclic ring systems can be a fused, bridged or spiro ring system. Heterocyclyl polycyclic ring systems can include one or more heteroatoms in one or more rings. A heterocyclyl group can be saturated or partially unsaturated. Saturated heterocycloalkyl groups can be termed “heterocycloalkyl”. Partially unsaturated heterocycloalkyl groups can be termed “heterocycloalkenyl” if the heterocyclyl contains at least one double bond, or “heterocycloalkynyl” if the heterocyclyl contains at least one triple bond. In one embodiment, the heterocyclyl has, for example, 3 to 18 ring atoms (3- to 18-membered heterocyclyl), 4 to 18 ring atoms (4- to 18-membered heterocyclyl), 5 to 18 ring atoms (3- to 18- membered heterocyclyl), 4 to 8 ring atoms (4- to 8-membered heterocyclyl), or 5 to 8 ring atoms (5- to 8-membered heterocyclyl). Whenever it appears herein, a numerical range such as “3 to 18” refers to each integer in the given range; e.g., “3 to 18 ring atoms” means that the heterocyclyl group can consist of 3 ring atoms, 4 ring atoms, 5 ring atoms, 6 ring atoms, 7 ring atoms, 8 ring atoms, 9 ring atoms, 10 ring atoms, etc., up to and including 18 ring atoms. Examples of heterocyclyl groups include, but are not limited to, imidazolyl, imidazolidinyl, oxazolyl, oxazolidinyl, thiazolyl, thiazolidinyl, pyrazolidinyl, pyrazolyl, isoxazolidinyl, isoxazolyl, isothiazolidinyl, isothiazolyl, morpholinyl, pyrrolyl, pyrrolidinyl, furyl, tetrahydrofuryl, thiophenyl, pyridinyl, piperidinyl, quinolyl, and isoquinolyl. Unless otherwise specified, a heterocyclyl group is optionally substituted.

[0088] As used herein, and unless otherwise specified, the term “aryl” refers to a monocyclic aromatic group and / or multicyclic monovalent aromatic group that contain at least one aromatic hydrocarbon ring. In certain embodiments, the aryl has from 6 to 18 ring carbon atoms (C6- C18aryl), from 6 to 14 ring carbon atoms (C6-C14aryl), or from 6 to 10 ring carbon atoms (C6- C10 aryl). Examples of aryl groups include, but are not limited to, phenyl, naphthyl, fluorenyl, azulenyl, anthryl, phenanthryl, pyrenyl, biphenyl, and terphenyl. The term “aryl” also refers to bicyclic, tricyclic, or other multicyclic hydrocarbon rings, where at least one of the rings is aromatic and the others of which may be saturated, partially unsaturated, or aromatic, for example, dihydronaphthyl, indenyl, indanyl, or tetrahydronaphthyl (tetralinyl). Unless otherwise specified, an aryl group is optionally substituted.

[0089] As used herein, and unless otherwise specified, the term “heteroaryl” refers to a monocyclic aromatic group and / or multicyclic aromatic group that contains at least one aromaticring, wherein at least one aromatic ring contains one or more (e.g., one, one or two, one to three, or one to four) heteroatoms independently selected from O, S, and N. The heteroaryl may be attached to the main structure at any heteroatom or carbon atom. In certain embodiments, the heteroaryl has from 5 to 20, from 5 to 15, or from 5 to 10 ring atoms. The term “heteroaryl” also refers to bicyclic, tricyclic, or other multicyclic rings, where at least one of the rings is aromatic and the others of which may be saturated, partially unsaturated, or aromatic, wherein at least one aromatic ring contains one or more heteroatoms independently selected from O, S, and N. Examples of monocyclic heteroaryl groups include, but are not limited to, pyrrolyl, pyrazolyl, pyrazolinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, furanyl, thienyl, oxadiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, and triazinyl. Examples of bicyclic heteroaryl groups include, but are not limited to, indolyl, benzothiazolyl, benzoxazolyl, benzothienyl, quinolinyl, tetrahydroisoquinolinyl, isoquinolinyl, benzimidazolyl, benzopyranyl, indolizinyl, benzofuranyl, isobenzofuranyl, chromonyl, coumarinyl, cinnolinyl, quinoxalinyl, indazolyl, purinyl, pyrrolopyridinyl, furopyridinyl, thienopyridinyl, dihydroisoindolyl, and tetrahydroquinolinyl. Examples of tricyclic heteroaryl groups include, but are not limited to, carbazolyl, benzindolyl, phenanthrollinyl, acridinyl, phenanthridinyl, and xanthenyl. Unless otherwise specified, a heteroaryl group is optionally substituted.

[0090] When the groups described herein are said to be “substituted,” they may be substituted with any appropriate substituent or substituents. Illustrative examples of substituents include, but are not limited to, those found in the exemplary compounds and embodiments provided herein, as well as: a halogen atom such as F, CI, Br, or I; cyano; oxo (=O); hydroxyl (- OH); alkyl; alkenyl; alkynyl; cycloalkyl; aryl; -(C=O)OR’; -O(C=O)R’; -C(=O)R’; -OR’; - S(O)xR’; -S-SR’; -C(=O)SR’; -SC(=O)R’; -NR’R’; -NR’C(=O)R’; -C(=O)NR’R’; - NR’C(=O)NR’R’; -OC(=O)NR’R’; -NR’C(=O)OR’; -NR’S(O) xNR’R’; -NR’S(O) xR’; and - S(O) xNR’R’, wherein: R’ is, at each occurrence, independently H, C1-C15 alkyl or cycloalkyl, and x is 0, 1 or 2. In some embodiments the substituent is a C1-C12alkyl group. In other embodiments, the substituent is a cycloalkyl group. In other embodiments, the substituent is a halo group, such as fluoro. In other embodiments, the substituent is an oxo group. In other embodiments, the substituent is a hydroxyl group. In other embodiments, the substituent is an alkoxy group (-OR’). In other embodiments, the substituent is a carboxyl group. In other embodiments, the substituent is an amino group (-NR’R’).

[0091] As used herein, and unless otherwise specified, the term “optional” or “optionally” (e.g., optionally substituted) means that the subsequently described event of circumstances may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. For example, “optionally substituted alkyl” means that the alkyl radical may or may not be substituted and that the description includes both substituted alkyl radicals and alkyl radicals having no substitution.

[0092] As used herein, and unless otherwise specified, the term “pharmaceutically acceptable salt” includes both acid and base addition salts.

[0093] Examples of pharmaceutically acceptable acid addition salts include, but are not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as, but not limited to, acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4- acetamidobenzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, 2-oxo-glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, mucic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, propionic acid, pyroglutamic acid, pyruvic acid, salicylic acid, 4-aminosalicylic acid, sebacic acid, stearic acid, succinic acid, tartaric acid, thiocyanic acid, p-toluenesulfonic acid, trifluoroacetic acid, undecylenic acid, and the like.

[0094] Examples of pharmaceutically acceptable base addition salt include, but are not limited to, salts prepared from addition of an inorganic base or an organic base to a free acid compound. Salts derived from inorganic bases include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. In one embodiment, the inorganic salts are the ammonium, sodium, potassium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurringsubstituted amines, cyclic amines and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, deanol, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, benethamine, benzathine, ethylenediamine, glucosamine, methylglucamine, theobromine, triethanolamine, tromethamine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins and the like. In one embodiment, the organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline and caffeine.

[0095] A compound provided herein may contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)- or, as (D)- or (L)- for amino acids. Unless otherwise specified, a compound provided herein is meant to include all such possible isomers, as well as their racemic and optically pure forms. Optically active (+) and (-), (R)- and (S)-, or (D)- and (L)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, for example, chromatography and fractional crystallization. Conventional techniques for the preparation / isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC). When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers. Likewise, all tautomeric forms are also intended to be included.

[0096] As used herein, and unless otherwise specified, the term “isomer” refers to different compounds that have the same molecular formula. “Stereoisomers” are isomers that differ only in the way the atoms are arranged in space. “Atropisomers” are stereoisomers from hindered rotation about single bonds. “Enantiomers” are a pair of stereoisomers that are non-superimposable mirror images of each other. A mixture of a pair of enantiomers in any proportion can be known as a “racemic” mixture. “Diastereoisomers” are stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other.

[0097] “Stereoisomers” can also include E and Z isomers, or a mixture thereof, and cis and trans isomers or a mixture thereof. In certain embodiments, a compound described herein is isolated as either the E or Z isomer. In other embodiments, a compound described herein is a mixture of the E and Z isomers.

[0098] “Tautomers” refers to isomeric forms of a compound that are in equilibrium with each other. The concentrations of the isomeric forms will depend on the environment the compound is found in and may be different depending upon, for example, whether the compound is a solid or is in an organic or aqueous solution.

[0099] It should also be noted a compound described herein can contain unnatural proportions of atomic isotopes at one or more of the atoms. For example, the compounds may be radiolabeled with radioactive isotopes, such as for example tritium (3H), iodine-125 (125I), sulfur-35 (35S), or carbon-14 (14C), or may be isotopically enriched, such as with deuterium (2H), carbon-13 (13C), or nitrogen-15 (15N). As used herein, an “isotopolog” is an isotopically enriched compound. The term “isotopically enriched” refers to an atom having an isotopic composition other than the natural isotopic composition of that atom. “Isotopically enriched” may also refer to a compound containing at least one atom having an isotopic composition other than the natural isotopic composition of that atom. The term “isotopic composition” refers to the amount of each isotope present for a given atom. Radiolabeled and isotopically enriched compounds are useful as e.g., research reagents (e.g., binding assay reagents) and diagnostic agents (e.g., for in vivo imaging). All isotopic variations of a compound described herein, whether radioactive or not, are intended to be encompassed within the scope of the embodiments provided herein. In some embodiments, there are provided isotopologs of a compound described herein, for example, the isotopologs are deuterium, carbon-13, and / or nitrogen-15 enriched. As used herein, “deuterated”, means a compound wherein at least one hydrogen (H) has been replaced by deuterium (indicated by D or2H), that is, the compound is enriched in deuterium in at least one position.

[0100] It should be noted that if there is a discrepancy between a depicted structure and a name for that structure, the depicted structure is to be accorded more weight.

[0101] As used herein, and unless otherwise specified, the term “pharmaceutically acceptable carrier, diluent or excipient” includes without limitation any adjuvant, carrier, excipient, glidant,sweetening agent, diluent, preservative, dye / colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier which has been approved by the United States Food and Drug Administration as being acceptable for use in humans or domestic animals.

[0102] The term “polynucleotide” or “nucleic acid,” as used interchangeably herein, refers to polymers of nucleotides of any length and includes, e.g., DNA and RNA. The nucleotides can be deoxyribonucleotides, ribonucleotides, modified nucleotides or bases, and / or their analogs, or any substrate that can be incorporated into a polymer by DNA or RNA polymerase or by a synthetic reaction. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and their analogs. A polynucleotide may comprise natural or synthetic nucleobases. Nucleic acid can be in either single- or double-stranded forms. As used herein and unless otherwise specified, “nucleic acid” also includes nucleic acid mimics such as locked nucleic acids (LNAs), peptide nucleic acids (PNAs), and morpholinos. “Oligonucleotide,” as used herein, refers to short synthetic polynucleotides that are generally, but not necessarily, fewer than about 200 nucleotides in length. The terms “oligonucleotide” and “polynucleotide” are not mutually exclusive. The description above for polynucleotides is equally and fully applicable to oligonucleotides. In one embodiment, a polynucleotide is isolated.

[0103] In some embodiments, a polynucleotide has a mass of about 1 kilodalton (kDa) to about 50 kDa. In some embodiments, a polynucleotide has a mass of about 1 kDa to 10 kDa. In some embodiments, a polynucleotide has a mass of about 10 kDa to 20 kDa. In some embodiments, a polynucleotide has a mass of about 10 kDa to about 25 kDa. In some embodiments, a polynucleotide has a mass of about 15 kDa to about 50 kDa. In some embodiments, a polynucleotide has a mass of about 20 kDa to about 50 kDa. In some embodiments, a polynucleotide has a mass of about 25 kDa to about 50 kDa. In some embodiments, a polynucleotide has a mass of about 30 kDa to about 50 kDa. In some embodiments, a polynucleotide has a mass of about 40 kDa to about 50 kDa. In some embodiments, a polynucleotide has a mass of about 1 kDa, about 5 kDa, about 10 kDa, about 15 kDa, about 20 kDa, about 25 kDa, about 30 kDa, about 35 kDa, about 40 kDa, about 45 kDa, or about 50 kDa. In some embodiments, a polynucleotide has a mass of less than about 50 kDa. In some embodiments, a polynucleotide has a mass of less than about 45 kDa, less than about 40kDa, less than about 35 kDa, less than about 30 kDa, less than about 25 kDa, less than about 20 kDa, less than about 15 kDa, less than about 10 kDa, or less than about 5 kDa.

[0104] In some embodiments, a polynucleotide comprises at least 15 nucleotides or at least 15 base pairs. In some embodiments, a polynucleotide comprises at least 20 nucleotides or at least 20 base pairs. In some embodiments, a polynucleotide comprises at least 25 nucleotides or at least 25 base pairs. In some embodiments, a polynucleotide comprises 15 to 30 nucleotides or 15 to 30 base pairs. In some embodiments, a polynucleotide comprises 25 to 50 nucleotides or 25 to 50 base pairs. In some embodiments, a polynucleotide comprises 25 to 100 nucleotides or 25 to 100 base pairs.

[0105] In some embodiments, a polynucleotide is 10 bases to 1 kilobase (kb) in length. In some embodiments a polynucleotide is 10 bases to 10 kilobases (kb) in length. In some embodiments, a polynucleotide is 1 kb to 50 kb in length. In some embodiments, a polynucleotide is less than 50 kb in length.

[0106] In some embodiments, a polynucleotide is 10 base pairs to 1 kilobase (kb) pairs in length. In some embodiments a polynucleotide is 10 base pairs to 10 kb pairs in length. In some embodiments, a polynucleotide is 1 kb pairs to 50 kb base pairs in length. In some embodiments, a polynucleotide is less than 50 kb base pairs in length.

[0107] An “isolated nucleic acid” is a nucleic acid, for example, an RNA, DNA, or a mixed nucleic acids, which is substantially separated from other RNA or DNA sequences (e.g., genomic DNA sequences) as well as proteins or complexes, such as ribosomes and polymerases, which naturally accompany a native sequence. An “isolated” nucleic acid molecule is one which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid molecule. Moreover, an “isolated” nucleic acid molecule, such as an mRNA molecule, siRNA, or cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized. A nucleic acid that is substantially free of cellular material includes preparations of the nucleic acid having less than about 30%, 20%, 10%, or 5% (by dry weight) of other nucleic acids. The term "substantially free of culture medium" includes preparations of the nucleic acid in which the culture medium represents less than about 50%, 20%, 10%, or 5% of the volume of the preparation. The term "substantially freeof chemical precursors or other chemicals" includes preparations in which the nucleic acid is separated from chemical precursors or other chemicals which are involved in the synthesis of the nucleic acid. In specific embodiments, such preparations of the nucleic acid have less than about 50%, 30%, 20%, 10%, 5% (by dry weight) of chemical precursors or compounds other than the nucleic acid of interest. In a specific embodiment, one or more nucleic acid molecules encoding an antigen as described herein are isolated or purified. The term embraces nucleic acid sequences that have been removed from their naturally occurring environment, and includes recombinant or cloned DNA or RNA isolates and chemically synthesized analogues or analogues biologically synthesized by heterologous systems. A substantially pure molecule may include isolated forms of the molecule.

[0108] The term “encoding nucleic acid” or grammatical equivalents thereof would be understood by a person of skill in the art and encompasses (a) a nucleic acid molecule in its native state or when manipulated by methods well known to those skilled in the art that can be transcribed to produce mRNA which is then translated into a peptide and / or polypeptide, and (b) the mRNA molecule itself. As the person skilled in the art will appreciate, the antisense strand is the complement of such a nucleic acid molecule, and the encoding sequence can be deduced therefrom. The term “coding region” would be understood by a person of skill in the art and generally refers to a portion in an encoding nucleic acid sequence that is translated into a peptide or polypeptide. The term “untranslated region” or “UTR” would be understood by a person of skill in the art and generally refers to the portion of an encoding nucleic acid that is not translated into a peptide or polypeptide. Depending on the orientation of a UTR with respect to the coding region of a nucleic acid molecule, a UTR is referred to as the 5’-UTR if located to the 5’-end of a coding region, and a UTR is referred to as the 3’-UTR if located to the 3’-end of a coding region.

[0109] As used herein, the term “mRNA” would be understood by a person of skill in the art and includes a message RNA molecule comprising one or more open reading frames (ORF) that can be translated by a cell or an organism provided with the mRNA to produce one or more peptide or protein product. The region containing the one or more ORFs is generally referred to as the coding region of the mRNA molecule. In certain embodiments, the mRNA molecule further comprises one or more untranslated regions (UTRs).

[0110] In some embodiments, the mRNA is a monocistronic mRNA that comprises only one ORF. In some embodiments, the monocistronic mRNA encodes a peptide or protein comprising at least one epitope of a selected antigen (e.g., a pathogenic antigen or a tumor associated antigen). In some embodiments, the mRNA is a multicistronic mRNA that comprises two or more ORFs. In some embodiments, the multicistronic mRNA encodes two or more peptides or proteins that can be the same or different from each other. In some embodiments, each peptide or protein encoded by a multicistronic mRNA comprises at least one epitope of a selected antigen. In some embodiments, different peptides or proteins encoded by a multicistronic mRNA each comprises at least one epitope of different antigens. In any of the embodiments described herein, the at least one epitope can be at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 epitopes of an antigen. For example, a multicistronic mRNA may comprise 2 to 10 epitopes.

[0111] The term “nucleobases” encompasses purines and pyrimidines, including natural compounds adenine, thymine, guanine, cytosine, uracil, inosine, and natural or synthetic analogs or derivatives thereof.

[0112] The term “peptide” as used herein refers to a polymer containing between two and fifty (2-50) amino acid residues linked by one or more covalent peptide bond(s). The terms apply to naturally occurring amino acid polymers as well as amino acid polymers in which one or more amino acid residues is a non-naturally occurring amino acid (e.g., an amino acid analog or non-natural amino acid). In some embodiments, a peptide has a mass of about 1 kilodalton (kDa) to about 10 kDa. In some embodiments, a peptide has a mass of about 5 kDa to about 10 kDa. In some embodiments, a peptide has a mass of about 2 kDa to about 8 kDa. In some embodiments, a peptide has a mass of about 1 kDa to about 5 kDa. In some embodiments, a peptide has a mass of about 1 kDa, about 2 kDa, about 3 kDa, about 4 kDa, or about 5 kDa. In some embodiments, a peptide has a mass of about 6 kDa, about 7 kDa, about 8 kDa, about 9 kDa, or about 10 kDa. In some embodiments, a peptide is negatively supercharged. In some embodiments, a peptide has a mass of about 1 kilodalton (kDa) to about 10 kDa and is negatively supercharged.

[0113] The terms “polypeptide” and “protein” are used interchangeably herein to refer to a polymer of greater than fifty (50) amino acid residues linked by covalent peptide bonds. That is,a description directed to a polypeptide applies equally to a description of a protein, and vice versa. The terms apply to naturally occurring amino acid polymers as well as amino acid polymers in which one or more amino acid residues is a non-naturally occurring amino acid (e.g., an amino acid analog). As used herein, the terms encompass amino acid chains of any length, including full length proteins (e.g., antigens).

[0114] In some embodiments, a polypeptide has a mass of about 10 kilodaltons (kDa) to about 50 kDa. In some embodiments, a polypeptide has a mass of about 15 kDa to about 50 kDa. In some embodiments, a polypeptide has a mass of about 20 kDa to about 50 kDa. In some embodiments, a polypeptide has a mass of about 25 kDa to about 50 kDa. In some embodiments, a polypeptide has a mass of about 30 kDa to about 50 kDa. In some embodiments, a peptide has a mass of about 40 kDa to about 50 kDa. In some embodiments, a polypeptide has a mass of about 10 kDa to about 25 kDa. In some embodiments, a polypeptide has a mass of about 10 kDa, about 20 kDa, about 30 kDa, about 40 kDa, or about 50 kDa. In some embodiments, a polypeptide has a mass of less than about 50 kDa. In some embodiments, a polypeptide has a mass of less than about 45 kDa, less than about 40 kDa, less than about 35 kDa, less than about 30 kDa, less than about 25 kDa, less than about 20 kDa, or less than about 15 kDa. In some embodiments, a polypeptide is negatively supercharged. In some embodiments, a polypeptide has a mass of less than about 50 kDa and is negatively supercharged. In some embodiments, a polypeptide has a mass of about 1 kDa to about 50 kDa and is negatively supercharged.

[0115] The term “antibody,” “immunoglobulin,” or “Ig” is used interchangeably herein, and is used in the broadest sense and specifically covers, for example, monoclonal antibodies (including agonist, antagonist, neutralizing antibodies, full length or intact monoclonal antibodies), antibody compositions with polyepitopic or monoepitopic specificity, polyclonal or monovalent antibodies, multivalent antibodies, multispecific antibodies (e.g., bispecific antibodies so long as they exhibit the desired biological activity), formed from at least two intact antibodies, single chain antibodies, single domain antibodies (e.g., VHH) and fragments thereof (e.g., domain antibodies). An antibody can be human, humanized, chimeric and / or affinity matured, as well as an antibody from other species, for example, mouse, rabbit, llama, etc. The term “antibody” is intended to include a polypeptide product of B cells within the immunoglobulin class of polypeptides that is able to bind to a specific molecular antigen and iscomposed of two identical pairs of polypeptide chains, wherein each pair has one heavy chain (about 50-70 kDa) and one light chain (about 25 kDa), each amino-terminal portion of each chain includes a variable region of about 100 to about 130 or more amino acids, and each carboxy-terminal portion of each chain includes a constant region. See, e.g., Antibody Engineering (Borrebaeck ed., 2d ed.1995); and Kuby, Immunology (3d ed.1997). Antibodies also include, but are not limited to, synthetic antibodies, recombinantly produced antibodies, single domain antibodies including from Camelidae species (e.g., llama or alpaca) or their humanized variants, intrabodies, anti-idiotypic (anti-Id) antibodies, and functional fragments (e.g., antigen-binding fragments) of any of the above, which refers to a portion of an antibody heavy or light chain polypeptide that retains some or all of the binding activity of the antibody from which the fragment was derived. Non-limiting examples of functional fragments (e.g., antigen-binding fragments) include single-chain Fvs (scFv) (e.g., including monospecific, bispecific, etc.), Fab fragments, F(ab’) fragments, F(ab)2 fragments, F(ab’)2 fragments, disulfide-linked Fvs (dsFv), Fd fragments, Fv fragments, diabody, triabody, tetrabody, and minibody. In particular, antibodies provided herein include immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, for example, antigen-binding domains or molecules that contain an antigen-binding site that binds to an antigen (e.g., one or more CDRs of an antibody). Such antibody fragments can be found in, for example, Harlow and Lane, Antibodies: A Laboratory Manual (1989); Mol. Biology and Biotechnology: A Comprehensive Desk Reference (Myers ed., 1995); Huston et al., 1993, Cell Biophysics 22:189- 224; Plückthun and Skerra, 1989, Meth. Enzymol.178:497-515; and Day, Advanced Immunochemistry (2d ed.1990). The antibodies or antigen-binding fragments thereof can be of any class (e.g., IgG, IgE, IgM, IgD, and IgA) or any subclass (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2) of immunoglobulin molecule. In some embodiments, an antibody is a monoclonal antibody. In some embodiments, an antibody is an anti-TGFβR1 or anti-TGFβR2 antibody. In some embodiments, a functional fragment of an antibody is a functional fragment of an anti-TGFβR1 or anti-TGFβR2 antibody. In some embodiments, an antigen-binding fragment of an antibody is an antigen-binding fragment of an antibody anti-TGFβR1 or anti- TGFβR2 antibody.

[0116] In some embodiments, an antibody has a mass of about 10 kilodaltons (kDa) to about 50 kDa. In some embodiments, an antibody has a mass of about 15 kDa to about 50 kDa. Insome embodiments, an antibody has a mass of about 20 kDa to about 50 kDa. In some embodiments, an antibody has a mass of about 25 kDa to about 50 kDa. In some embodiments, an antibody has a mass of about 30 kDa to about 50 kDa. In some embodiments, an antibody has a mass of about 40 kDa to about 50 kDa. In some embodiments, an antibody has a mass of about 10 kDa to about 25 kDa. In some embodiments, an antibody has a mass of about 10 kDa, about 20 kDa, about 30 kDa, about 40 kDa, or about 50 kDa. In some embodiments, an antibody has a mass of less than about 50 kDa. In some embodiments, an antibody has a mass of less than about 45 kDa, less than about 40 kDa, less than about 35 kDa, less than about 30 kDa, less than about 25 kDa, less than about 20 kDa, or less than about 15 kDa. In some embodiments, an antibody has a mass of less than about 50 kDa. In some embodiments, an antibody is negatively supercharged. In some embodiments, an antibody has a mass of less than about 50 kDa and is negatively supercharged. In some embodiments, an antibody has a mass of about 1 kDa to about 50 kDa and is negatively supercharged.

[0117] In some embodiments, an antigen-binding fragment has a mass of about 10 kilodaltons (kDa) to about 50 kDa. In some embodiments, an antigen-binding fragment has a mass of about 15 kDa to about 50 kDa. In some embodiments, an antigen-binding fragment has a mass of about 20 kDa to about 50 kDa. In some embodiments, an antigen-binding fragment has a mass of about 25 kDa to about 50 kDa. In some embodiments, an antigen-binding fragment has a mass of about 30 kDa to about 50 kDa. In some embodiments, an antigen- binding fragment has a mass of about 40 kDa to about 50 kDa. In some embodiments, an antigen-binding fragment has a mass of about 10 kDa to about 25 kDa. In some embodiments, an antigen-binding fragment has a mass of about 10 kDa, about 20 kDa, about 30 kDa, about 40 kDa, or about 50 kDa. In some embodiments, an antigen-binding fragment has a mass of less than about 50 kDa. In some embodiments, an antigen-binding fragment has a mass of less than about 45 kDa, less than about 40 kDa, less than about 35 kDa, less than about 30 kDa, less than about 25 kDa, less than about 20 kDa, or less than about 15 kDa. In some embodiments, an antigen-binding fragment has a mass of less than about 50 kDa. In some embodiments, an antigen-binding fragment is negatively supercharged. In some embodiments, an antigen-binding fragment has a mass of less than about 50 kDa and is negatively supercharged. In some embodiments, an antigen-binding fragment has a mass of about 1 kDa to about 50 kDa and is negatively supercharged.

[0118] As used herein, the term “monoclonal antibody” refers to an antibody obtained from a population of homogenous or substantially homogeneous antibodies. The term “monoclonal” is not limited to any particular method for making the antibody. Generally, a population of monoclonal antibodies can be generated by cells, a population of cells, or a cell line.

[0119] The term “antigen” refers to a substance that can be recognized by the immune system of a subject (including by the adaptive immune system). In a specific embodiment, the antigen is capable of triggering an immune response after a subject is contacted with the antigen (including an antigen-specific immune response). In certain embodiments, the antigen is a molecule (e.g., a protein) associated with a diseased cell, such as a cell infected by a pathogen or a neoplastic cell. In certain embodiments, the antigen is a molecule (e.g., a protein) associated with a diseased cell associated with atherosclerosis, a cardiovascular disease, pulmonary hypertension (e.g., pulmonary arterial hypertension or secondary pulmonary hypertension), a lung cancer, a lung metastasis, chronic obstructive pulmonary disease (COPD), bronchiolitis obliterans, bronchiolitis obliterans organizing pneumonia (BOOP), or pulmonary fibrosis, or a fibrotic lung disease. In some embodiments, an antigen has a mass of about 10 kilodaltons (kDa) to about 50 kDa. In some embodiments, an antigen has a mass of about 15 kDa to about 50 kDa. In some embodiments, an antigen has a mass of about 20 kDa to about 50 kDa. In some embodiments, an antigen has a mass of about 25 kDa to about 50 kDa. In some embodiments, an antigen has a mass of about 30 kDa to about 50 kDa. In some embodiments, an antigen has a mass of about 40 kDa to about 50 kDa. In some embodiments, an antigen has a mass of about 10 kDa to about 25 kDa. In some embodiments, an antigen has a mass of about 10 kDa, about 20 kDa, about 30 kDa, about 40 kDa, or about 50 kDa. In some embodiments, an antigen has a mass of less than about 50 kDa. In some embodiments, an antigen has a mass of less than about 45 kDa, less than about 40 kDa, less than about 35 kDa, less than about 30 kDa, less than about 25 kDa, less than about 20 kDa, or less than about 15 kDa. In some embodiments, an antigen is negatively supercharged. In some embodiments, an antigen has a mass of less than about 50 kDa and is negatively supercharged. In some embodiments, an antigen has a mass of about 1 kDa to about 50 kDa and is negatively supercharged.

[0120] In the context of a peptide or polypeptide, the term “fragment” as used herein refers to a peptide or polypeptide that comprises less than the full length amino acid sequence. Such a fragment may arise, for example, from a truncation at the amino terminus, a truncation at thecarboxy terminus, and / or an internal deletion of a residue(s) from the amino acid sequence. Fragments may, for example, result from alternative RNA splicing or from in vivo protease activity. In some embodiments, a fragment of a polypeptide comprises an amino acid sequence of at least 5 contiguous amino acid residues, at least 10 contiguous amino acid residues, at least 15 contiguous amino acid residues, at least 20 contiguous amino acid residues, at least 25 contiguous amino acid residues, at least 30 contiguous amino acid residues, at least 40 contiguous amino acid residues, at least 50 contiguous amino acid residues, at least 60 contiguous amino residues, at least 70 contiguous amino acid residues, at least 80 contiguous amino acid residues, at least 90 contiguous amino acid residues, at least contiguous 100 amino acid residues, at least 125 contiguous amino acid residues, at least 150 contiguous amino acid residues, at least 175 contiguous amino acid residues, at least 200 contiguous amino acid residues, at least 250 contiguous amino acid residues, at least 300 contiguous amino acid residues, at least 350 contiguous amino acid residues, or at least 400 contiguous amino acid residues. In some embodiments, a fragment of a polypeptide comprises an amino acid sequence of at least 450 contiguous amino acid residues, at least 500 contiguous amino acid residues, at least 550 contiguous amino acid residues, at least 600 contiguous amino acid residues, at least 650 contiguous amino acid residues, at least 700 contiguous amino acid residues, at least 750 contiguous amino acid residues, at least 800 contiguous amino acid residues, at least 850 contiguous amino acid residues, at least 900 contiguous amino acid residues, or at least 950 contiguous amino acid residues of the amino acid sequence of a polypeptide. For example, a fragment of a polypeptide may comprise 10 to 100, 10 to 500, 100 to 500, or 200 to 500 contiguous amino acid residues of the amino acid sequence of a polypeptide. In another example, a fragment of a polypeptide may comprise 500 to 800, or 700 to 950 contiguous amino acid residues of the amino acid sequence of a polypeptide. In a specific embodiment, a fragment of a peptide or polypeptide retains at least 1, at least 2, at least 3, or more functions of the peptide or polypeptide.

[0121] In some embodiments, a fragment of a polypeptide has a mass of about 10 kilodaltons (kDa) to about 50 kDa. In some embodiments, a fragment of a polypeptide has a mass of about 15 kDa to about 50 kDa. In some embodiments, a fragment of a polypeptide has a mass of about 20 kDa to about 50 kDa. In some embodiments, a fragment of a polypeptide has a mass of about 25 kDa to about 50 kDa. In some embodiments, a fragment of a polypeptide has a mass of about30 kDa to about 50 kDa. In some embodiments, a fragment of a polypeptide has a mass of about 40 kDa to about 50 kDa. In some embodiments, a fragment of a polypeptide has a mass of about 10 kDa to about 25 kDa. In some embodiments, a fragment of a polypeptide has a mass of about 10 kDa, about 20 kDa, about 30 kDa, about 40 kDa, or about 50 kDa. In some embodiments, a fragment of a polypeptide has a mass of less than about 50 kDa. In some embodiments, a fragment of a polypeptide has a mass of less than about 45 kDa, less than about 40 kDa, less than about 35 kDa, less than about 30 kDa, less than about 25 kDa, less than about 20 kDa, or less than about 15 kDa. In some embodiments, a fragment of a polypeptide is negatively supercharged. In some embodiments, a fragment of a polypeptide has a mass of less than about 50 kDa and is negatively supercharged. In some embodiments, a fragment of a polypeptide has a mass of about 1 kDa to about 50 kDa and is negatively supercharged.

[0122] The term “epitope” is understood by a person of skill in the art and generally refers to the site on the surface of an antigen molecule to which a single antibody molecule binds, such as a localized region on the surface of an antigen that is capable of being bound to one or more antigen binding regions of an antibody, and that has antigenic or immunogenic activity in an animal, such as a mammal (e.g., a human), that is capable of eliciting an immune response. An epitope having immunogenic activity is a portion of a polypeptide that elicits an antibody response in an animal. An epitope having antigenic activity is a portion of a polypeptide to which an antibody binds as determined by any method well known in the art, including, for example, by an immunoassay. Antigenic epitopes need not necessarily be immunogenic. Epitopes often consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and have specific three dimensional structural characteristics as well as specific charge characteristics. Antibody epitopes may be linear epitopes or conformational epitopes. Linear epitopes are formed by a continuous sequence of amino acids in a protein. Conformational epitopes are formed of amino acids that are discontinuous in the protein sequence, but which are brought together upon folding of the protein into its three-dimensional structure. Induced epitopes are formed when the three dimensional structure of the protein is in an altered conformation, such as following activation or binding of another protein or ligand. In some embodiments, an epitope is a three-dimensional surface feature of a polypeptide. In some embodiments, an epitope is linear feature of a polypeptide. Generally, an antigen has several ormany different epitopes and may react with many different antibodies. In some embodiments, the epitope is an epitope of TGFβR1 or TGFβR2.

[0123] The term “administer” or “administration” in the context of administration to a patient refers to the act of injecting or otherwise physically delivering a substance as it exists outside the body (e.g., a lipid nanoparticle composition as described herein) into a patient, such as by mucosal, intradermal, intravenous, intramuscular delivery, and / or any other method of physical delivery described herein or known in the art. When atherosclerosis, a cardiovascular disease, pulmonary hypertension (e.g., pulmonary arterial hypertension or secondary pulmonary hypertension), a lung cancer, a lung metastasis, chronic obstructive pulmonary disease (COPD), bronchiolitis obliterans, bronchiolitis obliterans organizing pneumonia (BOOP), pulmonary fibrosis, or a fibrotic lung disease, or a symptom thereof, is being treated, administration of the substance typically occurs after the onset of the disease or condition, or a symptom thereof. When atherosclerosis, a cardiovascular disease, pulmonary hypertension (e.g., pulmonary arterial hypertension or secondary pulmonary hypertension), a lung cancer, a lung metastasis, chronic obstructive pulmonary disease (COPD), bronchiolitis obliterans, bronchiolitis obliterans organizing pneumonia (BOOP), pulmonary fibrosis, or a fibrotic lung disease, or a symptom thereof, is being prevented, administration of the substance typically occurs before the onset of the disease or condition, or a symptom thereof.

[0124] The term “target” as used herein may refer to a particular polynucleotide, peptide, or protein of interest. For example, a target RNA is an RNA of interest. In another example, a target protein is a protein of interest. In another example, a target gene is a gene of interest.

[0125] The term “targeted delivery” or the verb form “target” as used herein refers to the process that promotes the arrival of a delivered agent (such as a therapeutic payload molecule in a lipid nanoparticle composition as described herein) at a specific organ, tissue, cell and / or intracellular compartment (referred to as the targeted location) more than any other organ, tissue, cell or intracellular compartment (referred to as the non-target location). Targeted delivery can be detected using methods known in the art, for example, by comparing the concentration of the delivered agent in a targeted cell population with the concentration of the delivered agent at a non-target cell population after systemic administration. In specific embodiments, a composition described herein results in targeted delivery to endothelial cells. In some embodiments,administration of a composition described herein to subject results in at least a two-fold, at least a three-fold, at least a four-fold, at least a five-fold, at least a six-fold, at least a seven-fold, at least an eight-fold, or at least a nine-fold greater than delivery to endothelial cells than to non- endothelial cells (see, e.g., Example 8). In some embodiments, administration of a composition described herein to a subject results in targeted delivery to endothelial cells in one or more (e.g., 2, 3, or 4), or all of the spleen, liver, lung, aorta endothelium, and heart of the subject (see, e.g., Example 8). In some embodiments, administration of a composition described herein to a subject results in targeted delivery to endothelial cells in the spleen, liver, lung, aorta endothelium, and heart of the subject (see, e.g., Example 8). In some embodiments, administration of a composition described herein to a subject results in targeted delivery to endothelial cells in the lung, aorta endothelium, and heart of the subject (see, e.g., Example 8). In specific embodiments, a particle (e.g., a nanoparticle) described herein results in targeted delivery to endothelial cells. In specific embodiments, administration of a particle (e.g., a nanoparticle) described herein to a subject results in at least a two-fold, at least a three-fold, at least a four-fold, at least a five-fold, at least a six-fold, at least a seven-fold, at least an eight-fold, or at least a nine-fold greater delivery to endothelial cells than to non-endothelial cells. In specific embodiments, administration of a particle (e.g., a nanoparticle) described herein to a subject results in targeted delivery to tissues and / or organs comprising endothelial cells (e.g., the heart or lung). In some embodiments, administration of a particle (e.g., a nanoparticle) described herein to a subject results in targeted delivery to endothelial cells in one or more (e.g., 2, 3, or 4), or all of in the spleen, liver, lung, aorta endothelium, and heart of the subject (see, e.g., Example 8). In some embodiments, a particle (e.g., a nanoparticle) described herein results in targeted delivery to endothelial cells in the spleen, liver, lung, aorta endothelium, and heart of the subject (see, e.g., Example 8). In some embodiments, administration of a particle(s) (e.g., a nanoparticle(s)) described herein to a subject results in at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of the particle(s) being delivered to endothelial cells in one or more of the liver, lung, heart, and aorta of the subject (see, e.g. Example 8). In some embodiments, administration of a particle(s) (e.g., a nanoparticle(s)) described herein to a subject results in at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of the particle(s) being delivered to endothelial cells in the liver, lung, heart, and aorta of the subject (see, e.g. Example 8). In some embodiments, administration of a particle (e.g., a nanoparticle) described herein to asubject for use in delivery of an agent to endothelial cells reduces the systemic side effect that may damage normal tissues and organs (see, e.g., Example 8). In some embodiments, administration of a particle (e.g., a nanoparticle) described herein to a subject for use in delivery of an agent (e.g., siRNA or miRNA) to endothelial cells reduces or bypasses the toxicities of global administration of such an agent (see, e.g., Example 8).

[0126] An “effective amount” is generally an amount sufficient to reduce the severity and / or frequency of one or more symptoms, reduces the number of symptoms, prevents the occurrence of one or more symptoms, and / or improves or remediates the damage that results from or is associated with an endothelial-dependent disorder. An “effective amount” is generally an amount sufficient to reduce the severity and / or frequency of one or more symptoms, reduces the number of symptoms, prevents the occurrence of one or more symptoms, and / or improves or remediates the damage that results from or is associated with atherosclerosis, a cardiovascular disease, pulmonary hypertension (e.g., pulmonary arterial hypertension or secondary pulmonary hypertension), a lung cancer, a lung metastasis, chronic obstructive pulmonary disease (COPD), bronchiolitis obliterans, bronchiolitis obliterans organizing pneumonia (BOOP), pulmonary fibrosis, or a fibrotic lung disease. In some embodiments, an effective amount of TGFβR1 siRNA comprises a concentration disclosed in the Example section, infra.

[0127] The term “side effects” encompasses unwanted and / or adverse effects of a particle (e.g., an LNP), an agent, or the combination of a particle (e.g., an LNP) and an agent. Unwanted effects are not necessarily adverse. An adverse effect might be harmful, uncomfortable, or risky. Examples of side effects include, diarrhea, cough, gastroenteritis, wheezing, nausea, vomiting, anorexia, abdominal cramping, fever, pain, loss of body weight, dehydration, alopecia, dyspnea, insomnia, dizziness, mucositis, nerve and muscle effects, fatigue, dry mouth, loss of appetite, rashes or swellings at the site of administration, flu-like symptoms such as fever, chills, and fatigue, digestive tract problems, and allergic reactions. Additional undesired effects experienced by patients are numerous and known in the art. Many are described in Physician’s Desk Reference (68th ed.2014).

[0128] The terms “subject” and “patient” may be used interchangeably herein. As used herein, in some embodiments, a subject is a mammal, such as a non-primate (e.g., cow, pig, horse, cat, dog, rat, etc.) or a primate (e.g., monkey and human). In specific embodiments, thesubject is a human. In some embodiments, the mammal is a human or non-human subject. In some embodiments, the non-primate is a farm animal or pet (e.g., cow, pig, horse, cat, dog, goat, sheep, donkey, etc.). In some embodiments, the subject has been diagnosed with an endothelial- dependent disorder. In some embodiments, the subject has been diagnosed with atherosclerosis, a cardiovascular disease, pulmonary hypertension (e.g., pulmonary arterial hypertension or secondary pulmonary hypertension), a lung cancer, a lung metastasis, chronic obstructive pulmonary disease (COPD), bronchiolitis obliterans, bronchiolitis obliterans organizing pneumonia (BOOP), pulmonary fibrosis, or a fibrotic lung disease. In some embodiments, the subject is or has experienced one or more symptoms of an endothelial-dependent disorder. In some embodiments, the subject is or has experienced one or more symptoms of atherosclerosis, a cardiovascular disease, pulmonary hypertension (e.g., pulmonary arterial hypertension or secondary pulmonary hypertension), a lung cancer, a lung metastasis, chronic obstructive pulmonary disease (COPD), bronchiolitis obliterans, bronchiolitis obliterans organizing pneumonia (BOOP), pulmonary fibrosis, or a fibrotic lung disease.

[0129] Cardiovascular diseases (CVDs) are a group of disorders of the heart and blood vessels. Cardiovascular diseases include, but are not limited to, (i) coronary heart disease – a disease of the blood vessels supplying the heart muscle; (ii) cerebrovascular disease – a disease of the blood vessels supplying the brain; (iii) peripheral arterial disease – a disease of blood vessels supplying the arms and legs; (iv) rheumatic heart disease – damage to the heart muscle and heart valves from rheumatic fever, caused by streptococcal bacteria; (v) congenital heart disease – birth defects that affect the normal development and functioning of the heart caused by malformations of the heart structure from birth; and (vi) deep vein thrombosis and pulmonary embolism – blood clots in the leg veins, which can dislodge and move to the heart and lungs. In some embodiments, cardiovascular diseases also include heart attacks and strokes, which are usually acute events and are mainly caused by a blockage that prevents blood from flowing to the heart or brain. Examples of cardiovascular diseases include arteriovenous malformations (AVMs), aneurysms, atherosclerosis, cardiac fibrosis, vascular remodeling of the retina (retinopathy), and valvular heart disease.

[0130] "Pulmonary hypertension” or “PH” is a disease syndrome characterized by high blood pressure that affects the arteries in the lungs and the right side of the heart. PH can be due tounknown (e.g., idiopathic) causes (e.g., primary pulmonary hypertension) or secondary to (e.g., caused by) another disease, disorder, or condition (e.g., secondary pulmonary hypertension).

[0131] “Pulmonary hypertension” or “PH” is characterized by a mean pulmonary arterial pressure (mPAP) of greater than 20 mm Hg. In some embodiments, the PH is characterized by a mean pulmonary arterial pressure (mPAP) of greater than 21 mm Hg. In some embodiments, the PH is characterized by a mean pulmonary arterial pressure (mPAP) of greater than 22 mm Hg. In some embodiments, the PH is characterized by a mean pulmonary arterial pressure (mPAP) of greater than 23 mm Hg. In some embodiments, the PH is characterized by a mean pulmonary arterial pressure (mPAP) of greater than 24 mm Hg. In some embodiments, the PH is characterized by a mean pulmonary arterial pressure (mPAP) of greater than 25 mm Hg. In some embodiments, the PH is characterized by a pulmonary arterial wedge pressure (PAWP) of greater than or equal to 15 mm Hg, and / or a pulse volume recording (PVR) of greater than or equal to 3 Wood units. There are generally five PH groups, which may be subdivided into smaller groups. The five PH groups include pulmonary arterial hypertension (“PAH”), pulmonary hypertension due to left heart disease, pulmonary hypertension due to lung disease, pulmonary hypertension due to blood clots in the lungs, and blood and other disorders that lead to pulmonary hypertension. See, e.g., Mandras et al., Concise Review For Clinicians 95(9) p1978-1988. PAH may be idiopathic, heritable, drug- and toxin-induced, or associated with various conditions, such as, e.g., connective tissue diseases, HIV infection, portal hypertension, and congenital heart disease. Id. Secondary pulmonary hypertension generally is due to underlying diseases or risk factors, including underlying heart and lung disease.

[0132] As used herein, the term “TGFβR1 polynucleotide” refers to a polynucleotide encoding a protein called transforming growth factor beta receptor 1. TGFβR1 polynucleotide may be human or non-human (e.g., a non-human primate, dog, cat, pig, horse, etc.). An example of a human TFGβR1 polynucleotide sequence is provided at GenBank Accession No. BC071181.1, which is reproduced below as SEQ ID NO:9:GACAATTTTACTTGTGTGACAGATGGGCTCTGCTTTGTCTCTGTCACAGAGACCACA GACAAAGTTATACACAACAGCATGTGTATAGCTGAAATTGACTTAATTCCTCGAGAT AGGCCGTTTGTATGTGCACCCTCTTCAAAAACTGGGTCTGTGACTACAACATATTGC TGCAATCAGGACCATTGCAATAAAATAGAACTTCCAACTACTGGTTTACCATTGCTT GTTCAGAGAACAATTGCGAGAACTATTGTGTTACAAGAAAGCATTGGCAAAGGTCG ATTTGGAGAAGTTTGGAGAGGAAAGTGGCGGGGAGAAGAAGTTGCTGTTAAGATAT TCTCCTCTAGAGAAGAACGTTCGTGGTTCCGTGAGGCAGAGATTTATCAAACTGTAA TGTTACGTCATGAAAACATCCTGGGATTTATAGCAGCAGACAATAAAGACAATGGT ACTTGGACTCAGCTCTGGTTGGTGTCAGATTATCATGAGCATGGATCCCTTTTTGATT ACTTAAACAGATACACAGTTACTGTGGAAGGAATGATAAAACTTGCTCTGTCCACGG CGAGCGGTCTTGCCCATCTTCACATGGAGATTGTTGGTACCCAAGGAAAGCCAGCCA TTGCTCATAGAGATTTGAAATCAAAGAATATCTTGGTAAAGAAGAATGGAACTTGCT GTATTGCAGACTTAGGACTGGCAGTAAGACATGATTCAGCCACAGATACCATTGATA TTGCTCCAAACCACAGAGTGGGAACAAAAAGGTACATGGCCCCTGAAGTTCTCGAT GATTCCATAAATATGAAACATTTTGAATCCTTCAAACGTGCTGACATCTATGCAATG GGCTTAGTATTCTGGGAAATTGCTCGACGATGTTCCATTGGTGGAATTCATGAAGAT TACCAACTGCCTTATTATGATCTTGTACCTTCTGACCCATCAGTTGAAGAAATGAGA AAAGTTGTTTGTGAACAGAAGTTAAGGCCAAATATCCCAAACAGATGGCAGAGCTG TGAAGCCTTGAGAGTAATGGCTAAAATTATGAGAGAATGTTGGTATGCCAATGGAG CAGCTAGGCTTACAGCATTGCGGATTAAGAAAACATTATCGCAACTCAGTCAACAG GAAGGCATCAAAATGTAATTCTACAGCTTTGCCTGAACTCTCCTTTTTTCTTCAGATC TGCTCCTGGGTTTTAATTTGGGAGGTCAATTGTTCTACCTCACTGAGAGGGAACAGA AGGATATTGCTTCCTTTTGCAGCAGTGTAATAAAGTCAATTAAAAACTTCCCAGGAT TTCTTTGGACCCAGGAAACAGCCATGTGGGTCCTTTCTGTGCACTATGAACGCTTCTT TCCCAGGACAGAAAATGTGTAGTCTACCTTTATTTTTTATTAACAAAACTTGTTTTTT AAAAAGATGATTGCTGGTCTTAACTTTAGGTAACTCTGCTGTGCTGGAGATCATCTT TAAGGGCAAAGGAGTTGGATTGCTGAATTACAATGAAACATGTCTTATTACTAAAG AAAGTGATTTACTCCTGGTTAGTACATTCTCAGAGGATTCTGAACCACTAGAGTTTC CTTGATTCAGACTTTGAATGTACTGTTCTATAGTTTTTCAGGATCTTAAAACTAACAC TTATAAAACTCTTATCTTGAGTCTAAAAATGACCTCATATAGTAGTGAGGAACATAA TTCATGCAATTGTATTTTGTATACTATTATTGTTCTTTCACTTATTCAGAACATTACATGCCTTCAAAATGGGATTGTACTATACCAGTAAGTGCCACTTCTGTGTCTTTCTAATGG AAATGAGTAGAATTGCTGAAAGTCTCTATGTTAAAACCTATAGTGTTTGAATTCAAA AAGCTTATTTATCTGGGTAACCCAAACTTTTTCTGTTTTGTTTTTGGAAGGGTTTTTGT GGTATGTCATTTGGTATTCTATTCTGAAAATGCCTTTCTCCTACCAAAATGTGCTTAA GCCACTAAAGAAATGAAGTGGCATTAATTAGTAAATTATTAGCATGGTCATGTTTGA ATATTCTCACATCAAGCTTTTGCATTTTAATTGTGTTGTCTAAGTATACTTTTAAAAA ATCAAGTGGCACTCTAGATGCTTATAGTACTTTAATATTTGTAGCATACAGACTAAT TTTTCTAAAAGGGAAAGTCTGTCTAGCTGCTTGTGAAAAGTTATGTGGTATTCTGTA AGCCATTTTTTTCTTTATCTGTTCAAAGACTTATTTTTTAAGACATGAATTACATTTA AAATTAGAATATGGTTAATATTAAATAATAGGCCTTTTTCTAGGAAGGCGAAGGTAG TTAATAATTTGAATAGATAACAGATGTGCAAGAAAGTCACATTTGTTATGTATGTAG GAGTAAACGTTCGGTGGATCCTCTGTCTTTGTAACTGAGGTTAGAGCTAGTGTGGTT TTGAGGTCTCACTACACTTTGAGGAAGGCAGCTTTTAATTCAGTGTTTCCTTATGTGT GCGTACATTGCAACTGCTTACATGTAATTTATGTAATGCATTCAGTGCACCCTTGTTA CTTGGGAGAGGTGGTAGCTAAAGAACATTCTGAGTATAGGTTTTTCTCCATTTACAG ATGTCTTTGGTCAAATATTGAAAGCAAACTTGTCATGGTCTTCTTACATTAAGTTGAA ACTAGCTTATAATAACTGGTTTTTACTTCCAATGCTATGAAGTCTCTGCAGGGCTTTT ACAGTTTTCGAAGTCCTTTTATCACTGTGATCTTATTCTGAGGGGAGAAAAAACTAT CATAGCTCTGAGGCAAGACTTCGACTTTATAGTGCTATCAGTTCCCCGATACAGGGT CAGAGTAACCCATACAGTATTTTGGTCAGGAAGAGAAAGTGGCCATTTACACTGAA TGAGTTGCATTCTGATAATGTCTTATCTCTTATACGTAGAATAAATTTGAAAGACTAT TTGATCTTAAAACCAAAGTAATTTTAGAATGAGTGACATATTACATAGGAATTTAGT GTCAATTTCATGTGTTTAAAAACATCATGGGAAAAATGCTTAGAGGTTACTATTTTG ACTACAAAGTTGAGTTTTTTTCTGTAGTTACCATAATTTCATTGAAGCAAATGAATG AGTTTGAGAGGTTTGTTTTTATAGTTGTGTTGTATTACTTGTTTAATAATAATCTCTA ATTCTGTGATCAGGTACTTTTTTTGTGGGGGTTTTTTTTTTGTTTTTTTTTTTTTTTGTT GTTGTTTTTGGGCCATTTCTAAGCCTACCAGATCTGCTTTATGAAATCCAGGGGACC AATGCATTTTATCACTAAAACTATTTTTATATAATTTTAAGAATATACCAAAAGTTGT CTGATTTAAAGTTGTAATACATGATTTCTCACTTTCATGTAAGGTTATCCACTTTTGC TGAAGATATTTTTTATTGAATCAAAGATTGAGTTACAATTATACTTTTCTTACCTAAG TGGATAAAATGTACTTTTGATGAATCAGGGAATTTTTTTAAAGTTGGAGTTTAGTTCTT(SEQ ID NO:9) Additional examples of polynucleotide sequences encoding a human TGFβR1 include the nucleotide sequences provided in TABLE 1, infra. In some embodiments, a polynucleotide encodes a TGFβR1 isoform. In some embodiments, a polynucleotide comprises a sequence of a transcript found at GenBank Gene ID No.7046. In some embodiments, a polynucleotide encodes a mature form of human TGFβR1.

[0133] “TGFβR1” is also known as, e.g., TGFBR1, TGFR1, ALK-5, ACVRLK4, TBR-I, Activin A Receptor Type II-Like Protein Kinase Of 53kD, Serine / Threonine-Protein Kinase Receptor R4, Transforming Growth Factor Beta Receptor I, Activin Receptor-Like Kinase 5, TGF-Beta Receptor Type-1, TGFR-1, ESS1, MSSE, SKR4, LDS1A, AAT5, and LDS1. TGFβR1 is a receptor for TGF-beta cytokines (e.g., TGFβ1, TGFβ2 and TGFβ3) and transduces the TGF-beta signal from the cell surface to the cytoplasm. For example, a heterodimeric receptor complex composed of TGFβR1 and TGFβR2 molecules bound to a TGF-beta cytokine dimer results in the phosphorylation and the activation of TGFβR1 by TGFβR2. SMAD2 is phosphorylated by activated TGFβR1 and phosphorylated SMAD2 interacts with SMAD4 to form a SMAD2-SMAD4 complex, which is translocated to the nucleus where it modulates the transcription of TGF-beta-regulated genes. TGFβR1 may be human or non-human (e.g., a non- human primate, dog, cat, pig, horse, etc). Generally, the immature form of human TGFβR1 contains a signal peptide, an extracellular region, a transmembrane region, and a putative cytoplasmic protein kinase domain. An example of an amino acid sequence for human TGFβR1 may be found at GenBank No. NP_004603.1, which is reproduced below with the signal peptide (amino acid residues 1-33) underline. See, also UniProt Accession No. P36897, for information regarding human TGFβR1.RTVIHHRVPNEEDPSLDRPFISEGTTLKDLIYDMTTSGSGSGLPLLVQRT IARTIVLQESIGKGRFGEVWRGKWRGEEVAVKIFSSREERSWFREAEIYQ TVMLRHENILGFIAADNKDNGTWTQLWLVSDYHEHGSLFDYLNRYTVTVE GMIKLALSTASGLAHLHMEIVGTQGKPAIAHRDLKSKNILVKKNGTCCIA DLGLAVRHDSATDTIDIAPNHRVGTKRYMAPEVLDDSINMKHFESFKRAD IYAMGLVFWEIARRCSIGGIHEDYQLPYYDLVPSDPSVEEMRKVVCEQKL RPNIPNRWQSCEALRVMAKIMRECWYANGAARLTALRIKKTLSQLSQQEG IKM (SEQ ID NO:10) Additional examples of amino acid sequences for TGFβR1 include an amino acid sequence provided in TABLE 1, infra. In some embodiments, the TGFβR1 is the immature form. In some embodiments, the TGFβR1 is the mature form of TGFβR2 without the signal peptide. In some embodiments, the TGFβR1 is an isoform. TABLE 1: Human TGFβR1 Transcripts (GenBank Gene ID No.7046)

[0134] As used herein, the term “TGFβR2 polynucleotide “refers to a polynucleotide encoding a protein called transforming growth factor beta receptor 2. TGFβR2 is a receptor for TGF-beta cytokines (e.g., TGFβ1, TGFβ2 and TGFβ3). A heterodimeric receptor complex composed of TGFβR1 and TGFβR2 molecules bound to a TGF-beta cytokine dimer results in the phosphorylation of TGFβR1 by TGFβR2. TGFβR2 polynucleotide may be human or non- human (e.g., a non-human primate, dog, cat, pig, horse, etc). An example of a human TGFβR2 polynucleotide is found at GenBank Accession No. NM_001024847.3, which is reproduced below. 1 actcgcgcgc acggagcgac gacacccccg cgcgtgcacc cgctcgggac aggagccgga 61 ctcctgtgca gcttccctcg gccgccgggg gcctccccgc gcctcgccgg cctccaggcc 121 ccctcctggc tggcgagcgg gcgccacatc tggcccgcac atctgcgctg ccggcccggc 181 gcggggtccg gagagggcgc ggcgcggagg cgcagccagg ggtccgggaa ggcgccgtcc 241 gctgcgctgg gggctcggtc tatgacgagc agcggggtct gccatgggtc gggggctgct 301 caggggcctg tggccgctgc acatcgtcct gtggacgcgt atcgccagca cgatcccacc 361 gcacgttcag aagtcggatg tggaaatgga ggcccagaaa gatgaaatca tctgccccag 421 ctgtaatagg actgcccatc cactgagaca tattaataac gacatgatag tcactgacaa 481 caacggtgca gtcaagtttc cacaactgtg taaattttgt gatgtgagat tttccacctg 541 tgacaaccag aaatcctgca tgagcaactg cagcatcacc tccatctgtg agaagccaca 601 ggaagtctgt gtggctgtat ggagaaagaa tgacgagaac ataacactag agacagtttg 661 ccatgacccc aagctcccct accatgactt tattctggaa gatgctgctt ctccaaagtg 721 cattatgaag gaaaaaaaaa agcctggtga gactttcttc atgtgttcct gtagctctga 781 tgagtgcaat gacaacatca tcttctcaga agaatataac accagcaatc ctgacttgtt 841 gctagtcata tttcaagtga caggcatcag cctcctgcca ccactgggag ttgccatatc 901 tgtcatcatc atcttctact gctaccgcgt taaccggcag cagaagctga gttcaacctg 961 ggaaaccggc aagacgcgga agctcatgga gttcagcgag cactgtgcca tcatcctgga1021 agatgaccgc tctgacatca gctccacgtg tgccaacaac atcaaccaca acacagagct 1081 gctgcccatt gagctggaca ccctggtggg gaaaggtcgc tttgctgagg tctataaggc 1141 caagctgaag cagaacactt cagagcagtt tgagacagtg gcagtcaaga tctttcccta 1201 tgaggagtat gcctcttgga agacagagaa ggacatcttc tcagacatca atctgaagca 1261 tgagaacata ctccagttcc tgacggctga ggagcggaag acggagttgg ggaaacaata 1321 ctggctgatc accgccttcc acgccaaggg caacctacag gagtacctga cgcggcatgt 1381 catcagctgg gaggacctgc gcaagctggg cagctccctc gcccggggga ttgctcacct 1441 ccacagtgat cacactccat gtgggaggcc caagatgccc atcgtgcaca gggacctcaa 1501 gagctccaat atcctcgtga agaacgacct aacctgctgc ctgtgtgact ttgggctttc 1561 cctgcgtctg gaccctactc tgtctgtgga tgacctggct aacagtgggc aggtgggaac 1621 tgcaagatac atggctccag aagtcctaga atccaggatg aatttggaga atgttgagtc 1681 cttcaagcag accgatgtct actccatggc tctggtgctc tgggaaatga catctcgctg 1741 taatgcagtg ggagaagtaa aagattatga gcctccattt ggttccaagg tgcgggagca 1801 cccctgtgtc gaaagcatga aggacaacgt gttgagagat cgagggcgac cagaaattcc 1861 cagcttctgg ctcaaccacc agggcatcca gatggtgtgt gagacgttga ctgagtgctg 1921 ggaccacgac ccagaggccc gtctcacagc ccagtgtgtg gcagaacgct tcagtgagct 1981 ggagcatctg gacaggctct cggggaggag ctgctcggag gagaagattc ctgaagacgg 2041 ctccctaaac actaccaaat agctcttctg gggcaggctg ggccatgtcc aaagaggctg 2101 cccctctcac caaagaacag aggcagcagg aagctgcccc tgaactgatg cttcctggaa 2161 aaccaagggg gtcactcccc tccctgtaag ctgtggggat aagcagaaac aacagcagca 2221 gggagtgggt gacatagagc attctatgcc tttgacattg tcataggata agctgtgtta 2281 gcacttcctc aggaaatgag attgattttt acaatagcca ataacatttg cactttatta 2341 atgcctgtat ataaatatga atagctatgt tttatatata tatatatata tctatatatg 2401 tctatagctc tatatatata gccatacctt gaaaagagac aaggaaaaac atcaaatatt 2461 cccaggaaat tggttttatt ggagaactcc agaaccaagc agagaaggaa gggacccatg 2521 acagcattag catttgacaa tcacacatgc agtggttctc tgactgtaaa acagtgaact 2581 ttgcatgagg aaagaggctc catgtctcac agccagctat gaccacattg cacttgcttt 2641 tgcaaaataa tcattccctg cctagcactt ctcttctggc catggaacta agtacagtgg 2701 cactgtttga ggaccagtgt tcccggggtt cctgtgtgcc cttatttctc ctggactttt 2761 catttaagct ccaagcccca aatctggggg gctagtttag aaactctccc tcaacctagt2821 ttagaaactc taccccatct ttaatacctt gaatgttttg aaccccactt tttaccttca 2881 tgggttgcag aaaaatcaga acagatgtcc ccatccatgc gattgcccca ccatctacta 2941 atgaaaaatt gttctttttt tcatctttcc cctgcactta tgttactatt ctctgctccc 3001 agccttcatc cttttctaaa aaggagcaaa ttctcactct aggctttatc gtgtttactt 3061 tttcattaca cttgacttga ttttctagtt ttctatacaa acaccaatgg gttccatctt 3121 tctgggctcc tgattgctca agcacagttt ggcctgatga agaggatttc aactacacaa 3181 tactatcatt gtcaggacta tgacctcagg cactctaaac atatgttttg tttggtcagc 3241 acagcgtttc aaaaagtgaa gccactttat aaatatttgg agattttgca ggaaaatctg 3301 gatccccagg taaggatagc agatggtttt cagttatctc cagtccacgt tcacaaaatg 3361 tgaaggtgtg gagacactta caaagctgcc tcacttctca ctgtaaacat tagctctttc 3421 cactgcctac ctggacccca gtctaggaat taaatctgca cctaaccaag gtcccttgta 3481 agaaatgtcc attcaagcag tcattctctg ggtatataat atgattttga ctaccttatc 3541 tggtgttaag atttgaagtt ggccttttat tggactaaag gggaactcct ttaagggtct 3601 cagttagccc aagtttcttt tgcttatatg ttaatagttt taccctctgc attggagaga 3661 ggagtgcttt actccaagaa gctttcctca tggttaccgt tctctccatc atgccagcct 3721 tctcaacctt tgcagaaatt actagagagg atttgaatgt gggacacaaa ggtcccattt 3781 gcagttagaa aatttgtgtc cacaaggaca agaacaaagt atgagcttta aaactccata 3841 ggaaacttgt taatcaacaa agaagtgtta atgctgcaag taatctcttt tttaaaactt 3901 tttgaagcta cttattttca gccaaatagg aatattagag agggactggt agtgagaata 3961 tcagctctgt ttggatggtg gaaggtctca ttttattgag atttttaaga tacatgcaaa 4021 ggtttggaaa tagaacctct aggcaccctc ctcagtgtgg gtgggctgag agttaaagac 4081 agtgtggctg cagtagcata gaggcgccta gaaattccac ttgcaccgta gggcatgctg 4141 ataccatccc aatagctgtt gcccattgac ctctagtggt gagtttctag aatactggtc 4201 cattcatgag atattcaaga ttcaagagta ttctcacttc tgggttatca gcataaactg4261 gaatgtagtg tcagaggata ctgtggcttg ttttgtttat gttttttttt cttattcaag 4321 aaaaaagacc aaggaataac attctgtagt tcctaaaaat actgactttt ttcactacta 4381 tacataaagg gaaagtttta ttcttttatg gaacacttca gctgtactca tgtattaaaa 4441 taggaatgtg aatgctatat actcttttta tatcaaaagt ctcaagcact tatttttatt 4501 ctatgcattg tttgtctttt acataaataa aatgtttatt agattgaata aagcaaaata 4561 ctcaggtgag catcctgcct cctgttccca ttcctagtag ctaaa (SEQ ID NO:11) Additional examples of polynucleotide sequences encoding a human TGFβR2 include the nucleotide sequences provided in TABLE 2, infra. In some embodiments, a polynucleotide encodes TGFβR2 isoform. In some embodiments, a polynucleotide comprises a sequence of a transcript found at GenBank Gene ID No.7048. In some embodiments, a polynucleotide encodes a mature form of human TGFβR2.

[0135] “TGFβR2” is also known as, e.g., TGFBR2, TGFR2, Transforming Growth Factor, Beta Receptor II, TGFR-2, AAT3, FAA3, LDS1B, LDS2, LDS2B, MFS2, RIIC, TAAD2, TGFbeta-RII, transforming growth factor beta receptor 2, TBR-ii, or TBRII. TGFβR2 may be human or non-human (e.g., a non-human primate, dog, cat, pig, horse, etc). TGFβR2 is a receptor for TGF-beta cytokines (e.g., TGFβ1, TGFβ2 and TGFβ3) and transduces the TGF-beta signal from the cell surface to the cytoplasm. For example, a heterodimeric receptor complex composed of TGFβR1 and TGFβR2 molecules bound to a TGF-beta cytokine dimer results in the phosphorylation and the activation of TGFβR1 by TGFβR2. Generally, the immature form of human TGFβR2 contains a signal peptide, an extracellular region, a transmembrane region, and a putative cytoplasmic domain. An example of an amino acid sequence for human TGFβR2 may be found at UniProt / Swiss Prot Accession No. P37173, which is reproduced below with the signal peptide underline. See, also UniProt ID.19939, for information regarding human TGFβR2. MGRGLLRGLWPLHIVLWTRIASTIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFS TCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASP KCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLLVIFQVTGISLLPPLGVAIS VIIIFYCYRVNRQQKLSSTWETGKTRKLMEFSEHCAIILEDDRSDISSTCANNINHNTELLP IELDTLVGKGRFAEVYKAKLKQNTSEQFETVAVKIFPYEEYASWKTEKDIFSDINLKHENILQFLTAEERKTELGKQYWLITAFHAKGNLQEYLTRHVISWEDLRKLGSSLARGIAHLHS DHTPCGRPKMPIVHRDLKSSNILVKNDLTCCLCDFGLSLRLDPTLSVDDLANSGQVGTA RYMAPEVLESRMNLENVESFKQTDVYSMALVLWEMTSRCNAVGEVKDYEPPFGSKVR EHPCVESMKDNVLRDRGRPEIPSFWLNHQGIQMVCETLTECWDHDPEARLTAQCVAER FSELEHLDRLSGRSCSEEKIPEDGSLNTTK (SEQ ID NO:12) Additional examples of amino acid sequences for TGFβR2 include an amino acid sequence provided in TABLE 2, infra. In some embodiments, the TGFβR2 is the immature form. In some embodiments, the TGFβR2 is the mature form of TGFβR2 without the signal peptide. In some embodiments, the TGFβR2 is an isoform. TABLE 2: Human TGFβR2 Transcripts (GenBank Gene ID No.7048)

[0136] As used herein, and unless otherwise indicated, the term “about” or “approximately” means an acceptable error for a particular value as determined by one of ordinary skill in the art, which depends in part on how the value is measured or determined. In some embodiments, the term “about” or “approximately” means within 1, 2, 3, or 4 standard deviations of a recited numerical value or range and includes the recited numerical value or range. In some embodiments, the term “about” or “approximately” means within 20%, 15%, 10%, 9%, 8%, 7%,6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.05%, or less of a given value or range and includes the recited value or range.

[0137] The singular terms “a,” “an,” and “the” as used herein include the plural reference unless the context clearly indicates otherwise.

[0138] As used herein, the terms “comprise(s)”, “includes”, “comprising” and “including” can be used interchangeably. The terms “comprise(s)”, “includes”, “comprising” and “including” are to be interpreted as specifying the presence of the stated features or components as referred to, but does not preclude the presence or addition of one or more features, or components, or groups thereof. Additionally, the terms “comprise(s)”, “includes”, “comprising” and “including” are intended to include examples encompassed by the term “consisting of”. Consequently, the term “consisting of” can be used in place of the terms “comprise(s)”, “includes”, “comprising” and “including” to provide for more specific embodiments.

[0139] As used herein, the conjunctive term “and / or” between multiple recited elements is understood as encompassing both individual and combined options. For instance, where two elements are conjoined by “and / or,” a first option refers to the applicability of the first element without the second. A second option refers to the applicability of the second element without the first. A third option refers to the applicability of the first and second elements together. Any one of these options is understood to fall within the meaning, and therefore satisfy the requirement of the term “and / or” as used herein. Concurrent applicability of more than one of the options is also understood to fall within the meaning, and therefore satisfy the requirement of the term “and / or.”

[0140] As used herein, the term “consists of,” or variations such as “consist of” or “consisting of,” as used throughout the specification and claims, indicate the inclusion of any recited integer or group of integers, but that no additional integer or group of integers can be added to the specified method, structure, or composition.

[0141] A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, the descriptions in the Experimental section and examples are intended to illustrate but not limit the scope of invention described in the claims. 7.3 Compounds

[0142] In one embodiment, provided herein is a compound of Formula (I):(I), or a pharmaceutically acceptable salt thereof, wherein: each R1is independently hydrogen or a group of formula (i): (i); each R2is independently hydrogen or a group of formula (i); and R3is independently substituted or unsubstituted alkyl; substituted or unsubstituted alkenyl; substituted or unsubstituted alkynyl; substituted or unsubstituted heteroalkyl; substituted or unsubstituted heteroalkenyl; substituted or unsubstituted heteroalkynyl; substituted or unsubstituted carbocyclyl; substituted or unsubstituted heterocyclyl; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; or a hydrophilic polymer; provided that at least one R1or at least one R2is a group of formula (i).

[0143] In one embodiment, 4 to 12 of R1and R2are a group of formula (i). In one embodiment, 4 to 11 of R1and R2are a group of formula (i). In one embodiment, 9 of R1and R2are a group of formula (i). In one embodiment, 6 of R1and 3 of R2are a group of formula (i). In one embodiment, 8 of R1and R2are a group of formula (i). In one embodiment, 6 of R1and 2 of R2are a group of formula (i). In one embodiment, 7 of R1and R2are a group of formula (i). In one embodiment, 6 of R1and 1 of R2are a group of formula (i). In one embodiment, 6 of R1and R2are a group of formula (i). In one embodiment, 6 of R1are a group of formula (i). In one embodiment, 5 of R1and R2are a group of formula (i). In one embodiment, 5 of R1are a group of formula (i). In one embodiment, 4 of R1and R2are a group of formula (i). In one embodiment, 4 of R1are a group of formula (i).

[0144] As used herein, when the group R3is depicted as bisecting a carbon-carbon bond, e.g., of the group of the formula (i), it is understood that R3may be substituted at either carbon.

[0145] In one embodiment, the group of formula (i) represents a group of formula (i-a) or a group of formula (i-b):(i-a) (i-b).

[0146] In one embodiment, the group of formula (i) is a group of formula (i-a):(i-a).

[0147] In one embodiment, the group of formula (i) is a group of formula (i-a-1) or (i-a-2):(i-a-1) (i-a-2).

[0148] In one embodiment, the group of formula (i) is a group of formula (i-b):(i-b).

[0149] In one embodiment, the group of formula (i) is a group of formula (i-b-1) or (i-b-2):(i-b-1) (i-b-2).

[0150] In one embodiment, each instance of R3is independently substituted or unsubstituted alkyl; substituted or unsubstituted alkenyl; substituted or unsubstituted heteroalkyl.

[0151] In one embodiment, each instance of R3is independently substituted or unsubstituted alkyl. In some embodiments, each instance of R3is independently substituted or unsubstitutedC8-C50 alkyl. In some embodiments, each instance of R3is independently substituted or unsubstituted C10-C18 alkyl. In one embodiment, the alkyl is C10 alkyl. In one embodiment, the alkyl is C11alkyl. In one embodiment, the alkyl is C12alkyl. In one embodiment, the alkyl is C13alkyl. In one embodiment, the alkyl is C14 alkyl. In one embodiment, the alkyl is C15 alkyl. In one embodiment, the alkyl is C16 alkyl. In one embodiment, the alkyl is C17 alkyl. In one embodiment, the alkyl is C18alkyl.

[0152] In one embodiment, each instance of R3is unsubstituted. In some embodiments, each instance of R3is independently -(CH2)nCH3, and n is an integer from 10 to 18. In some embodiments, each instance of R3is independently -(CH2)7CH3. In some embodiments, each instance of R3is independently -(CH2)8CH3. In some embodiments, each instance of R3is independently -(CH2)9CH3. In some embodiments, each instance of R3is independently - (CH2)10CH3. In some embodiments, each instance of R3is independently -(CH2)11CH3. In some embodiments, each instance of R3is independently -(CH2)12CH3. In some embodiments, each instance of R3is independently -(CH2)12CH3. In some embodiments, each instance of R3is independently -(CH2)14CH3. In some embodiments, each instance of R3is independently - (CH2)15CH3. In some embodiments, each instance of R3is independently -(CH2)16CH3. In some embodiments, each instance of R3is independently -(CH2)17CH3.

[0153] In one embodiment, each instance of R3is a substituted alkyl. In certain embodiments, each instance of R3is substituted with one or more fluorine substituents. In some embodiments, each instance of R3is independently -(CF2)nCF3, and n is an integer from 10 to 18. In some embodiments, each instance of R3is independently -(CF2)12CF3.

[0154] In one embodiment, each instance of R3is independently substituted or unsubstituted alkenyl. In some embodiments, each instance of R3is independently substituted or unsubstituted C8-C50 alkenyl. In some embodiments, each instance of R3is independently substituted or unsubstituted C10-C18 alkenyl. In some embodiments, each instance of R3is independently substituted or unsubstituted C13alkenyl. In some embodiments, each instance of R3is independently unsubstituted C13 alkenyl. In some embodiments, the alkenyl is a polyunsaturated fatty acid derivative. In some embodiments, the polyunsaturated fatty acid derivative comprises myristoleic, palmitoleic, sapienic, oleic, linoleic, alpha-linoleic, arachinodonic, eicosapentaenoic, erucic, or docosahexaenoic.

[0155] In some embodiments, wherein R3is defined as a C8-C50 alkyl or C8-C50 alkenyl groups, such groups are meant to encompass lipophilic groups (also referred to as a “lipid tail”). Lipophilic groups comprise a group of molecules that include fats, waxes, oils, fatty acids, and the like. Lipid tails present in these lipid groups can be saturated and unsaturated, depending on whether or not the lipid tail comprises double bonds. The lipid tail can also comprise different lengths, often categorized as medium (i.e., with tails between 7-12 carbons, e.g., C7-12alkyl or C7-12alkenyl), long (i.e., with tails greater than 12 carbons and up to 22 carbons, e.g., C13-22alkyl or C13-22 alkenyl), or very long (i.e., with tails greater than 22 carbons, e.g., C23-30 alkyl or C23-30 alkenyl).

[0156] In one embodiment, each instance of R3is independently substituted or unsubstituted alkynyl. In some embodiments, each instance of R3is independently substituted or unsubstituted C8-C50 alkynyl. In some embodiments, each instance of R3is independently substituted or unsubstituted C10-C18alkynyl. In some embodiments, each instance of R3is independently substituted or unsubstituted C13 alkynyl. In some embodiments, each instance of R3is independently unsubstituted C13 alkynyl.

[0157] In one embodiment, each instance of R3is independently substituted or unsubstituted heteroalkyl. In some embodiments, each instance of R3is independently substituted or unsubstituted C8-C50 heteroalkyl. In some embodiments, each instance of R3is independently substituted or unsubstituted C10-C18heteroalkyl. In some embodiments, each instance of R3is independently substituted or unsubstituted C13heteroalkyl. In some embodiments, each instance of R3is independently unsubstituted C13 heteroalkyl. In some embodiments, each instance of R3is independently -(CH2)nOCH3, and n is an integer from 10 to 18. In some embodiments, each instance of R3is independently -CH2O(CH2)nCH3, and n is an integer from 8 to 18. In some embodiments, each instance of R3is independently -(CH2)12OCH3. In some embodiments, each instance of R3is independently -CH2O(CH2)9CH3.

[0158] In one embodiment, each instance of R3is independently substituted or unsubstituted heteroalkenyl. In some embodiments, each instance of R3is independently substituted or unsubstituted C8-C50 heteroalkenyl. In some embodiments, each instance of R3is independently substituted or unsubstituted C10-C18heteroalkenyl. In some embodiments, each instance of R3isindependently substituted or unsubstituted C13 heteroalkenyl. In some embodiments, each instance of R3is unsubstituted C13 heteroalkenyl.

[0159] In one embodiment, each instance of R3 is independently substituted or unsubstituted heteroalkynyl. In some embodiments, each instance of R3 is independently substituted or unsubstituted C8-C50 heteroalkynyl. In some embodiments, each instance of R3 is independently substituted or unsubstituted C10-C18 heteroalkynyl. In some embodiments, each instance of R3 is independently substituted or unsubstituted C13 heteroalkynyl. In some embodiments, each instance of R3 is unsubstituted C13 heteroalkynyl.

[0160] In one embodiment, each instance of R3is independently substituted or unsubstituted carbocyclyl. In one embodiment, each instance of R3is a substituted carbocyclyl. In one embodiment, each instance of R3is an unsubstituted carbocyclyl.

[0161] In one embodiment, each instance of R3is independently substituted or unsubstituted heterocyclyl. In one embodiment, each instance of R3is a substituted heterocyclyl. In one embodiment, each instance of R3is an unsubstituted heterocyclyl.

[0162] In one embodiment, each instance of R3is independently substituted or unsubstituted aryl. In one embodiment, each instance of R3is substituted aryl. In one embodiment, each instance of R3is unsubstituted aryl.

[0163] In one embodiment, each instance of R3is independently substituted or unsubstituted heteroaryl. In one embodiment, each instance of R3is substituted heteroaryl. In one embodiment, each instance of R3is unsubstituted heteroaryl.

[0164] In one embodiment, each instance of R3is a hydrophilic polymer. As used herein, a “polymer” refers to a compound comprised of at least 3 (e.g., at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, etc.) repeating covalently bound structural units. By extension, a “hydrophilic polymer” is a polymer, as defined herein, further comprises at least one group (e.g., an oxygen, nitrogen, and / or sulfur atom) in the repeating structural unit capable of hydrogen bonding. The hydrophilic polymer is preferably biocompatible (i.e., non-toxic). Exemplary hydrophilic polymers include, but are not limited to, polypeptides (e.g., poly-L-lysine), cellulose polymers (e.g., hydroxyethylcellulose, ethylcellulose, carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose (HPMC)), dextran polymers, polymaleic acid polymers,poly(acrylic acid) polymers, poly(vinylalcohol) polymers, polyvinylpyrrolidone (PVP) polymers, and polyethyleneglycol (PEG) polymers.

[0165] In one embodiment, the hydrophilic polymer is a polyethyleneglycol polymer, e.g., of formula (ii):(ii) wherein: R4is hydrogen; acyl; silyl; a hydroxyl protecting group; substituted or unsubstituted alkyl; substituted or unsubstituted alkenyl; substituted or unsubstituted alkynyl; substituted or unsubstituted heteroalkyl; substituted or unsubstituted heteroalkenyl; substituted or unsubstituted heteroalkynyl; substituted or unsubstituted carbocyclyl; substituted or unsubstituted heterocyclyl; substituted or unsubstituted aryl; or substituted or unsubstituted heteroaryl; and v is an integer between 3 to 600, inclusive.

[0166] In certain embodiments, R4is hydrogen. In certain embodiments, R4is acyl. In certain embodiments, R4is a hydroxyl protecting group. In certain embodiments, R4is substituted or unsubstituted alkyl. In certain embodiments, R4is a substituted alkyl. In certain embodiments, R4is an unsubstituted alkyl. In certain embodiments, R4is -CH3(a “polyethyleneglycol monomethylether” polymer). In certain embodiments, R4is substituted or unsubstituted alkenyl. In certain embodiments, R4is substituted or unsubstituted alkynyl. In certain embodiments, R4is substituted or unsubstituted heteroalkyl. In certain embodiments, R4is substituted or unsubstituted heteroalkenyl. In certain embodiments, R4is substituted or unsubstituted heteroalkynyl. In certain embodiments, R4is substituted or unsubstituted carbocyclyl. In certain embodiments, R4is substituted or unsubstituted heterocyclyl. In certain embodiments, R4is substituted or unsubstituted aryl. In certain embodiments, R4is substituted or unsubstituted heteroaryl.

[0167] In certain embodiments, v is an integer between 3 to 300, 3 to 200, 3 to 100, 3 to 90, 3 to 80, 3 to 70, 3 to 60, 3 to 50, 5 to 50, 10 to 50, 15 to 50, 20 to 50, 20 to 40, 20 to 30, 20 to 25, 30 to 50, and 40 to 50, inclusive. PEG600corresponds, on average, to a v of about 13.2. PEG1000corresponds, on average, to a v of about 22.7, wherein R4is -OCH3. PEG2000 corresponds, on average, to a v of about 45.4.

[0168] In certain embodiments, the number average molar mass (Mn) of the polyethyleneglycol polymer is ≤ l0,000. In certain embodiments, the number average molar mass (Mn) of the polyethyleneglycol polymer is ≤ 10,000, ≤ 9000, ≤ 8000, ≤ 7000, ≤ 6000, ≤ 5000, ≤ 4000, ≤ 3000, or ≤ 2000. In certain embodiments, the number average molar mass (Mn) of the polyethyleneglycol polymer is between about 100 to about 10,000, inclusive; e.g., between about 100 to about 5000, between about 100 to about 4000, between about 100 to about 3000, between about 100 to about 2500, between about 100 to about 2000, between about 100 to about 1500, between about 100 to about 1000, between about 100 to about 900, between about 100 to about 800, between about 100 to about 700, between about 100 to about 600, between about 100 to about 500, between about 100 to about 400, between about 100 to about 300, between about 100 to about 200, between about 100 to about 1500, between about 2500 to about 10000, between about 2500 to about 9000, between about 2500 to about 8000, between about 2500 to about 7000, between about 2500 to about 6000, between about 2500 to about 5000, between about 2500 to about 4000, or between about 2500 to about 3000, inclusive. In certain embodiments, the number average molar mass (Mn) of the polyethyleneglycol polymer is 1000 (PEG1000). In certain embodiments, the number average molar mass (Mn) of the polyethyleneglycol polymer is 2000 (PEG2000).

[0169] In one embodiment of the compound of formula (I), the group of formula (i) is a group of formula (i-a):(i-a).

[0170] In one embodiment, 4 to 11 of R1and R2are a group of formula (i-a). In one embodiment, 9 of R1and R2are a group of formula (i-a). In one embodiment, 6 of R1and 3 of R2are a group of formula (i-a). In one embodiment, 8 of R1and R2are a group of formula (i-a). In one embodiment, 6 of R1and 2 of R2are a group of formula (i-a). In one embodiment, 7 of R1and R2are a group of formula (i-a). In one embodiment, 6 of R1and 1 of R2are a group of formula (i-a). In one embodiment, 6 of R1and R2are a group of formula (i). In one embodiment, 6 of R1are a group of formula (i-a). In one embodiment, 5 of R1and R2are a group of formula (i-a). In one embodiment, 5 of R1are a group of formula (i-a). In oneembodiment, 4 of R1and R2are a group of formula (i-a). In one embodiment, 4 of R1are a group of formula (i-a).

[0171] In one embodiment, 6 of R1and 3 of R2are a group of formula (i-a) and each instance of R3is independently substituted or unsubstituted alkyl. In one embodiment, each instance of R3is unsubstituted alkyl. In one embodiment, each instance of R3is unsubstituted C13 alkyl. In one embodiment, each instance of R3is n-tridecane.

[0172] In one embodiment, 6 of R1and 2 of R2are a group of formula (i-a) and each instance of R3is independently substituted or unsubstituted alkyl. In one embodiment, each instance of R3is unsubstituted alkyl. In one embodiment, each instance of R3is unsubstituted C13alkyl. In one embodiment, each instance of R3is n-tridecane.

[0173] In one embodiment, 6 of R1and 1 of R2are a group of formula (i-a) and each instance of R3is independently substituted or unsubstituted alkyl. In one embodiment, each instance of R3is unsubstituted alkyl. In one embodiment, each instance of R3is unsubstituted C13alkyl. In one embodiment, each instance of R3is n-tridecane.

[0174] In one embodiment, 6 of R1are a group of formula (i-a) and each instance of R3is independently substituted or unsubstituted alkyl. In one embodiment, each instance of R3is unsubstituted alkyl. In one embodiment, each instance of R3is unsubstituted C13alkyl. In one embodiment, each instance of R3is n-tridecane.

[0175] In one embodiment, 5 of R1are a group of formula (i-a) and each instance of R3is independently substituted or unsubstituted alkyl. In one embodiment, each instance of R3is unsubstituted alkyl. In one embodiment, each instance of R3is unsubstituted C13 alkyl. In one embodiment, each instance of R3is n-tridecane.

[0176] In one embodiment, 4 of R1are a group of formula (i-a) and each instance of R3is independently substituted or unsubstituted alkyl. In one embodiment, each instance of R3is unsubstituted alkyl. In one embodiment, each instance of R3is unsubstituted C13 alkyl. In one embodiment, each instance of R3is n-tridecane.

[0177] In one embodiment, the compound is a compound in Table 3, or a pharmaceutically acceptable salt thereof. Table 3.

[0178] In some embodiments, also provided herein is a polyethyleneimine compound of formula (I) wherein each R1and R2is H (i.e. N1,N1-bis(2-aminoethyl)-N2,N2-bis(2-(bis(2- aminoethyl)amino)ethyl)ethane-1,2-diamine) for use in the manufacture of polyethyleneimine compounds of formula (I) wherein at least one R1or R2is not H (e.g., a compound shown in Table 3).

[0179] In some embodiments, one or more of the compounds described herein has fewer cationic groups and / or lower toxicity than higher molecular weight polyethyleneimine species(see, e.g., Example 8). In some embodiments, one or more of the compounds described herein is more homogeneous than higher molecular weight polyethyleneimine species (see, e.g., Example 8). In some embodiments, one or more of the compounds described herein has fewer cationic groups and / or lower toxicity than 7C1 (Dahlman et al., Nat Nanotechnol 9, 648-655 (2014)). In some embodiments, one or more of the compounds described herein more homogeneous than 7C1 (Dahlman et al., Nat Nanotechnol 9, 648-655 (2014)).

[0180] In some embodiments, a compound provided herein is one described in the Example section infra (e.g., Example 1 or Example 8). In some embodiments, a compound provided herein produced by the methods described in the Example section infra (e.g., Example 1 or Example 8).

[0181] It is understood that any embodiment of the compounds provided herein, as set forth above, and any specific substituent and / or variable in the compound provided herein, as set forth above, may be independently combined with other embodiments and / or substituents and / or variables of the compounds to form embodiments not specifically set forth above. In addition, in the event that a list of substituents and / or variables is listed for any particular group or variable, it is understood that each individual substituent and / or variable may be deleted from the particular embodiment and / or claim and that the remaining list of substituents and / or variables will be considered to be within the scope of embodiments provided herein.

[0182] It is understood that in the present description, combinations of substituents and / or variables of the depicted formulae are permissible only if such contributions result in stable compounds. 7.4 Methods for Making Compounds

[0183] Provided herein is a use of a polyethyleneimine compound of formula (I) wherein each R1and R2is H (i.e. N1,N1-bis(2-aminoethyl)-N2,N2-bis(2-(bis(2- aminoethyl)amino)ethyl)ethane-1,2-diamine) for the manufacture of polyethyleneimine compounds of formula (I) wherein at least one R1or R2is not H (e.g. a compound shown in Table 3).

[0184] The compounds of formula (I) and Table 3, can be made using conventional organic syntheses and commercially available starting materials. By way of example and not limitation,compounds of formula (I) and Table 3, can be prepared as outlined in Scheme 1, shown below, as well as in the examples set forth herein. It should be noted that one skilled in the art would know how to modify the procedures set forth in the illustrative schemes and examples to arrive at the desired products. In some embodiments, the compounds of formula (I) and Table are made using a well-defined small molecule starting material, which is advantageous for identifying and separating the most potent and tolerable compounds, and scale-up, characterization, and manufacturing of the compounds (see, e.g., Example 8). In some embodiments, use of a well- defined small molecule starting material in the methods described herein fixes and / or controls the maximum number of tertiary amines for lipidation resulting in a more well defined and controlled lipid product mixture that can be purified to isolate an optimized product (see, e.g., Example 8). In some embodiments, the methods for making compounds described herein result in a lipid product having reduced heterogeneity and / or increased consistency as compared to product mixtures obtained using less well defined and / or higher molecular weight polyethyleneimine starting materials (see, e.g., Example 8). In some embodiments, the methods for making compounds described herein result in a lipid product having reduced heterogeneity and / or increased consistency as compared to 7C1 (see, e.g., Example 8). Scheme 1

[0185] Nucleophilic attack of an amino group of the polyethyleneimine polymer at the least sterically hindered carbon of the epoxide provides a group of the formula (i-a) (route a), while nucleophilic attack at the more sterically hindered carbon of the epoxide provides a group of the formula (i-b) (route b ), of Scheme 2.

[0186] Compounds of the present invention may comprise a mixture of products attached thereto arising from route (a) and route (b) depending on the preference, or lack thereof, of the mode of addition. Formulae that depict this bisecting bond may comprise a mixture ofcompounds. The bisecting group R3depicted in the formula (i) encompasses all contemplated modes of addition as shown in Scheme 2. Scheme 2

[0187] In certain embodiments, the conjugation reaction depicted in Scheme 2 results in a mixture comprising more groups conjugated to a group of formula (i-a) than to a group of formula (i-b ), e.g., the reaction mixture comprises greater than 50%, greater than 60%, greater than 70%, greater than 80%, greater than 90%, greater than 95%, greater than 99%, between about 60% to about 100%, between about 70% to about 100%, between about 80% to about 100%, between about 90% to about 100%, between about 95% to about 100%, or between about 99% to about 100%, of a conjugated group attached to a group of formula (i-a).

[0188] In certain embodiments, the reaction mixture comprises only conjugated groups attached to a group formula (i-a).

[0189] In one embodiment, the compound of Formula (I) is isolated. In one embodiment, the compound of Formula (I) has a purity of about 99%, about 95%, about 90%, about 85%, about 80%, about 75%, about 70%, about 65%, about 60%, about 55%, or about 50%. In one embodiment, the compound of Formula (I), wherein each R1and R2is independently hydrogen or a group of formula (i-a) has a purity of about 99%, about 95%, about 90%, about 85%, about 80%, about 75%, about 70%, about 65%, about 60%, about 55%, or about 50%.

[0190] In some embodiments, the epoxide is chiral, i.e., having (R) or (S) stereochemistry. In such embodiments, the conjugation reaction depicted in Scheme 2 provides a chiral conjugated polyethyleneimine polymer. Chiral compounds can be characterized in a variety of ways well known in the art, e.g., obtaining the optical rotation and / or NMR analysis after chemical modification of the optically active compound with a chiral derivatizing agent are methods useful in evaluating the chirality of a polymer.

[0191] In some embodiments, wherein the epoxide is chiral, the conjugation reaction depicted in Scheme 2 results in a mixture comprising more groups conjugated to a group of formula (R)-(i-a) than to a group of formula (S)-(i-a), e.g., the reaction mixture comprises greater than 50%, greater than 60%, greater than 70%, greater than 80%, greater than 90%, greater than 95%, greater than 99%, between about 60% to about 100%, between about 70% to about 100%, between about 80% to about 100%, between about 90% to about 100%, between about 95% to about 100%, or between about 99% to about 100%, of a conjugated group attached to a group of formula (R)-(i-a).

[0192] In certain embodiments, the reaction mixture comprises only conjugated groups attached to a group formula (R)-(i-a).

[0193] In some embodiments, wherein the epoxide is chiral, the conjugation reaction depicted in Scheme 2 results in a mixture comprising more groups conjugated to a group of formula (S)-(i-a) than to a group of formula (R)-(i-a), e.g., the reaction mixture comprises greater than 50%, greater than 60%, greater than 70%, greater than 80%, greater than 90%, greater than 95%, greater than 99%, between about 60% to about 100%, between about 70% to about 100%, between about 80% to about 100%, between about 90% to about 100%, between about 95% to about 100%, or between about 99% to about 100%, of a conjugated group attached to a group of formula (S)-(i-a).

[0194] In certain embodiments, the reaction mixture comprises only conjugated groups attached to a group formula (S)-(i-a).

[0195] In certain embodiments, wherein one epoxide is used in the conjugation reaction, each instance of R3is the same in the compound of Formula (I). For example, in certain embodiments, each instance of R3is the same wherein R3is a substituted or unsubstituted alkyl. In certain embodiments, each instance of R3is the same wherein R3is an unsubstituted alkyl. In certain embodiments, each instance of R3is the same wherein R3is selected from the group consisting of -C8H17, -C9H19, -C10H21, -C11H23, -C12H25, -C13H27, -C14H29, -C15H31, -C16H33, - C17H35, -C18H37, -C19H39, and -C20H41. In certain embodiments, each instance of R3is the samewherein R3is selected from the group consisting of -C8H17, -C9H19, -C10H21, -C11H23, -C12H25, - C13H27, -C14H29, -C15H31, and -C16H33. 7.5 Particles

[0196] In one embodiment, a compound described herein may be used to form delivery devices. The compounds described herein have several properties that make them particularly suitable in the preparation of delivery devices. These include: 1) the ability of the compounds to complex and “protect” labile agents; 2) the ability to buffer the pH in the endosome; 3) the ability to act as a “proton sponge” and cause endosomolysis; and 4) the ability to neutralize the charge on negatively charged agents.

[0197] In some embodiments, a compound described herein is used to form a particle or plurality of particles containing an agent to be delivered. In some embodiments, a plurality of particles is a colloidal dispersion (e.g., colloidal suspension) of a particle (e.g., colloid) described herein that is distributed in a dispersion medium (e.g., a liquid). A compound described herein may be used to encapsulate an agent including, but not limited to, an organic molecule (e.g., cholesterol), an inorganic molecule, a nucleic acid, a protein, a peptide, a polynucleotide, a targeting agent, an isotopically labeled organic or inorganic molecule, a vaccine, an immunological agent, etc. Other exemplary agents are described in greater detail herein. A particle may comprise other materials such as polymers (e.g., synthetic polymers (e.g., PEG, PLGA), natural polymers (e.g., phospholipids)). In some embodiments, a compound described herein is mixed with one or more agents (e.g., cholesterol) and / or one or more other materials (e.g., polymers). For example, a compound described herein may be mixed with an amount of an agent and an amount of a polymer, or mixed with an amount of an agent alone, to produce a particle or plurality of particles.

[0198] In some embodiments, a particle (e.g., a nanoparticle) comprising a compound according to Formula (I) as described herein facilitates endosomal escape in vivo. In some embodiments, a particle (e.g., a nanoparticle) comprising a compound set forth in Table 3 facilitates endosomal escape in vivo. In some embodiments, the compound is Compound 1. In some embodiments, the compound is Compound 9. In some embodiments, the compound is Compound 8. In some embodiments, the compound is Compound 7. In some embodiments, the compound is Compound 6. In some embodiments, the compound is Compound 5.

[0199] In some embodiments, the diameter of a particle or the average diameter of a plurality of particles ranges from about 1 nm to about 150 nm. In some embodiments, the diameter of a particle or the average diameter of a plurality of particles ranges from about 1 nm to about 140 nm. In some embodiments, the diameter of a particle or the average diameter of a plurality of particles ranges from about 1 nm to about 130 nm. In some embodiments, the diameter of a particle or the average diameter of a plurality of particles ranges from about 1 nm to about 120 nm. In some embodiments, the diameter of a particle or the average diameter of a plurality of particles ranges from about 1 nm to about 110 nm. In some embodiments, the diameter of a particle or the average diameter of a plurality of particles ranges from about 1 nm to about 100 nm. In some embodiments, the diameter of a particle or the average diameter of a plurality of particles ranges from about 1 nm to about 10 nm. In some embodiments, the diameter of a particle or the average diameter of a plurality of particles ranges from about 10 nm to about 50 nm. In some embodiments, the diameter of a particle or the average diameter of a plurality of particles ranges from about 10 nm to about 100 nm. In some embodiments, the diameter of a particle or the average diameter of a plurality of particles ranges from about 25 to about 70 nm. In some embodiments, the diameter of a particle or the average diameter of a plurality of particles ranges from about 35 to about 60 nm. In some embodiments, the diameter of a particle or the average diameter of a plurality of particles ranges from about 40 nm to about 50 nm. In some embodiments, the diameter of a particle or the average diameter of a plurality of particles ranges from about 50 nm to about 150 nm. In some embodiments, the diameter of a particle or the average diameter of a plurality of particles ranges from about 50 nm to about 140 nm. In some embodiments, the diameter of a particle or the average diameter of a plurality of particles ranges from about 50 nm to about 130 nm. In some embodiments, the diameter of a particle or the average diameter of a plurality of particles ranges from about 50 nm to about 120 nm. In some embodiments, the diameter of a particle or the average diameter of a plurality of particles ranges from about 50 nm to about 110 nm. In some embodiments, the diameter of a particle or the average diameter of a plurality of particles ranges from about 50 nm to about 100 nm. In some embodiments, the diameter of a particle or the average diameter of a plurality of particles ranges from about 1 to about 5 nm. In some embodiments, the diameter of a particle or the average diameter of a plurality of particles is about 10 nm, about 11 nm, about 12 nm, about 13 nm, about 14 nm, about 15 nm, about 16 nm, about 17 nm, about 18 nm, about 19 nm, about 20nm. In specific embodiments, the diameter of a particle or the average diameter of a plurality of particles is about 21 nm, about 22 nm, about 23 nm, about 24 nm, about 25 nm, about 26 nm, about 27 nm, about 28 nm, about 29 nm, or about 30 nm. In some embodiments, the diameter of a particle or the average diameter of a plurality of particles is about 31 nm, about 32 nm, about 33 nm, about 34 nm, about 35 nm, about 36 nm, about 37 nm, about 38 nm, about 39 nm, or about 40 nm. In some embodiments, the diameter of a particle or the average diameter of a plurality of particles is about 41 nm, about 42 nm, about 43 nm, about 44 nm, about 45 nm, about 46 nm, about 47 nm, about 48 nm, about 49 nm, or about 50 nm. In some embodiments, the diameter of a particle or the average diameter of a plurality of particles is about 51 nm, about 52 nm, about 53 nm, about 54 nm, about 55 nm, about 56 nm, about 57 nm, about 58 nm, about 59 nm, or about 60 nm. In some embodiments, the diameter of a particle or the average diameter of a plurality of particles is about 61 nm, about 62 nm, about 63 nm, about 64 nm, about 65 nm, about 66 nm, about 67 nm, about 68 nm, about 69 nm, or about 70 nm. In some embodiments, the diameter of a particle or the average diameter of a plurality of particles is about 71 nm, about 72 nm, about 73 nm, about 74 nm, about 75 nm, about 76 nm, about 77 nm, about 78 nm, about 79 nm, or about 80 nm. In some embodiments, the diameter of a particle or the average diameter of a plurality of particles is about 81 nm, about 82 nm, about 83 nm, about 84 nm, about 85 nm, about 86 nm, about 88 nm, about 88 nm, about 89 nm, or about 90 nm. In some embodiments, the diameter of a particle or the average diameter of a plurality of particles is about 91 nm, about 92 nm, about 93 nm, about 94 nm, about 95 nm, about 96 nm, about 97 nm, about 98 nm, about 99 nm, or about 100 nm. In some embodiments, the diameter of a particle or the average diameter of a plurality of particles is about 110 nm, about 111 nm, about 112 nm, about 113 nm, about 114 nm, about 115 nm, about 116 nm, about 117 nm, about 118 nm, or about 119 nm. In some embodiments, the diameter of a particle or the average diameter of a plurality of particles is about 120 nm, about 121 nm, about 122 nm, about 123 nm, about 124 nm, about 125 nm, about 126 nm, about 127 nm, about 128 nm, or about 129 nm. In some embodiments, the diameter of a particle or the average diameter of a plurality of particles is about 130 nm, about 131 nm, about 132 nm, about 133 nm, about 134 nm, about 135 nm, about 136 nm, about 137 nm, about 138 nm, or about 139 nm. In some embodiments, the diameter of a particle or the average diameter of a plurality of particles is about a size set forth in FIG.11A. The size of a particle may beassessed using Malvern Zetasizer. or as described in the Example section, infra (e.g., Example 8).

[0200] A particle or plurality of particles described herein may be prepared using any method known in the art. These methods include, but are not limited to, spray drying, single and double emulsion solvent evaporation, solvent extraction, phase separation, simple and complex coacervation, and other methods for preparation of particles well known to those of ordinary skill in the art. In some embodiments, the method of preparing particles comprises double emulsion solvent evaporation and / or spray drying. The conditions used in preparing particles may be altered to yield particles of a desired size or property (e.g., hydrophobicity, hydrophilicity, external morphology, “stickiness,” shape, etc.). The method of preparing particles and the conditions (e.g., solvent, temperature, concentration, air flow rate, etc.) used may also depend on the agent being encapsulated and / or the composition of the matrix.

[0201] Methods developed for making particles for delivery of encapsulated agents are described in the literature (for example, Doubrow, M., Ed., “Microcapsules and Nanoparticles in Medicine and Pharmacy,” CRC Press, Boca Raton, 1992; Mathiowitz and Langer, J. Controlled Release 5:13-22, 1987; Mathiowitz et al., Reactive Polymers 6:275-283, 1987; Mathiowitz et al., J. Appl. Polymer Sci.35:755-774, 1988; each of which is incorporated herein by reference). In a specific embodiment, nanoparticles (e.g., lipid nanoparticles) are produced as described in Example 2, infra. In a specific embodiment, nanoparticles (e.g., lipid nanoparticles) are produced as described in Example 8, infra.

[0202] If a plurality of particles prepared by any of the above methods has an average size range outside of the desired range, the desired particles can be selected based on size, for example, by using a sieve. The particles described herein may also be coated. In certain embodiments, the particles are coated with a targeting agent. In some embodiments, the particles are not coated with a targeting agent. In some embodiments, the particles are coated to achieve desirable surface properties (e.g., a particular charge).

[0203] In one embodiment, a particle described herein is a nanoparticle. In some embodiments, a plurality of particles described herein is a plurality of nanoparticles. In some embodiments, a plurality of nanoparticles is a colloidal dispersion of a nanoparticle as described herein. The characteristics of a nanoparticle or plurality of nanoparticles may depend on thecomponents thereof. For example, a nanoparticle including cholesterol as a structural lipid may have different characteristics than a nanoparticle that includes a different structural lipid. Similarly, the characteristics of a nanoparticle may depend on the absolute or relative amounts of its components. For instance, a nanoparticle including a higher molar fraction of a phospholipid may have different characteristics than a nanoparticle including a lower molar fraction of a phospholipid. Characteristics may also vary depending on the method and conditions of preparation of the nanoparticles.

[0204] A nanoparticle or plurality of nanoparticles described herein may be characterized by a variety of methods. For example, microscopy (e.g., transmission electron microscopy or scanning electron microscopy) may be used to examine the morphology and size distribution of nanoparticles. Dynamic light scattering or potentiometry (e.g., potentiometric titrations) may be used to measure the zeta potential of nanoparticles. Dynamic light scattering may also be utilized to determine particle sizes. Instruments such as the Zetasizer Nano ZS (Malvem Instruments Ltd, Malvem, and Worcestershire, UK) may also be used to measure multiple characteristics of nanoparticles, such as particle size, polydispersity index, and zeta potential.

[0205] A nanoparticle or plurality of nanoparticles described herein may have a size or mean size, respectively, of between tens of nm and hundreds of nm. In some embodiments, the size of a nanoparticle or mean size of a plurality of nanoparticles is from about 10 nm to about 150 nm, such as about 10 nm, about 15 nm, about 20 nm, about 25 nm, about 30 nm, about 35 nm, about 40 nm, about 45 nm, about 50 nm, about 55 nm, about 60 nm, about 65 nm, about 70 nm, about 75 nm, about 80 nm, about 85 nm, about 90 nm, about 95 nm, about 100 nm, about 105 nm, about 110 nm, about 115 nm, about 120 nm, about 125 nm, about 130 nm, about 135 nm, about 140 nm, about 145 nm, or about 150 nm. In some embodiments, the size of a nanoparticle or mean size of a plurality of nanoparticles is from about 10 nm to about 100 nm, about 35 nm to about 70 nm, about 50 nm to about 100 nm, from about 50 nm to about 90 nm, from about 50 nm to about 80 nm, from about 50 nm to about 70 nm, from about 50 nm to about 60 nm, from about 60 nm to about 100 nm, from about 60 nm to about 90 nm, from about 60 nm to about 80 nm, from about 60 nm to about 70 nm, from about 70 nm to about 100 nm, from about 70 nm to about 90 nm, from about 70 nm to about 80 nm, from about 80 nm to about 100 nm, from about 80 nm to about 90 nm, or from about 90 nm to about 100 nm. In some embodiments, the size of a nanoparticle or mean size of a plurality of nanoparticles is from about 100 nm to about 150 nm.In some embodiments, the size of a nanoparticle or mean size of a plurality of nanoparticles is from about 120 nm to about 150 nm. In some embodiments, the size of a nanoparticle or mean size of a plurality of nanoparticles is from about 130 nm to about 150 nm. In some embodiments, the size of a nanoparticle or mean size of a plurality of nanoparticles is from about 140 nm to about 150 nm. In some embodiments, the size of a nanoparticle or mean size of a plurality of nanoparticles is from about 70 nm to about 100 nm. In some embodiments, the size of a nanoparticle or mean size of a plurality of nanoparticles is about 35 nm to about 60 nm. In some embodiments, the size of a nanoparticle or mean size of a plurality of nanoparticles is about 70 nm. In some embodiments, the size of a nanoparticle or mean size of a plurality of nanoparticles is about 80 nm. In some embodiments, the size of a nanoparticle or mean size of a plurality of nanoparticles is about 100 nm. In some embodiments, the size of a nanoparticle or mean size of a plurality of nanoparticles is the size of a particle or mean size of a plurality of particles as described herein. In some embodiments, the size of a nanoparticle or mean size of a plurality of nanoparticles is about a size set forth in FIG.11A. The size of a nanoparticle may be assessed using Malvern Zetasizer. or as described in the Example section, infra (e.g., Example 8).

[0206] A plurality of nanoparticles as described herein may be relatively homogenous. A polydispersity index (PDI) may be used to indicate the homogeneity of a plurality of nanoparticles, e.g., the particle size distribution of the nanoparticles. A small (e.g., less than 0.3) polydispersity index generally indicates a narrow particle size distribution. The polydispersity index (PDI) may be assessed using Malvern Zetasizer, or as described in the Example section, infra (e.g., Example 8). A plurality of nanoparticles described herein may have a polydispersity index of from about 0 to about 0.25, such as 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.20, 0.21, 0.22, 0.23, 0.24, or 0.25. In some embodiments, the polydispersity index of the plurality of nanoparticles is from about 0.05 to about 0.11. In some embodiments, the polydispersity index of the plurality of nanoparticles is from about 0.10 to about 0.20. In some embodiments, the polydispersity index of the plurality of nanoparticles is about 0.05, about 0.06, about 0.07, about 0.08, about 0.09, about 0.10, or about 0.11. In some embodiments, 50% or more of the nanoparticles in a plurality of nanoparticles have about the same PDI, size distribution, size shape, surface characteristics and / or inner structure. In some embodiments, 60% or more of the nanoparticles in a plurality of nanoparticleshave about the same PDI, size distribution, size shape, surface characteristics and / or inner structure. In some embodiments, 70% or more of the nanoparticles in a plurality of nanoparticles have about the same PDI, size distribution, size shape, surface characteristics and / or inner structure. In some embodiments, 80% or more of the nanoparticles in a plurality of nanoparticles have about the same PDI, size distribution, size shape, surface characteristics and / or inner structure. In some embodiments, 90% or more of the nanoparticles in a plurality of nanoparticles have about the same PDI, size distribution, size shape, surface characteristics and / or inner structure.

[0207] The efficiency of encapsulation of an agent described herein describes the amount of agent that is encapsulated or otherwise associated with a nanoparticle after preparation, relative to the initial amount provided. The encapsulation efficiency is desirably high (e.g., close to 100 %). The encapsulation efficiency may be measured, for example, by comparing the amount of agent in a solution containing the nanoparticle before and after breaking up the nanoparticle with one or more organic solvents or detergents. Fluorescence may be used to measure the amount of free agent (e.g., RNA) in a solution. For the nanoparticles described herein, the encapsulation efficiency of an agent may be at least 50 %, for example 50 %, 55 %, 60 %, 65 %, 70 %, 75 %, 80 %, 85 %, 90 %, 91 %, 92 %, 93 %, 94 %, 95 %, 96 %, 97 %, 98 %, 99 %, or 100 %. In some embodiments, the encapsulation efficiency is at least 70 %. In some embodiments, the encapsulation efficiency is at least 75 %. In some embodiments, the encapsulation efficiency is at least 80 %. In some embodiments, the encapsulation efficiency is at least 85 %. In some embodiments, the encapsulation efficiency is at least 90 %.

[0208] In some embodiments, the concentration of agent encapsulated in a nanoparticle described herein is about 1 µg / mL to 350 µg / mL quantified by, e.g., the UPLC method. In some embodiments, the concentration of agent encapsulated in a nanoparticle described herein is about 50 µg / mL to 350 µg / mL quantified by, e.g., the UPLC method. In some embodiments, the concentration of agent encapsulated in a nanoparticle described herein is about 100 µg / mL to 350 µg / mL quantified by, e.g., the UPLC method. In some embodiments, the concentration of agent encapsulated in a nanoparticle described herein is about 200 µg / mL to 350 µg / mL quantified by, e.g., the UPLC method. In some embodiments, the concentration of agent encapsulated in a nanoparticle described herein is about 300 µg / mL to 350 µg / mL quantified by, e.g., the UPLC method. In some embodiments, the concentration of agent encapsulated in ananoparticle described herein is about a concentration set forth in FIG.11A. In some embodiments, the agent is a polynucleotide (e.g., siRNA, miRNA, or mRNA). In some embodiments, the agent is TGFβR1 siRNA.

[0209] The zeta potential of a nanoparticle or plurality of nanoparticles may be used to indicate the electrokinetic potential of the nanoparticles. The zeta potential may be assessed using Malvern Zetasizer, or as described in the Example section, infra (e.g., Example 8). For example, the zeta potential may describe the surface charge of a nanoparticle. Nanoparticles with relatively low charges, positive or negative, are generally desirable, as more highly charged species may interact undesirably with cells, tissues, and other elements in the body. In some embodiments, the zeta potential of a nanoparticle is from about -10 mV to about +20 mV, from about -10 mV to about +15mV, from about -10 mV to about +10 mV, from about -10 mV to about +5 mV, from about -10 mV to about 0 mV, from about -10 mV to about -5 mV, from about -5 mV to about +20 mV, from about -5 mV to about +15 mV, from about -5 mV to about +10 mV, from about -5 mV to about +5 mV, from about -5 mV to about 0 mV, from about 0 mV to about +20 mV, from about 0 mV to about +15 mV, from about 0 mV to about +10 mV, from about 0 mV to about +5 mV, from about +5 mV to about +20 mV, from about +5 mV to about +15 mV, or from about +5 mV to about +10 mV. In some embodiments, the zeta potential of a nanoparticle is from about –14 mV to about 3.5 mV. In some embodiments, the zeta potential of a nanoparticle is about -13.9 mV, about -9 mV, about -6.8 mV, about -3.8 mV, about -2.2 mV, or about 3.5 mV. In some embodiments, the zeta potential of a nanoparticle is a zeta potential set forth in FIG.11A.

[0210] In some embodiments, a nanoparticle or plurality of nanoparticles has an apparent acid dissociation constant (pKa) of 5-8. In some embodiments, a nanoparticle or plurality of nanoparticles has an apparent acid dissociation constant (pKa) of 7.0-7.5. In some embodiments, a nanoparticle or plurality of nanoparticles has an apparent acid dissociation constant (pKa) of 6- 7. In some embodiments, a nanoparticle or plurality of nanoparticles has an apparent acid dissociation constant (pKa) of 5, 5.5, 6, 6.5, 7, 7.5, or 8. The apparent pKa may be measured by techniques known to one of skill in the art. For example, acid-base titration and 2-(p-toluidino)- 6-naphthalene sulfonic acid (TNS) fluorescent methods may be used to determine the apparent pKa.

[0211] In some embodiments, a nanoparticle described herein comprises a lipid component including at least one lipid, such as a compound according to Formula (I) as described herein. In some embodiments, a nanoparticle comprises a lipid component that is one of the compounds described herein. Nanoparticles may also include one or more other lipid or non-lipid components as described herein.

[0212] In some embodiments, a nanoparticle described herein comprises a lipid component a compound according to Formula (I) as described herein and a PEG lipid (e.g., PEG-lipid DMPE- PEG 2000). In some embodiments, a nanoparticle described herein comprises a lipid component a compound according to Formula (I) as described herein and PEG-lipid DMPE-PEG 2000. In some embodiments, a nanoparticle described herein comprises cholesterol and / or a phospholipid. In some embodiments, a nanoparticle described herein does not comprise cholesterol and / or a phospholipid.

[0213] In some embodiments, a nanoparticle described herein comprises a lipid component a compound set forth in Table 3 and a PEG lipid (e.g., PEG-lipid DMPE-PEG 2000). In some embodiments, a nanoparticle described herein comprises a lipid component a compound set forth in Table 3 and PEG-lipid DMPE-PEG 2000. In some embodiments, a nanoparticle described herein comprises cholesterol and / or a phospholipid. In some embodiments, a nanoparticle described herein does not comprise cholesterol and / or a phospholipid. In some embodiments, the compound is Compound 1. In some embodiments, the compound is Compound 9. In some embodiments, the compound is Compound 8. In some embodiments, the compound is Compound 7. In some embodiments, the compound is Compound 6. In some embodiments, the compound is Compound 5.

[0214] In one embodiment, the compounds described herein may also be used to prepare micelles or liposomes. In addition, an agent as described herein may be included in a micelle or liposome. Micelles and liposomes are particularly useful in delivering hydrophobic agents such as hydrophobic molecules. When the micelle or liposome is complexed with (e.g., encapsulates or covers) a polynucleotide it is referred to as a “lipoplex.” Many techniques for preparing micelles, liposomes, and lipoplexes are known in the art, and any method may be used with the compounds described herein to make micelles and liposomes.

[0215] In certain embodiments, liposomes are formed through spontaneous assembly. In other embodiments, liposomes are formed when thin lipid films or lipid cakes are hydrated and stacks of lipid crystalline bilayers become fluid and swell. The hydrated lipid sheets detach during agitation and self-close to form large, multilamellar vesicles (LMV). This prevents interaction of water with the hydrocarbon core of the bilayers at the edges . Once these particles have formed, reducing the size of the particle can be modified through input of sonic energy (sonication) or mechanical energy (extrusion). See Walde, P. “Preparation of Vesicles (Liposomes)” In Encylopedia of Nanoscience and Nanotechnology; Nalwa, H. S. Ed. American Scientific Publishers: Los Angeles, 2004; Vol.9, pp.43-79; Szoka et al., “Comparative Properties and Methods of Preparation of Lipid Vesicles (Liposomes )” Ann. Rev. Biophys. Bioeng.9:467-508, 1980; each of which is incorporated herein. The preparation of liposomes involves preparing the compounds described herein for hydration, hydrating the compounds with agitation, and sizing the vesicles to achieve a homogenous distribution of liposomes. Compounds are first dissolved in an organic solvent to assure a homogeneous mixture. The solvent is then removed to form a polymer-derived film. This polymer-derived film is thoroughly dried to remove residual organic solvent by placing the vial or flask on a vacuum pump overnight. Hydration of the polymer-derived film is accomplished by adding an aqueous medium and agitating the mixture. Disruption of LMV suspensions using sonic energy typically produces small unilamellar vesicles (SUV) with diameters in the range of 15-50 nm. Lipid extrusion is a technique in which a lipid / polymer suspension is forced through a polycarbonate filter with a defined pore size to yield particles having a diameter near the pore size of the filter used. Extrusion through filters with 100 nm pores typically yields large, unilamellar polymer-derived vesicles (LUY) with a mean diameter of 120-140 nm.

[0216] In some embodiments (e.g., liposomes containing RNAi molecules), the liposomes are prepared by lipid extrusion (e.g., as described herein).

[0217] Certain compounds described herein can spontaneously self assemble around certain molecules, such as DNA and RNA, to form liposomes. In some embodiments, the application of liposomes is for the delivery of polynucleotides. Use of conjugated lipomers allows for simple assembly of liposomes without the need for additional steps or devices such as an extruder. The following scientific papers described other methods for preparing liposomes and micelles: Dahlman et al., “In vivo endothelial siRNA delivery using polymeric nanoparticles with lowmolecular weight” Nat. Nanotechnol.9(8):648-655, 2014; Narang et al., “Cationic Lipids with Increased DNA Binding Affinity for Nonviral Gene Transfer in Dividing and Nondividing Cells” Bioconjugate Chem.16: 156-68, 2005; Hofland et al., “Formation of stable cationic lipid / DNA complexes for gene transfer” Proc. Natl. Acad. Sci. USA 93:7305-7309, July 1996; Byk et al., “Synthesis, Activity, and Structure-Activity Relationship Studies of Novel Cationic Lipids for DNA Transfer” J. Med. Chem.41(2):224-235, 1998; Wu et al., “Cationic Lipid Polymerization as a Novel Approach for Constructing New DNA Delivery Agents” Bioconjugate Chem.12:251- 57, 2001; Lukyanov et al., “Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs” Advanced Drug Delivery Reviews 56: 1273-1289, 2004; Tranchant et al., “Physicochemical optimisation of plasmid delivery by cationic lipids” J. Gene Med.6:S24-S35, 2004; van Balen et al., “Liposome / Water Lipophilicity: Methods, Information Content, and Pharmaceutical Applications” Medicinal Research Rev.24(3):299-324, 2004; each of which is incorporated herein by reference.

[0218] In some embodiments, a nanoparticle is one described in the Example section below. In some embodiments, a nanoparticle described herein comprises a compound of Formula (I) and has one or more of the characteristics of a nanoparticle described in the Example section below. In a specific embodiment, a nanoparticle described herein comprises a compound of Formula (I) and is less toxic than a 7C1 nanoparticle (see, e.g., Example 4, infra). In one embodiment, a nanoparticle described herein comprises a compound of Formula (I) and has fewer side effects than, e.g., a 7C1 nanoparticle. In specific embodiments, a nanoparticle described herein comprises a compound of Formula (I) and targets endothelial cells (see, e.g., Example 8, infra). In some embodiments, a nanoparticle described herein comprises a compound of Formula (I) and has an acceptable safety profile up to at least 3 mg / kg in mice and 2 mg / kg tested in non-human primates (NHPs) (see, e.g., Example 8, infra). In some embodiments, a nanoparticle described herein comprises a compound of Formula (I) and is well-tolerated, targets endothelial cells, and maintains potency after 2 weeks in NHPs (see, e.g., Example 8, infra). In some embodiments, a nanoparticle described herein comprises a compound of Formula (I) and exhibits no to low toxicity and targets endothelial cells. In some embodiments, a nanoparticle described herein comprises a compound of Formula (I) and exhibits no toxicity, targets endothelial cells, and maintains potency after 2 weeks in NHPs (see, e.g., Example 8, infra). In some embodiments, a nanoparticle described herein comprises a compound of Formula (I) and causes no adverse sideseffects, targets endothelial cells, and maintains potency after 2 weeks in NHPs (see, e.g., Example 8, infra). 7.5.1 Polymer Conjugated Lipids

[0219] In some embodiments, a nanoparticle comprises a lipid component comprising one or more polymer conjugated lipids (e.g., PEGylated lipid (PEG lipid)). Without being bound by the theory, it is contemplated that a polymer conjugated lipid component in a nanoparticle can improve of colloidal stability and / or reduce protein absorption of the nanoparticle. Without being bound by the theory, it is contemplated that a polymer conjugated lipid component in a nanoparticle prevents nanoparticle aggregation, prolongs the nanoparticles’ circulation time in the blood, and / or improves colloidal stability. In some embodiments, a polymer conjugated lipid is a cationic lipid. Exemplary cationic lipids that can be used in connection with the present disclosure include but are not limited to PEG-modified phosphatidylethanolamines, PEG- modified phosphatidic acids, PEG-modified ceramides, PEG-modified dialkylamines, PEG- modified diacylglycerols, PEG-modified dialkylglycerols, and mixtures thereof. For example, a PEG lipid may be PEG-c-DOMG, PEG-DMG, PEG-DLPE, PEG-DMPE, PEG-DPPC, PEG- DSPE, Ceramide-PEG2000, or Chol-PEG2000. In one embodiment, the PEG lipid is 1,2- dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000] (DMPE-PEG2000). In a specific embodiment, the PEG lipid is a PEG lipid described in the Example section (e.g., Example 1 or Example 8).

[0220] In one embodiment, a polymer conjugated lipid is a pegylated lipid. In some embodiments, a pegylated diacylglycerol (PEG-DAG) is a 1-(monomethoxy- polyethyleneglycol)-2,3-dimyristoylglycerol (PEG-DMG), a pegylated phosphatidylethanoloamine (PEG-PE), a PEG succinate diacylglycerol (PEG-S-DAG) (e.g., 4-O- (2’,3’-di(tetradecanoyloxy)propyl-1-O-(ω-methoxy(polyethoxy)ethyl)butanedioate (PEG-S- DMG)), a pegylated ceramide (PEG-cer), or a PEG dialkoxypropylcarbamate (e.g., ω- methoxy(polyethoxy)ethyl-N-(2,3-di(tetradecanoxy)propyl)carbamate or 2,3- di(tetradecanoxy)propyl-N-(ω-methoxy(polyethoxy)ethyl)carbamate.

[0221] In some embodiments, the pegylated lipid (e.g., DMPE-PEG 2000) prevents nanoparticle aggregation. In some embodiments, the pegylated lipid (e.g., DMPE-PEG 2000) prolongs the nanoparticles’ circulation time in the blood. In some embodiments, the pegylatedlipid (e.g., DMPE-PEG 2000) improves colloidal stability. In some embodiments, the pegylated lipid (e.g., DMPE-PEG 2000) prevents nanoparticle aggregation, prolongs the nanoparticles’ circulation time in the blood, and improves colloidal stability.

[0222] In one embodiment, the polymer conjugated lipid is present in a concentration ranging from about 0.25 to about 2.5 mg / mL. In one embodiment, the polymer conjugated lipid is present in a concentration ranging from about 1.0 to about 2.5 mg / mL. In one embodiment, the polymer conjugated lipid is present in a concentration of about 0.3 mg / mL. In some embodiments, the polymer conjugated lipid is present at concentration such as set forth in the Example section, infra (e.g., Example 2 or Example 8).

[0223] In one embodiment, the molar ratio of a lipid compound described herein (e.g., a compound of Formula (I)) to a polymer conjugated lipid described herein ranges from about 10:1 to about 3:1. In one embodiment, the molar ratio of a lipid compound described herein (e.g., a compound of Formula (I)) to a polymer conjugated lipid described herein is about 10:1, about 9:1, about 8:1, about 7:1, about 6:1, about 5:1, about 4:1, or about 3:1. In one embodiment, the molar ratio of a lipid compound described herein (e.g., a compound of Formula (I)) to a polymer conjugated lipid described herein is about 6:1. In some embodiments, the molar ratio of a lipid compound described herein (e.g., a compound of Formula (I)) to a polymer conjugated lipid described herein has a molar ratio described in the Example section, infra (e.g., Example 2 or 8).

[0224] In one embodiment, the weight ratio of a lipid compound described herein (e.g., a compound of Formula (I)) to a polymer conjugated lipid described herein ranges from about 10:1 to about 1:5. In one embodiment, the weight ratio of a lipid compound described herein (e.g., a compound of Formula (I)) to a polymer conjugated lipid described herein ranges from about 6:1 to about 1:2. In one embodiment, the weight ratio of a lipid compound described herein (e.g., a compound of Formula (I)) to a polymer conjugated lipid described herein is about 10:1, about 9:1, about 8:1, about 7:1, about 6:1, about 5:1, about 4:1, about 3:1, about 2:1, about 1:1, or about 1:2. In one embodiment, the weight ratio of a lipid compound described herein (e.g., a compound of Formula (I)) to a polymer conjugated lipid described herein is about 6:1. In one embodiment, the weight ratio of a lipid compound described herein (e.g., a compound of Formula (I)) to polymer conjugated lipid described herein is about 7:1.2. In some embodiments, the weight ratio of a lipid compound described herein (e.g., a compound of Formula (I)) to apolymer conjugated lipid described herein has a weight ratio described in the Example section, infra (e.g., Example 2 or 8). 7.5.2 Agents

[0225] In some embodiments, the agents to be delivered to a cell(s) or subject by a particle (e.g., a nanoparticle) or plurality of particles (e.g., a plurality of nanoparticles) described herein may be any substance capable of producing an effect, whether physical, chemical or biological. In some embodiments, an agent to be delivered is a therapeutic, prophylactic, or diagnostic agent. Any chemical compound to be administered to a subject may be delivered using the complexes, particles (e.g., nanoparticles), micelles, or liposomes described herein. The agent may be an organic molecule (e.g., cholesterol, a drug), an inorganic molecule, a nucleic acid, a protein, a peptide, a polynucleotide, a targeting agent, an isotopically labeled organic or inorganic molecule, a vaccine, an immunological agent, etc. In certain embodiments, a mixture of agents described herein may be delivered by a particle (e.g., a nanoparticle) or plurality of particles (e.g., nanoparticles) described herein.

[0226] In some embodiments, an agent is an organic molecule having pharmaceutical activity, e.g., a drug or therapeutic agent. In some embodiments, an agent comprises a drug. In some embodiments, an agent is a substance used in the treatment of a disease, disorder or condition.

[0227] In some embodiments, the agents to be delivered to a cell(s) (e.g., an endothelial cell(s)) or subject by a particle (e.g., a nanoparticle) or plurality of particles (e.g., nanoparticles) described herein are capable of modulating (e.g., downregulating or upregulating) one or more activities of a target protein. In some embodiments, the agents to be delivered to a cell(s) (e.g., an endothelial cell(s)) or subject by a particle (e.g., a nanoparticle) or plurality of particles (e.g., nanoparticles) described herein are capable of modulating signaling mediated by a target protein (e.g., downregulating or upregulating signaling mediated by a target protein). In some embodiments, an agent downregulates signaling induced by target protein. In some embodiments, an agent prevents binding of a target protein to its receptor or ligand. In some embodiments, an agent modulates (e.g., downregulates or upregulates) gene expression of a target. The agent may modulate (e.g., downregulate or upregulate) gene expression at the RNA level and / or protein level.

[0228] In some embodiments, the agents to be delivered to a cell(s) (e.g., an endothelial cell(s)) or subject by a particle (e.g., a nanoparticle) or plurality of particles (e.g., nanoparticles) described herein are capable of modulating (e.g., downregulating) one or more activities of TGFβR1 or TGFβR2. In some embodiments, the agents to be delivered to a cell(s) (e.g., an endothelial cell(s)) or subject by a particle (e.g., a nanoparticle) or plurality of particles (e.g., nanoparticles) described herein are capable of modulating TGFβ-mediated signaling (e.g., downregulating TGFβ-mediated signaling). In some embodiments, an agent downregulates TGFβ signaling induced by, e.g., TGFβ1, TGFβ2, TGFβ3, binding to TGFβR1 and / or TGFβR2. In some embodiments, an agent prevents binding of TGFβR1 or TGFβR2 to a TGFβ cytokine, e.g., TGFβ1, TGFβ2, or TGFβ3. In some embodiments, an agent downregulates TGFβR1 and / or TGFβR2 gene expression. The agent may downregulate TGFβR1 or TGFβR2 gene expression at the RNA level and / or protein level. In some embodiments, the agents to be delivered to a cell(s) or subject by a particle (e.g., a nanoparticle) or plurality of particles (e.g., nanoparticles) described herein are lung cancer antigens or antibodies or fragments thereof that bind to a lung cancer antigen. In some embodiments, a mixture of agents described herein may be delivered by a particle (e.g., a nanoparticle) or plurality of particles (e.g., nanoparticles) described herein.

[0229] In some embodiments, an agent has a mass of about 10 kilodaltons (kDa) to about 50 kDa. In some embodiments, an agent has a mass of about 15 kDa to about 50 kDa. In some embodiments, an agent has a mass of about 20 kDa to about 50 kDa. In some embodiments, an agent has a mass of about 25 kDa to about 50 kDa. In some embodiments, an agent has a mass of about 30 kDa to about 50 kDa. In some embodiments, an agent has a mass of about 40 kDa to about 50 kDa. In some embodiments, an agent has a mass of about 10 kDa to about 25 kDa. In some embodiments, an agent has a mass of about 1 kDa, about 2 kDa, about 3 kDa, about 4 kDa, or about 5 kDa. In some embodiments, an agent has a mass of about 6 kDa, about 7 kDa, about 8 kDa, or about 9 kDa. In some embodiments, an agent has a mass of about 10 kDa, about 20 kDa, about 30 kDa, about 40 kDa, or about 50 kDa. In some embodiments, an agent has a mass of less than about 50 kDa. In some embodiments, an agent has a mass of less than about 45 kDa, less than about 40 kDa, less than about 35 kDa, less than about 30 kDa, less than about 25 kDa, less than about 20 kDa, or less than about 15 kDa. In some embodiments, an agent has a mass of less than about 50 kDa. In some embodiments, an agent is negatively supercharged. In some embodiments, an agent has a mass of less than about 50 kDa and is negatively supercharged. Insome embodiments, an agent has a mass of about 1 kDa to about 50 kDa and is negatively supercharged.

[0230] In some embodiments, a negatively supercharged agent (e.g., an agent comprising a peptide, protein, or a fragment thereof) is one that features negatively charged amino acid side chains at solvent-exposed residues, typically through amino acid substitution of non-negative amino acids (e.g., polar non-negative amino acids) at its solvent exposed surface with negatively charged side chains (e.g., a natural or unnatural negatively charged side chain). See, e.g., Thompson et al., Methods in Enzymology, 2012, 503:293-319 for approaches to producing a negatively supercharged protein, peptide or fragment thereof. In specific embodiments, a negatively supercharged peptide, protein, or fragment thereof preserves much of the original function of its original amino acid sequence (e.g., retains activity of its original amino acid sequence). The AvNAPSA value (average number of neighboring atoms per side chain atom) of an amino acid residue of a peptide, protein, or fragment thereof is a value that measures the solvent accessibility or burial of amino acid side chains at the atom-level, which can be calculated from 3-dimensional models of an amino acid sequence (e.g., using Rosetta software). A cutoff of 10 Å can be used for determination of neighboring atoms. AvNAPSA values of 50- 150 are typical for surface residues, whereas AvNAPSA values of >150 are typical for core residues (e.g., buried from solvent). In some embodiments, a negatively supercharged peptide, protein, or fragment thereof comprises one or more amino acid substitutions of solvent-exposed amino acids with a negatively charged amino acid (e.g., negatively charged amino acid side chain). In some embodiments, a negatively supercharged peptide, protein, or fragment thereof comprises one or more amino acid substitutions of hydrophilic amino acids with a negatively charged amino acid (e.g., negatively charged amino acid side chain). In some embodiments, a negatively supercharged peptide, protein, or fragment thereof comprises one or more amino acid substitutions of amino acids having side chains that are not buried from solvent with a negatively charged amino acid (e.g., negatively charged amino acid side chain). In some embodiments, a negatively supercharged peptide, protein, or fragment thereof comprises one or more amino acid substitutions of polar non-negative amino acids with a negatively charged amino acid (e.g., negatively charged amino acid side chain). In some embodiments, a negatively supercharged peptide, protein, or fragment thereof comprises one or more amino acid substitutions of amino acids having an AvNAPSA value of less than 150 (e.g., less than 125, less than 100, less than 75,or less than 50) with a negatively charged amino acid (e.g., negatively charged amino acid side chain).

[0231] In some embodiments, the one or more amino acids to be substituted (e.g., solvent- exposed, hydrophilic, not buried from solvent, polar non-negative, and / or AvNAPSA value less than 150) is selected from an arginine (Arg), lysine (Lys), asparagine (Asn), glutamine (Gln), histidine (His), serine (Ser), or threonine (Thr). In some embodiments, the negatively charged amino acid is selected from aspartic acid (Asp), glutamic acid (Glu), or a negatively charged non-natural amino acid (e.g., a negatively charged amino acid side chain, such as aspartate, glutamate, or negatively charged non-natural amino acid side chain). In some embodiments, a negatively supercharged peptide, protein, or fragment thereof comprises substitution of one or more arginine (Arg), lysine (Lys), asparagine (Asn), glutamine (Gln), histidine (His), serine (Ser), or threonine (Thr) with an aspartic acid (Asp), glutamic acid (Glu), or a negatively charged non-natural amino acid. In specific embodiments, a negatively supercharged peptide, protein, or fragment thereof comprises substitution of one or more arginine (Arg), lysine (Lys), or glutamine (Gln) with a glutamic acid (Glu) with aspartic acid (Asp), glutamic acid (Glu), or a negatively charged non-natural amino acid (e.g., a negatively charged amino acid side chain, such as aspartate, glutamate, or negatively charged non-natural amino acid side chain). In specific embodiments, a negatively supercharged peptide, protein, or fragment thereof comprises substitution of one or more asparagine (Asn) with an aspartic acid (Asp). In some embodiments, the amino acid substitution is an amino acid replacement substitution (e.g., the length of the supercharged sequence compared to original is unchanged). In some embodiments, the amino acid substitution comprises replacement of one or more amino acids with an amino acid sequence of different length (e.g., the length of the supercharged sequence is shorter or longer compared to original).

[0232] In some embodiments, an agent comprises an antibody(ies) (e.g., a monoclonal antibody) or an antigen-binding fragment thereof. In some embodiments, an agent is a functional antibody fragment (e.g., antigen-binding fragment). In some embodiments, an agent comprises an antigen-binding fragment (e.g., a Fab fragment). In some embodiments, an antibody or an antigen-binding fragment thereof specifically binds to a target associated with a disease, disorder, or condition. In some embodiments, an antibody or an antigen-binding fragment thereof specifically binds to a target associated with a disease, disorder, or condition.

[0233] In some embodiments, an agent comprises an antibody(ies) (e.g., a monoclonal antibody) or an antigen-binding fragment thereof. In some embodiments, an antibody or an antigen-binding fragment thereof binds to TGFβR1 or TGFβR2. In some embodiments, an antibody or an antigen-binding fragment thereof specifically binds to TGFβR1 or TGFβR2. In some embodiments, an antibody or an antigen-binding fragment thereof binds to human TGFβR1 or human TGFβR2. In some embodiments, an antibody or an antigen-binding fragment thereof specifically binds to human TGFβR1 or human TGFβR2. In some embodiments, the antibody or an antigen-binding fragment thereof is human or humanized.

[0234] In some embodiments, an antibody or an antigen-binding fragment thereof inhibits the binding of TGFβR1 (e.g., human TGFβR1) or TGFβR2 (e.g., human TGFβR2) to a TGFβ cytokine (e.g., TGFβ1, TGFβ2, and / or TGFβ3). In some embodiments, an antibody or an antigen-binding fragment thereof competes with TGFβR1 (e.g., human TGFβR1) or TGFβR2 (e.g., human TGFβR2) for binding to a TGFβ cytokine (e.g., TGFβ1, TGFβ2, and / or TGFβ3). Antibodies that bind to TGFβR1 (e.g., human TGFβR1) or TGFβR2 (e.g., human TGFβR2) are known to those of skill in the art.

[0235] In some embodiments, an antibody or an antigen-binding fragment thereof that binds to TGFβR1 is selected from antibody clone number AFB19414, 4H5-6E6-7H2, 3G1-C4-E10, or MBS Catalog Nos. MBS8584437, MBS9241182, MBS8541252, or MBS8309778.

[0236] In some embodiments, an antibody or antigen-binding fragment thereof that binds to TGFβR2 is selected from antibody clone number 2C10-2G4-6C8, ABT-TGFR2, 2F11, or MBS Catalog Nos. MBS1563955, MBS8541457, MBS179443, MBS8309979, MBS3019813, MBS3019814, or MBS8584638.

[0237] With regard terms such as “specific binding,” “specifically binds to,” or “is specific for” means binding that is measurably different from a non-specific interaction. Specific binding can be measured, for example, by determining binding of a molecule compared to binding of a control molecule, which generally is a molecule of similar structure that does not have binding activity. For example, specific binding can be determined by competition with a control molecule that is similar to the target, for example, an excess of non-labeled target. In this case, specific binding is indicated if the binding of the labeled target to a probe is competitively inhibited by excess unlabeled target. An antibody or an antigen-binding fragment thereof thatspecifically binds to an antigen can be identified, for example, by immunoassays, Octet®, Biacore®, or other techniques known to those of skill in the art. In some embodiments, an antibody or an antigen-binding fragment thereof specifically binds to an antigen when it binds to an antigen with higher affinity than to any cross-reactive antigen as determined using experimental techniques, such as radioimmunoassays (RIA) and enzyme linked immunosorbent assays (ELISAs). Typically, a specific or selective reaction will be at least twice background signal or noise and may be more than 10 times background. See, e.g., Fundamental Immunology 332-36 (Paul ed., 2d ed.1989) for a discussion regarding binding specificity. In some embodiments, the extent of binding of an antibody or an antigen-binding fragment thereof to a “non-target” protein is less than about 10% of the binding of the antibody or antigen-binding fragment thereof to its particular target antigen, for example, as determined by fluorescence activated cell sorting (FACS) analysis or RIA.

[0238] “Binding affinity” generally refers to the strength of the sum total of noncovalent interactions between a single binding site of a molecule (e.g., a binding protein such as an antibody) and its binding partner (e.g., an antigen). Unless indicated otherwise, as used herein, “binding affinity” refers to intrinsic binding affinity which reflects a 1:1 interaction between members of a binding pair (e.g., antibody and antigen). The affinity of a binding molecule X for its binding partner Y can generally be represented by the equilibrium dissociation constant (KD). Affinity can be measured by common methods known in the art, including those described herein. Low-affinity antibodies generally bind antigen slowly and tend to dissociate readily, whereas high-affinity antibodies generally bind antigen faster and tend to remain bound longer. A variety of methods of measuring binding affinity are known in the art, any of which can be used for purposes of the present disclosure. Specific illustrative embodiments include the following. In one embodiment, the “KD” or “KD value” may be measured by assays known in the art, for example by a binding assay. The KD may be measured in a RIA, for example, performed with the Fab version of an antibody of interest and its antigen (Chen et al., 1999, J. Mol Biol 293:865-81). The KD or KD value may also be measured by using biolayer interferometry (BLI) or surface plasmon resonance (SPR) assays by Octet®, using, for example, an Octet®Red96 system, or by Biacore®, using, for example, a Biacore®TM-2000 or a Biacore®TM-3000. An “on-rate” or “rate of association” or “association rate” or “kon” may also be determined with the same biolayer interferometry (BLI) or surface plasmon resonance(SPR) techniques described above using, for example, the Octet®Red96, the Biacore®TM-2000, or the Biacore®TM-3000 system.

[0239] In some embodiments, an antibody(ies) or an antigen-binding fragment thereof binds to a lung cancer antigen. For example, an antibody or an antigen-binding fragment thereof may bind to a lung cancer antigen or a lung metastasis antigen, such as, e.g., MAGE-A3, MAGE-A4, membrane associated glycoprotein (MUC-1), and EGF, GD2, and mesothelin (see below for other examples of lung cancer antigens). In some embodiments, an antibody(ies) or an antigen- binding fragment thereof binds to a lung cancer tumor-associated antigen and / or lung cancer tumor-specific antigen. In some embodiments, an antibody(ies) or an antigen-binding fragment thereof binds to a lung cancer neoantigen. In some embodiments, an antibody or an antigen- binding fragment thereof specifically binds to a lung cancer tumor-associated antigen and / or a tumor-specific antigen. In some embodiments, an antibody(ies) or an antigen-binding fragment thereof binds to a lung metastasis.

[0240] In some embodiments, an agent comprises a peptide or protein or a fragment thereof. In some embodiments, an agent comprises a fragment of peptide or protein associated with a disease, disorder, or condition.

[0241] In some embodiments, an agent competes with a ligand for binding to a receptor. In some embodiments, an agent competes with a receptor for binding to a ligand. In some embodiments, an agent is a decoy of a peptide or protein associated with a disease, disorder, or condition.

[0242] In some embodiments, an agent comprises an antigen (e.g., a cancer antigen, a bacterial antigen, a viral antigen, a fungal antigen, a protozoan antigen, or parasitic antigen). In some embodiments, an agent comprises a tumor-associated antigen (TAA) or tumor-specific antigen. In some embodiments, an agent comprises a neoantigen.

[0243] In some embodiments, an agent comprises a peptide or protein, or a fragment thereof. In some embodiments, an agent comprises a fragment of TGFβR1 (e.g., human TGFβR1) or TGFβR2 (e.g., human TGFβR2), such as, e.g., a protein comprising the TGF-beta binding fragment of TGFβR1 or TGFβR2 that competes with TGFβR1 or TGFβR2 for binding to a TGF- beta cytokine (e.g.. TGFβ1, TGFβ2 or TGFβ3). In some embodiments, the agent is a decoy TGFβR1 (e.g.. human TGFβR1 decoy) or decoy TGFβR2 (e.g,. human TGFβR2 decoy).TGFβR1 and TGFβR2 decoys are known in the art; see, e.g., International Patent Application Publication No. WO 2018 / 138003 and U.S. Patent Application Publication No.2019 / 0352373, which are incorporated in their entity herein; Bollard et al.2002, Blood 99(9): 3179-318; Russo et al.2009, Int J Biochem Cell Biol 41:472-476; Penafuerte et al.2011, J Immunol. 186(12):6933-6944; and Zhang et al.2013, Gene Therapy 20,575-580.

[0244] In some embodiments, an agent comprises an antigen. In some embodiments, an agent comprises two or more antigens (e.g., 2, 3, 4, 5 or more antigens). In some embodiments, an agent comprises a neoantigen. In some embodiments, an antigen comprises two or more neoantigens (2, 3, 4, 5 or more neoantigens). In some embodiments, an agent comprises an epitope. In some embodiments, an agent comprises two or more epitopes. In some embodiments, an agent comprises an epitope of TGFβR1 or TGFβR2 (e.g., human TGFβR1 or human TGFβR2). In some embodiments, an agent comprises two or more epitopes of TGFβR1 or TGFβR2 (e.g., human TGFβR1 or human TGFβR2).

[0245] In some embodiments, an agent comprises a kinase. For example, the agent may be a kinase that modulates the TGFβR1 and / or TGFβR2 signaling pathway. In some embodiments, an agent comprises a phosphatase. For example, the agent may be a phosphatase that modulates the TGFβR1 and / or TGFβR2 signaling pathway.

[0246] In some embodiments, an agent (e.g., a protein or peptide) modulates the phosphorylation of TGFβR1 and / or TGFβR2 or a downstream signaling molecule. In some embodiments, an agent (e.g., a protein or peptide) modulates binding of TGFβR1 and / or TGFβR2 to a TGF-beta cytokine. In some embodiments, an agent (e.g., a protein or peptide) modulates the activation of TGFβR1 and / or TGFβR2 or a downstream signaling molecule.

[0247] In some embodiments, an agent comprises a lung cancer tumor-associated antigen or lung cancer tumor-specific antigen. In some embodiments, an agent comprises an epitope of a lung cancer tumor-associated antigen or a lung cancer tumor-specific antigen. In some embodiments, an agent comprises a lung metastasis antigen.

[0248] In some embodiments, a lung cancer tumor-associated antigen and / or lung cancer tumor-specific antigen is selected from include human epidermal growth factor receptor 2 (HER2), carcinoembryonic antigen (CEA), mucin 1 (MUC1), melanoma-associated antigen 1 (MAGE1), melanoma-associated antigen 3 (MAGE3), melanoma-associated antigen 4(MAGE4), preferentially expressed antigen of melanoma (PRAME), human telomerase reverse transcriptase (hTERT), survivin, six-transmembrane epithelial antigen (STEAP1), SRY-box 2 (SOX2), New York esophageal squamous cell Carcinoma-1 (NY-ESO-1), topoisomerase IIα (TOP2A), actin-related protein 3 (ACTR3), ribosomal protein S6 kinase A5 (RPS6KA5), PC4 and SFRS1 interacting protein 1 (PSIP1), disialoganglioside GD2 (GD2), or mesothelin.

[0249] In some embodiments, an agent comprises a polynucleotide. The polynucleotide may comprise RNA, DNA, or a hybrid thereof. In some embodiments, the polynucleotide is single stranded or double stranded. In some embodiments, the polynucleotide comprises mRNA or cDNA. In some embodiments, the polynucleotide comprises an RNAi-inducing agent, an RNAi agent, an siRNA, an shRNA, a miRNA, or an antisense RNA. In some embodiments, a polynucleotide comprises a ribozyme, a catalytic DNA, an RNA that induces triple helix formation, or aptamer. In a specific embodiment, an agent comprises an RNA molecule. In some embodiments, the RNA molecule comprises a shortmer, agomir, antagomir, antisense RNA, ribozyme, small interfering RNA (siRNA), asymmetrical interfering RNA (aiRNA), microRNA (miRNA), Dicer-substrate RNA, small hairpin RNA (shRNA), transfer RNA (tRNA), messenger RNA (mRNA), circular RNA (circRNA), or other form of RNA molecule known in the art. In some embodiments, a polynucleotide is an inhibitory RNA, such as, e.g., small interfering RNA (siRNA), asymmetrical interfering RNA (aiRNA), microRNA (miRNA), Dicer- substrate RNA, antisense oligonucleotide, or small hairpin RNA (shRNA), that targets TGFβR1 RNA or TGFβR2 RNA. In a specific embodiment, the RNA molecule comprises an miRNA (e.g., an miRNA described in the Example 3, infra). In a specific embodiment, the RNA molecule comprises an siRNA (e.g., an siRNA described in the Example 3 or Example 8, infra). In some embodiments, a polynucleotide is circularized. In some embodiments, a polynucleotide is part of a vector (e.g., a plasmid or viral vector).

[0250] In some embodiments, an agent comprises a double-stranded (ds) RNA or dsRNA- like (e.g., chemically modified RNA) oligonucleotide molecule directed to a target sequence RNA, wherein the dsRNA or dsRNA-like oligonucleotide molecule contains both a sense strand and an antisense strand. In specific embodiments, the dsRNA or dsRNA-like oligonucleotide molecule mediates messenger RNA (mRNA) degradation and / or inhibition of translation of the mRNA in a sequence-specific manner. In some embodiments, the dsRNA or dsRNA-like oligonucleotide reduces or knocks-down a target RNA. In some embodiments, the dsRNA ordsRNA-like oligonucleotide molecule reduces or knocks-down a target protein. In specific embodiments, the dsRNA or dsRNA-like oligonucleotide molecule reduces or knocks-down a target gene expression via an RNA-induced silencing complex (RISC) pathway. The sense strand and the antisense strand of the dsRNA or dsRNA-like (e.g., chemically modified RNA) oligonucleotide molecule may be the same length or different lengths. The sense strand and the antisense strand of the dsRNA agent, the dsRNA, RNA or dsRNA-like (e.g., chemically modified RNA) oligonucleotide molecule can each be 19 to 30 nucleotides in length. In specific embodiments, the sense strand and the antisense strand of the dsRNA or dsRNA-like oligonucleotide molecule are each no more than 30 nucleotides in length. In some embodiments, the sense strand and the antisense strand of the dsRNA or dsRNA-like oligonucleotide molecule are each independently 19 to 30 nucleotides in length. In some embodiments, the sense and the antisense strand of the dsRNA or dsRNA-like oligonucleotide molecule are each independently 20 to 30 nucleotides in length. In some embodiments, the sense and the antisense strand of the dsRNA or dsRNA-like oligonucleotide molecule are each independently 21 to 30 nucleotides in length. In some embodiments, the sense and the antisense strand of the dsRNA or dsRNA-like oligonucleotide molecule are each independently 19 to 25 nucleotides in length. In some embodiments, the sense and the antisense strand of the dsRNA or dsRNA-like oligonucleotide molecule are each independently 20 to 25 nucleotides in length. In certain embodiments, the sense and the antisense strand of the dsRNA or dsRNA-like oligonucleotide molecule are each independently 21 to 25 nucleotides in length. In some embodiments, the ds RNA or ds-RNA like oligonucleotide is an siRNA.

[0251] In some embodiments, an agent comprises a double-stranded (ds) RNA or dsRNA- like (e.g., chemically modified RNA) oligonucleotide molecule directed to a target sequence of TGFβR1 RNA, wherein the dsRNA or dsRNA-like oligonucleotide molecule contains both a sense strand and an antisense strand. In specific embodiments, the dsRNA or dsRNA-like oligonucleotide molecule mediates messenger RNA (mRNA) degradation and / or inhibition of translation of the mRNA in a sequence-specific manner. In some embodiments, the dsRNA or dsRNA-like oligonucleotide reduces or knocks-down TGFβR1 RNA. In some embodiments, the dsRNA or dsRNA-like oligonucleotide molecule reduces or knocks-down TGFβR1 RNA and TGFβR1 protein. In specific embodiments, the dsRNA or dsRNA-like oligonucleotide molecule reduces or knocks-down TGFβR1 gene expression via an RNA-induced silencing complex(RISC) pathway. The sense strand and the antisense strand of the dsRNA or dsRNA-like (e.g., chemically modified RNA) oligonucleotide molecule may be the same length or different lengths. The sense strand and the antisense strand of the dsRNA agent, the dsRNA, RNA or dsRNA-like (e.g., chemically modified RNA) oligonucleotide molecule can each be 19 to 30 nucleotides in length. In specific embodiments, the sense strand and the antisense strand of the dsRNA or dsRNA-like oligonucleotide molecule are each no more than 30 nucleotides in length. In some embodiments, the sense strand and the antisense strand of the dsRNA or dsRNA-like oligonucleotide molecule are each independently 19 to 30 nucleotides in length. In some embodiments, the sense and the antisense strand of the dsRNA or dsRNA-like oligonucleotide molecule are each independently 20 to 30 nucleotides in length. In some embodiments, the sense and the antisense strand of the dsRNA or dsRNA-like oligonucleotide molecule are each independently 21 to 30 nucleotides in length. In some embodiments, the sense and the antisense strand of the dsRNA or dsRNA-like oligonucleotide molecule are each independently 19 to 25 nucleotides in length. In some embodiments, the sense and the antisense strand of the dsRNA or dsRNA-like oligonucleotide molecule are each independently 20 to 25 nucleotides in length. In certain embodiments, the sense and the antisense strand of the dsRNA or dsRNA-like oligonucleotide molecule are each independently 21 to 25 nucleotides in length. In some embodiments, the ds RNA or ds-RNA like oligonucleotide is an siRNA.

[0252] In some embodiments, an agent comprises a double-stranded (ds) RNA or dsRNA- like (e.g., chemically modified RNA) oligonucleotide molecule directed to a target sequence of TGFβR2 RNA, wherein the dsRNA or dsRNA-like oligonucleotide molecule contains both a sense strand and an antisense strand. In specific embodiments, the dsRNA or dsRNA-like oligonucleotide molecule mediates messenger RNA (mRNA) degradation and / or inhibition of translation of the mRNA in a sequence-specific manner. In some embodiments, the dsRNA or dsRNA-like oligonucleotide reduces or knocks-down TGFβR2 RNA. In some embodiments, the dsRNA or dsRNA-like oligonucleotide molecule reduces or knocks-down TGFβR2 RNA and TGFβR2 protein. In specific embodiments, the dsRNA or dsRNA-like oligonucleotide molecule reduces or knocks-down TGFβR2 gene expression via an RNA-induced silencing complex (RISC) pathway. The sense strand and the antisense strand of the dsRNA or dsRNA-like (e.g., chemically modified RNA) oligonucleotide molecule may be the same length or different lengths. The sense strand and the antisense strand of the dsRNA agent, the dsRNA, RNA ordsRNA-like (e.g., chemically modified RNA) oligonucleotide molecule can each be 19 to 30 nucleotides in length. In specific embodiments, the sense strand and the antisense strand of the dsRNA or dsRNA-like oligonucleotide molecule are each no more than 30 nucleotides in length. In some embodiments, the sense strand and the antisense strand of the dsRNA or dsRNA-like oligonucleotide molecule are each independently 19 to 30 nucleotides in length. In some embodiments, the sense and the antisense strand of the dsRNA or dsRNA-like oligonucleotide molecule are each independently 20 to 30 nucleotides in length. In some embodiments, the sense and the antisense strand of the dsRNA or dsRNA-like oligonucleotide molecule are each independently 21 to 30 nucleotides in length. In some embodiments, the sense and the antisense strand of the dsRNA or dsRNA-like oligonucleotide molecule are each independently 19 to 25 nucleotides in length. In some embodiments, the sense and the antisense strand of a the dsRNA or dsRNA-like oligonucleotide molecule are each independently 20 to 25 nucleotides in length. In certain embodiments, the sense and the antisense strand of the dsRNA or dsRNA-like oligonucleotide molecule are each independently 21 to 25 nucleotides in length. In some embodiments, the ds RNA or ds-RNA like oligonucleotide is an siRNA.

[0253] The double stranded region formed by hybridization of the antisense strand and the sense strand of the dsRNA or dsRNA-like oligonucleotide molecule may be the entire length of both strands. For example, the antisense strand of the dsRNA or dsRNA-like oligonucleotide molecule may be 19 nucleotides in length, the sense strand of the dsRNA or dsRNA-like oligonucleotide molecule may be 19 nucleotides in length, and the double strand region formed by hybridization of the strands is 19 nucleotides. In a specific embodiment, the double-strand region of the dsRNA or dsRNA-like oligonucleotide molecule is long enough to serve as a substrate for the Dicer enzyme. In certain embodiments, the double strand region of the dsRNA or dsRNA-like oligonucleotide molecule is 15 to 30 base pairs in length. For example, the double strand region of a dsRNA or dsRNA-like oligonucleotide molecule described herein may be 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19- 28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24, 20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 base pairs in length. Ranges and lengths intermediate to the above recited ranges and lengths are also contemplated to be part of the disclosure. In some embodiments, the dsRNA ordsRNA-like oligonucleotide molecule comprises a double stranded region greater than 30 base pairs length and is processed to a functional duplex of, e.g., 15 to 30 base pairs, that targets the target sequence for cleavage. In some embodiments, a dsRNA or dsRNA-like oligonucleotide molecule described herein is siRNA. In specific embodiments, the dsRNA or dsRNA-like oligonucleotide molecule is not naturally occurring (e.g., is not a naturally occurring siRNA). In some embodiments, the dsRNA or dsRNA-like oligonucleotide molecule does not comprise a double stranded region of greater than 30 base pairs that is cleaved or otherwise processed to produce a functional duplex of, e.g., 15 to 30 base pairs, that targets the target sequence for cleavage. In some embodiments, the dsRNA or dsRNA-like oligonucleotide molecule is blunt ended. In some embodiments, the sense strand or the antisense strand of the dsRNA or dsRNA- like oligonucleotide molecule comprises an overhang. The overhang may be at the 5’ end, the 3’ end, or both the 5’ and 3’ end of either the sense strand or antisense strand of the dsRNA or dsRNA-like oligonucleotide molecule. In some embodiments, the sense strand and the antisense strand of the dsRNA or dsRNA-like oligonucleotide molecule comprise an overhang. The overhang of the sense strand may be at the 5’ end of the sense strand, and the overhang of the antisense strand may be at the 3’ end of the antisense strand. Alternatively, the overhang of the sense strand may be at the 3’ end of the sense strand, the overhang of the antisense strand may be at the 5’ end of the antisense strand. In certain embodiments, the overhang of a strand of the dsRNA or dsRNA-like oligonucleotide molecule comprises 1 to 5 nucleotides, 1 to 4 nucleotides, 1 to 3 nucleotides, or 1 to 2 nucleotides. In some embodiments, the overhang of a strand of the dsRNA or dsRNA-like oligonucleotide molecule comprises 2 to 5 nucleotides, 2 to 4 nucleotides, 2 to 3 nucleotides, 3 to 4 nucleotides, 3 to 4 nucleotides, or 4 to 5 nucleotides.

[0254] In some embodiments, the antisense strand of the dsRNA or dsRNA-like oligonucleotide molecule hybridizes to a particular region of a target RNA. For example, the antisense strand of the dsRNA or dsRNA-like oligonucleotide molecule hybridizes to a region of a particular exon of a target RNA. In another example, the antisense strand of the dsRNA or dsRNA-like molecule hybridizes to an untranslated region of a target RNA.

[0255] In some embodiments, the antisense strand of the dsRNA or dsRNA-like oligonucleotide molecule hybridizes to a particular region of TGFβR1 RNA or TGFβR2 RNA. For example, the antisense strand of the dsRNA or dsRNA-like oligonucleotide molecule hybridizes to a region of a particular exon of TGFβR1 RNA or TGFβR2 RNA. In anotherexample, the antisense strand of the dsRNA or dsRNA-like molecule hybridizes to an untranslated region of TGFβR1 RNA or TGFβR2 RNA. In some embodiments, the TGFβR1 RNA or TGFβR2 RNA is a transcript in Table 1 or 2, above.

[0256] As used herein, “target sequence” refers to a contiguous portion of a nucleotide sequence of a RNA molecule formed during the transcription of a target gene, for example a TGFβR1 gene (e.g., a human TGFβR1 gene) or a TGFβR2 gene (e.g., a human TGFβR2 gene), including mRNA that is a product of RNA processing of a primary transcription product (e.g., TGFβR1 or TGFβR2 mRNA) resulting from alternate splicing). In some embodiments, the contiguous portion of the nucleotide sequence is at least long enough to serve as a substrate for RNAi-directed cleavage at or near that portion of the nucleotide sequence of an mRNA molecule formed during the transcription of a target gene, for example a TGFβR1 gene (e.g., a human TGFβR1 gene) or TGFβR2 gene (e.g., a human TGFβR2 gene). In specific embodiments, the target sequence is about 15-30 nucleotides in length. For example, the target sequence can be from about 15-30 nucleotides, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 18-30, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20- 30, 20-25, 20-24,20-23, 20-22, 20-21, 21-30, 21-25, 21-24, 21-23, or 21-22 nucleotides in length. In some embodiments, the target sequence is 19-25 nucleotides in length. In some embodiments, the target sequence is 21-23 nucleotides in length. Ranges and lengths intermediate to the above recited ranges and lengths are also contemplated to be part of the disclosure. In specific embodiments, the target sequence comprises human TGFβR1 or human TGFβR2.

[0257] In a specific embodiment, the agent comprises siRNA directed to TGFβR1 (e.g., human TGFβR1), such as, e.g., an siRNA described in Example 3 or 8, infra. In some embodiments, the agent comprises the siRNA mouse TGFβR1 in Example 3 or 8, which comprises the sense strand of SEQ ID NO:5 and the antisense strand of SEQ ID NO:6. In a specific embodiment, the agent comprises the siRNA human TGFβR1 in Example 3 or 8, which comprises the sense strand of SEQ ID NO:7 and the antisense strand of SEQ ID NO:8. Without wishing to be bound by the theory, the agent comprising siRNA directed to TGFβR1 is useful in methods of treating endothelial-dependent disorders because TGFβR1 is expressed at very low levels in normal human endothelial cells and is upregulated in said disorders. Without wishing to be bound by the theory, the agent comprising siRNA directed to TGFβR1 is useful in methods of treating pulmonary hypertension (PH) because TGFβR1 is a PH disease-causing gene. Incertain embodiments, targeted delivery of the agent comprising siRNA directed to TGFβR1 minimizes or avoids systemic inhibition of TGFβ signaling and associated systemic pro- inflammatory effects. In some embodiments, targeted delivery of the agent comprising siRNA directed to TGFβR1 reduces the systemic side effect that may damage normal tissues and organs. In some embodiments, targeted delivery of the agent comprising siRNA directed to TGFβR1 reduces or bypasses the toxicities of global TGFβ inhibition.

[0258] In some embodiments, the agent comprises the siRNA targeting mouse TGFβR1 RNA referred to as S1 in Lai et al., J Environ Pathol Toxicol Oncol.2009; 28(2): 109–119 ((GAAGCGGACUACUAUGCUAUU (sense, 5’–3’; SEQ ID NO:13) and UUCUUCGCCUGAUGAUACGAU-P (antisense, 3’–5’; SEQ ID NO:14)). In some embodiments, the agent comprises the siRNA targeting mouse TGFβR1 RNA referred to as S2 in Lai et al., J Environ Pathol Toxicol Oncol.2009; 28(2): 109–119 ((AGGCGGUGCUCGCUUUGUAUU (sense, 5’–3’; SEQ ID NO:15) and UUUCCGCCACGAGCGAAACAU-P (antisense, 3’–5’; SEQ ID NO:16)). In some embodiments, the agent comprises the siRNA targeting mouse TGFβR1 RNA referred to as S3 in Lai et al., J Environ Pathol Toxicol Oncol.2009; 28(2): 109–119 ((ACAACGCCAUCUAUGAGAAUU (sense, 5’–3’; SEQ ID NO:17) and UUTGUUGCGGUAGAUAGUCUU-P (antisense, 3’–5’; SEQ ID NO:18)). In some embodiments, the agent comprises the siRNA targeting mouse TGFβR1 RNA referred to as S3 in Lai et al., J Environ Pathol Toxicol Oncol.2009; 28(2): 109–119 ((GAAACGGAAGCGCAUCGAAUU (sense, 5’–3’; SEQ ID NO:19) and UUCUUUGCCUUCGCGUAGCUU-P (antisense, 3’–5’; SEQ ID NO:20)).

[0259] In specific embodiments, the agent comprises an siRNA or shRNA of Santa Cruz Biotechnology catalog number sc-40222.

[0260] In specific embodiments, the agent comprises siRNA directed to TGFβR2 (e.g., human TGFβR2). In some embodiments, the agent comprises an siRNA or shRNA of Santa Cruz Biotechnology catalog number sc-36657.

[0261] In some embodiments, the agent comprises a Clustered Regularly Interspaced Short Palindromic Repeats (“CRISPR”) system.

[0262] In some embodiments, the agent is a diagnostic agent or detectable agent (e.g., fluorescent agent, radioactive agent, or chemical agent). In some embodiments, the diagnostic or detectable agent is a protein (e.g., fluorescent protein, radioactive protein, or enzyme). In some embodiments, the diagnostic or detectable agent is targeted by a detectable reagent (e.g., a fluorescent antibody, radioactive antibody, or enzyme that binds to the diagnostic or detectable agent). In some embodiments, a diagnostic agent or detectable agent comprises a gas; a metal; a commercially available imaging agent used in positron emissions tomography (PET), computer assisted tomography (CAT), single photon emission computerized tomography, x-ray, fluoroscopy, or magnetic resonance imaging (MRI); or a contrast agent. In some embodiments, the diagnostic agent or detectable agent is suitable for use in MRI (e.g., an MRI contrast agent such as gadolinium chelate, iron, magnesium, manganese, copper, or chromium). In some embodiments, the diagnostic agent or detectable agent is suitable for CAT and x-ray imaging (e.g., an iodine-based material).

[0263] In some embodiments, a diagnostic agent or detectable agent has a mass of about 10 kilodaltons (kDa) to about 50 kDa. In some embodiments, a diagnostic agent or detectable agent has a mass of about 15 kDa to about 50 kDa. In some embodiments, diagnostic agent or detectable agent has a mass of about 20 kDa to about 50 kDa. In some embodiments, a diagnostic agent or detectable agent has a mass of about 25 kDa to about 50 kDa. In some embodiments, a diagnostic agent or detectable agent has a mass of about 30 kDa to about 50 kDa. In some embodiments, a diagnostic agent or detectable agent has a mass of about 40 kDa to about 50 kDa. In some embodiments, a diagnostic agent or detectable agent has a mass of about 10 kDa to about 25 kDa. In some embodiments, a diagnostic agent or detectable agent has a mass of about 10 kDa, about 20 kDa, about 30 kDa, about 40 kDa, or about 50 kDa. In some embodiments, a diagnostic agent or detectable agent has a mass of less than about 50 kDa. In some embodiments, a diagnostic agent or detectable agent has a mass of less than about 45 kDa, less than about 40 kDa, less than about 35 kDa, less than about 30 kDa, less than about 25 kDa, less than about 20 kDa, or less than about 15 kDa. In some embodiments, a diagnostic agent or detectable agent has a mass of less than about 50 kDa. In some embodiments, a diagnostic agent or detectable agent is negatively supercharged. In some embodiments, a diagnostic agent or detectable agent has a mass of less than about 50 kDa and is negatively supercharged. In someembodiments, a diagnostic agent or detectable agent has a mass of about 1 kDa to about 50 kDa and is negatively supercharged.

[0264] In some embodiments, the agent comprises an antibiotic, nutritional supplement, or vaccine. In some embodiments, a vaccine comprises passive or active immunization. In some embodiments, a vaccine comprises an isolated protein or peptide, an inactivated organism or virus, a dead organism or virus, a genetically altered organism or virus, or a cell extract. In some embodiments, an agent comprises an antigen of bacterial, fungal, protozoan, or parasitic organism. These antigens may be in the form of a whole killed organism, peptide, protein, glycoprotein, carbohydrate, or combinations thereof.

[0265] In some embodiments, the agent to be delivered may be a mixture of agents described herein.

[0266] In some embodiments, the compounds described herein, and the complexes, liposomes, micelles, and particles (e.g., nanoparticles), prepared therefrom, may be modified to include a targeting agent since it is often desirable to target a particular cell, collection of cells, or tissue. A variety of targeting agents that direct pharmaceutical compositions to particular cells are known in the art (see, for example, Cotten et al., Methods Enzym.217:618, 1993; incorporated herein by reference). A targeting agent may be included throughout the particle or may be only on the surface. The targeting agent may be a protein, peptide, carbohydrate, glycoprotein, lipid, small molecule, nucleic acid, etc. The targeting agent may be used to target specific cells or tissues or may be used to promote endocytosis or phagocytosis of the particle. Examples of targeting agents include, but are not limited to, an antibody, fragment of an antibody (e.g., a functional antibody fragment), antigen-binding fragment of an antibody, low- density lipoprotein (LDL), transferrin, asialycoproteins, carbohydrate, receptor ligand, sialic acid, aptamer, etc. If the targeting agent is included throughout the particle, the targeting agent may be included in the mixture that is used to form the particles. If the targeting agent is only on the surface, the targeting agent may be covalently bonded to or associated with (e.g., by ionic, hydrophobic, hydrogen bonding, electrostatic, van der Waals, or other interactions) the formed particles using standard chemical techniques. In some embodiments, a particle (e.g., a nanoparticle) described herein does not comprise a targeting agent.

[0267] The payload of a particle (e.g., nanoparticle) described herein can be any agent described herein. In some embodiments, an agent comprises one or more peptides, proteins, or a fragment thereof (e.g., a negatively supercharged peptide, protein, or a fragment thereof) as the payload. The peptide, protein, or fragment thereof may be one described herein. For example, the peptide, protein or fragment thereof may be an antigen, antibody, decoy, kinase, or phosphatase.

[0268] In some embodiments, an agent comprises one or more polynucleotides (e.g., siRNA, miRNA, mRNA, or other types of RNA, or DNA molecules) as the payload. In some embodiments, the one or more polynucleotides (e.g., siRNA, miRNA, mRNA, or other types of RNA or DNA molecules) is conjugated or linked (directly or indirectly) to a targeting agent. The compounds disclosed herein are particularly useful in the administration of polynucleotides. For example, the compounds of Formula (I) possess tertiary amines, and although these amines are hindered, they are available to interact with a polynucleotide (e.g., DNA, RNA, synthetic analogs of DNA and / or RNA, DNA / RNA hydrids, etc.). Polynucleotides or derivatives thereof are contacted with the compounds disclosed herein under conditions suitable to form polynucleotide / lipomer complexes.

[0269] Without being bound by theory, the interaction of the lipomer compounds disclosed herein (e.g., compounds of Formula (I)) with a polynucleotide is thought to at least partially prevent the degradation of the polynucleotide. By neutralizing the charge on the backbone of the polynucleotide, the neutral or slightly-positively-charged complex is also able to more easily pass through the hydrophobic membranes (e.g., cytoplasmic, lysosomal, endosomal, nuclear) of the cell. In certain embodiments, the complex is slightly positively charged. In certain embodiments, the complex has a positives-potential, more preferably the ζ-potential is between 0 and +30.

[0270] The lipomer compounds disclosed herein (e.g., compounds of Formula (I)) are preferably at least partially provided as a salt (i.e., is protonated) so as to form a complex with the negatively charged polynucleotide. In certain embodiments, the resulting polynucleotide / lipomer complexes form particles that are useful in the delivery of polynucleotides to cells. In certain embodiments, more than one lipomer may be associated witha polynucleotide molecule. For example, the complex may include 1-100 lipomers, 1-1000 lipomers, 10-1000 lipomers, or 100-10,000 lipomers.

[0271] In some embodiments, the complex may form a particle. The size of particle formed varies based on the payload to be delivered (e.g., agent and / or compound used). In some embodiments, the diameter of a particle or the average diameter of a plurality of the particles ranges from 10-150 nm. In certain embodiments, the diameter of a particle or the average diameter of a plurality of the particles ranges from 10-100 nm. In certain embodiments, the diameter of a particle or the average diameter of a plurality of particles ranges from about 25 to about 70 nm. In certain embodiments, the diameter of a particle or the average diameter of a plurality of particles ranges from about 35 to about 60 nm. In certain embodiments, the diameter of a particle or the average diameter of a plurality of particles ranges from about 40 nm to about 50 nm. In certain embodiments, the diameter of a particle or the average diameter of a plurality of particles ranges from about 50 nm to about 100 nm. In certain embodiments, the diameter of a particle or the average diameter of a plurality of particles ranges from about 1 to about 5 nm. In some embodiments, the diameter of a particle or the average diameter of a plurality of particles is about 10 nm, about 11 nm, about 12 nm, about 13 nm, about 14 nm, about 15 nm, about 16 nm, about 17 nm, about 18 nm, about 19 nm, about 20 nm. In specific embodiments, the diameter of a particle or the average diameter of a plurality of particles is about 21 nm, about 22 nm, about 23 nm, about 24 nm, about 25 nm, about 26 nm, about 27 nm, about 28 nm, about 29 nm, or about 30 nm. In some embodiments, the diameter of a particle or the average diameter of a plurality of particles is about 31 nm, about 32 nm, about 33 nm, about 34 nm, about 35 nm, about 36 nm, about 37 nm, about 38 nm, about 39 nm, or about 40 nm. In some embodiments, the diameter of a particle or the average diameter of a plurality of particles is about 41 nm, about 42 nm, about 43 nm, about 44 nm, about 45 nm, about 46 nm, about 47 nm, about 48 nm, about 49 nm, or about 50 nm. In some embodiments, the diameter of a particle or the average diameter of a plurality of particles is about 51 nm, about 52 nm, about 53 nm, about 54 nm, about 55 nm, about 56 nm, about 57 nm, about 58 nm, about 59 nm, or about 60 nm. In some embodiments, the diameter of a particle or the average diameter of a plurality of particles is about 61 nm, about 62 nm, about 63 nm, about 64 nm, about 65 nm, about 66 nm, about 67 nm, about 68 nm, about 69 nm, or about 70 nm. In some embodiments, the diameter of a particle or the average diameter of a plurality of particles is about 71 nm, about 72 nm, about 73 nm, about 74 nm, about 75 nm,about 76 nm, about 77 nm, about 78 nm, about 79 nm, or about 80 nm. In some embodiments, the diameter of a particle or the average diameter of a plurality of particles is about 81 nm, about 82 nm, about 83 nm, about 84 nm, about 85 nm, about 86 nm, about 88 nm, about 88 nm, about 89 nm, or about 90 nm. In some embodiments, the diameter of a particle or the average diameter of a plurality of particles is about 91 nm, about 92 nm, about 93 nm, about 94 nm, about 95 nm, about 96 nm, about 97 nm, about 98 nm, about 99 nm, or about 100 nm. In some embodiments, the diameter of a particle or the average diameter of a plurality of particles is about 110 nm, about 130 nm, about 140 nm, or about 150 nm. In some embodiments, the diameter of a particle or the average diameter of a plurality of particles is about a size set forth in FIG.11A.

[0272] The particles may be associated with a targeting agent as described below. The film architecture is precisely designed and can be controlled to 1 nm precision with a range from 1 to 100 nm and with a definite knowledge of its molecular composition.

[0273] The polynucleotide may be complexed, encapsulated by the present lipomers (e.g., compounds of Formula (I)), or included in a composition comprising the present lipomers.

[0274] Exemplary forms of polynucleotides that can be included as payload include, but are not limited to, one or more of deoxyribonucleic acid (DNA), ribonucleic acid (RNA) including messenger mRNA (mRNA), hybrids thereof, RNAi-inducing agents, RNAi agents, siRNAs, shRNAs, miRNAs, antisense RNAs, ribozymes, catalytic DNA, RNAs that induce triple helix formation, aptamers, vectors, etc. In some embodiments, the payload comprises an RNA. RNA molecules that can be included as the payload include, but are not limited to, shortmers, agomirs, antagomirs, antisense, ribozymes, small interfering RNA (siRNA), asymmetrical interfering RNA (aiRNA), microRNA (miRNA), Dicer-substrate RNA (dsRNA), small hairpin RNA (shRNA), transfer RNA (tRNA), messenger RNA (mRNA), circular RNA (circRNA), and other forms of RNA molecules known in the art. In some embodiments, the RNA is an mRNA.

[0275] In some embodiments, the polynucleotide is an antisense RNA. In some embodiments, the polynucleotide is an antisense RNA that targets TGFβR1 (e.g., human TGFβR1) RNA or TGFβR2 (e.g., human TGFβR2) RNA.

[0276] In some embodiments, dsRNA, siRNA, shRNA, miRNA, mRNA, and / or antisense RNA can be designed and / or predicted using one or more of a large number of available algorithms. To give but a few examples, the following resources can be utilized to design and / orpredict dsRNA, siRNA, shRNA, miRNA, and / or mRNA: algorithms found at Alnylum Online, Dharmacon Online, OligoEngine Online, Molecula Online, Ambion Online, BioPredsi Online, RNAi Web Online, Chang Bioscience Online, Invitrogen Online, LentiWeb Online GenScript Online, Protocol Online; Reynolds et al., 2004, Nat. Biotechnol., 22:326; Naito et al., 2006, Nucleic Acids Res., 34:W448; Li et al., 2007, RNA, 13:1765; Yiu et al., 2005, Bioinformatics, 21:144; and Jia et al., 2006, BMC Bioinformatics, 7: 271; each of which is incorporated herein by reference).

[0277] In some embodiments, the polynucleotides that can be included as the payload comprises a siRNA molecule. Particularly, in some embodiments, the siRNA molecule is capable of selectively interfering with and downregulating the expression of a gene of interest (e.g., a target gene). In some embodiments, the siRNA molecule mediates messenger RNA (mRNA) degradation and / or inhibition of translation of the mRNA in a sequence-specific manner. In some embodiments, the siRNA molecule reduces or knocks-down a target RNA. In some embodiments, the siRNA molecule reduces or knocks-down a target protein. In some embodiments, the siRNA molecule reduces or knocks-down TGFβR2 RNA. In some embodiments, the siRNA payload selectively silences a gene associated with a particular disease, disorder, or condition upon administration to a subject in need thereof of a particle (e.g., nanoparticle) composition including the siRNA. In some embodiments, the siRNA molecule comprises a sequence that is complementary to an mRNA sequence encoding a protein product of interest (e.g., a target protein). Particularly, in some embodiments, the siRNA molecule is capable of selectively interfering with and downregulating the expression of the TGFβR1 gene (e.g., human TGFβR1 gene) or TGFβR2 gene (e.g., human TGFβR2 gene). In some embodiments, the siRNA molecule mediates messenger RNA (mRNA) degradation and / or inhibition of translation of the mRNA in a sequence-specific manner. In some embodiments, the siRNA molecule reduces or knocks-down TGFβR1 RNA. In some embodiments, the siRNA molecule reduces or knocks-down TGFβR1 RNA and TGFβR1 protein. In some embodiments, the siRNA molecule reduces or knocks-down TGFβR2 RNA. In some embodiments, the siRNA molecule reduces or knocks-down TGFβR2 RNA and TGFβR2 protein. In some embodiments, the siRNA payload selectively silences TGFβR1 gene (e.g., human TGFβR1 gene) or TGFβR2 gene (e.g., human TGFβR2 gene) expression upon administration to a subject in need thereof of a nanoparticle composition including the siRNA. In some embodiments, the siRNA moleculecomprises a sequence that is complementary to an mRNA sequence encoding a protein product of interest. In some embodiments, the siRNA is one described in Example 3 or Example 8.

[0278] In some embodiments, the polynucleotides that can be included as the payload comprises a shRNA molecule. In some embodiments, the polynucleotides that can be included as the payload comprises a shRNA molecule that targets TGFβR1 RNA (e.g., human TGFβR1 RNA) or TGFβR2 RNA (e.g., human TGFβR2 RNA) or a vector encoding the shRNA molecule. In some embodiments, the payload, upon administering to a target cell, produces shRNA inside the target cell. Constructs and mechanisms relating to shRNA are well known in the relevant arts.

[0279] In some embodiments, the polynucleotides that can be included as the payload comprises an mRNA molecule. Particularly, in some embodiments, the mRNA molecule encodes a polypeptide of interest, including any naturally or non-naturally occurring or otherwise modified polypeptide. A polypeptide encoded by an mRNA may be of any size and may have any secondary structure or activity. In some embodiments, the polypeptide encoded by an mRNA payload can have a beneficial (e.g., therapeutic) effect when expressed in a cell. In some embodiments, the polypeptide is an antibody or fragment thereof (e.g., Fab). In some embodiments, the polynucleotides that can be included as the payload comprises an mRNA molecule that encodes a protein comprising a fragment of TGFβR1 (e.g., human TGFβR1) or a fragment of TGFβR2 (e.g., human TGFβR2). In some embodiments, the polynucleotides that can be included as the payload comprises an mRNA molecule that encodes an antigen described herein. In some embodiments, the polynucleotides that can be included as the payload comprises an mRNA molecule that encodes an antibody or an antigen-binding fragment thereof. In some embodiments, the peptide or protein is naturally or non-naturally occurring or an otherwise modified peptide or protein. In some embodiments, the peptide or protein encoded by an mRNA payload can have a therapeutic effect when expressed in a cell.

[0280] In some embodiments, a nucleic acid molecule of the present disclosure comprises an mRNA molecule. In specific embodiments, the nucleic acid molecule comprises at least one coding region encoding a peptide or protein of interest (e.g., an open reading frame (ORF)). In some embodiments, the peptide or protein is an antigen. In some embodiments, the peptide or protein is an antibody or an antigen-binding fragment thereof (e.g., Fab). In some embodiments,the peptide or protein comprises a fragment of TGFβR1 (e.g., human TGFβR1) or a fragment of TGFβR2 (e.g., human TGFβR2). In some embodiments, the fragment of TGFβR1 (e.g., human TGFβR1) or TGFβR2 (e.g., human TGFβR2) comprises the extracellular domain of TGFβR1 or TGFβR2, respectively, or the fragment of TGFβR1 or TGFβR2 that binds to a TGFβ cytokine (e.g., TGFβ1, TGFβ2, or TGFβ3). In some embodiments, the peptide or protein comprises a TGFβR1 decoy (e.g., a human TGFβR1 decoy) or a TGFβR2 decoy (e.g., a human TGFβR2 decoy). In some embodiments, the nucleic acid molecule further comprises at least one untranslated region (UTR). In particular embodiments, the untranslated region (UTR) is located upstream (to the 5’-end) of the coding region, and is referred to herein as the 5’-UTR. In particular embodiments, the untranslated region (UTR) is located downstream (to the 3’-end) of the coding region, and is referred to herein as the 3’-UTR. In particular embodiments, the nucleic acid molecule comprises both a 5’-UTR and a 3’-UTR. In some embodiments, the 5’- UTR comprises a 5’-Cap structure. In some embodiments, the nucleic acid molecule comprises a Kozak sequence (e.g., in the 5’-UTR). In some embodiments, the nucleic acid molecule comprises a poly-A region (e.g., in the 3’-UTR). In some embodiments, the nucleic acid molecule comprises a polyadenylation signal (e.g., in the 3’-UTR). In some embodiments, the nucleic acid molecule comprises stabilizing region (e.g., in the 3’-UTR). In some embodiments, the nucleic acid molecule comprises a secondary structure. In some embodiments, the secondary structure is a stem-loop. In some embodiments, the nucleic acid molecule comprises a stem-loop sequence (e.g., in the 5’-UTR and / or the 3’-UTR). In some embodiments, the nucleic acid molecule comprises one or more intronic regions capable of being excised during splicing. In a specific embodiment, the nucleic acid molecule comprises one or more region selected from a 5’-UTR, and a coding region. In a specific embodiment, the nucleic acid molecule comprises one or more region selected from a coding region and a 3’-UTR. In a specific embodiment, the nucleic acid molecule comprises one or more region selected from a 5’-UTR, a coding region, and a 3’-UTR.

[0281] In some embodiments, the nucleic acid molecule of the present disclosure comprises at least one coding region. In some embodiments, the coding region is an open reading frame (ORF) that encodes for a single peptide or protein. In some embodiments, the coding region comprises at least two ORFs, each encoding a peptide or protein. In those embodiments where the coding region comprises more than one ORFs, the encoded peptides and / or proteins can bethe same as or different from each other. In some embodiments, the multiple ORFs in a coding region are separated by non-coding sequences. In specific embodiments, a non-coding sequence separating two ORFs comprises an internal ribosome entry sites (IRES).

[0282] Without being bound by the theory, it is contemplated that an internal ribosome entry sites (IRES) can act as the sole ribosome binding site, or serve as one of multiple ribosome binding sites of an mRNA. An mRNA molecule containing more than one functional ribosome binding site can encode several peptides or polypeptides that are translated independently by the ribosomes (e.g., multicistronic mRNA). Accordingly, in some embodiments, the nucleic acid molecule of the present disclosure (e.g., mRNA) comprises one or more internal ribosome entry sites (IRES).

[0283] In various embodiments, the nucleic acid molecule of the present disclosure encodes for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more than 10 peptides or proteins. Peptides and proteins encoded by a nucleic acid molecule can be the same or different. In some embodiments, the nucleic acid molecule of the present disclosure encodes a dipeptide (e.g., camosine and anserine). In some embodiments, the nucleic acid molecule encodes a tripeptide. In some embodiments, the nucleic acid molecule encodes a tetrapeptide. In some embodiments, the nucleic acid molecule encodes a pentapeptide. In some embodiments, the nucleic acid molecule encodes a hexapeptide. In some embodiments, the nucleic acid molecule encodes a heptapeptide. In some embodiments, the nucleic acid molecule encodes an octapeptide. In some embodiments, the nucleic acid molecule encodes a nonapeptide. In some embodiments, the nucleic acid molecule encodes a decapeptide.

[0284] In some embodiments, the nucleic acid molecule encodes a peptide or polypeptide that has at least about 15 amino acids. In some embodiments, the nucleic acid molecule encodes a peptide or polypeptide that has at least about 50 amino acids. In some embodiments, the nucleic acid molecule encodes a peptide or polypeptide that has at least about 100 amino acids. In some embodiments, the nucleic acid molecule encodes a peptide or polypeptide that has at least about 150 amino acids. In some embodiments, the nucleic acid molecule encodes a peptide or polypeptide that has at least about 300 amino acids. In some embodiments, the nucleic acid molecule encodes a peptide or polypeptide that has 15 to 50, 50 to 100, 100 to 200, or 200 to 500 amino acids.

[0285] In some embodiments, the nucleic acid molecule of the present disclosure is at least about 15 nucleotides (nt) in length. In some embodiments, the nucleic acid molecule of the present disclosure is at least about 20 nucleotides (nt) in length. In some embodiments, the nucleic acid molecule of the present disclosure is at least about 30 nucleotides (nt) in length. In some embodiments, the nucleic acid molecule is at least about 35 nt in length. In some embodiments, the nucleic acid molecule is at least about 40 nt in length. In some embodiments, the nucleic acid molecule is at least about 45 nt in length. In some embodiments the nucleic acid molecule is at least about 50 nt in length. In some embodiments, the nucleic acid molecule is at least about 55 nt in length. In some embodiments, the nucleic acid molecule is at least about 60 nt in length. In some embodiments, the nucleic acid molecule is at least about 65 nt in length. In some embodiments, the nucleic acid molecule is at least about 70 nt in length. In some embodiments, the nucleic acid molecule is at least about 75 nt in length. In some embodiments, the nucleic acid molecule is at least about 80 nt in length. In some embodiments the nucleic acid molecule is at least about 85 nt in length. In some embodiments, the nucleic acid molecule is at least about 90 nt in length. In some embodiments, the nucleic acid molecule is at least about 95 nt in length. In some embodiments, the nucleic acid molecule is at least about 100 nt in length. In some embodiments, the nucleic acid molecule is at least about 120 nt in length. In some embodiments, the nucleic acid molecule is at least about 140 nt in length. In some embodiments, the nucleic acid molecule is at least about 160 nt in length. In some embodiments, the nucleic acid molecule is at least about 180 nt in length. In some embodiments, the nucleic acid molecule is 10 to 100 nt, 10 to 50 nt, 50 to 100 nt, or 100 to 180 nt in length. In some embodiments, the nucleic acid molecule is 1000 to 2000 nt, 2000 to 5000 nt, or 5000 to 10000 nt in length.

[0286] In some embodiments, a nucleic acid molecule comprises at least 15 base pairs. In some embodiments, a nucleic acid molecule comprises at least 20 base pairs. In some embodiments, a nucleic acid molecule comprises at least 25 base pairs. In some embodiments, a nucleic acid molecule is 15 base pairs to 200 base pairs in length. In some embodiments, a nucleic acid molecule is 25 base pairs to 50 base pairs in length. In some embodiments, a nucleic acid molecule is 50 base pairs to 200 base pairs in length. In some embodiments, a nucleic acid molecule is 100 base pairs to 200 base pairs in length.

[0287] In some embodiments, a nucleic acid molecule has a mass of about 1 kilodalton (kDa) to about 50 kDa. In some embodiments, a nucleic acid molecule has a mass of about 1 kDa to 10kDa. In some embodiments, a nucleic acid molecule has a mass of about 10 kDa to 20 kDa. In some embodiments, a nucleic acid molecule has a mass of about 10 kDa to about 25 kDa. In some embodiments, a nucleic acid molecule has a mass of about 15 kDa to about 50 kDa. In some embodiments, a nucleic acid molecule has a mass of about 20 kDa to about 50 kDa. In some embodiments, a nucleic acid molecule has a mass of about 25 kDa to about 50 kDa. In some embodiments, a nucleic acid molecule has a mass of about 30 kDa to about 50 kDa. In some embodiments, a nucleic acid molecule has a mass of about 40 kDa to about 50 kDa. In some embodiments, a nucleic acid molecule has a mass of about 1 kDa, about 5 kDa, about 10 kDa, about 15 kDa, about 20 kDa, about 25 kDa, about 30 kDa, about 35 kDa, about 40 kDa, about 45 kDa, or about 50 kDa. In some embodiments, a nucleic acid molecule has a mass of less than about 50 kDa. In some embodiments, a nucleic acid molecule has a mass of less than about 45 kDa, less than about 40 kDa, less than about 35 kDa, less than about 30 kDa, less than about 25 kDa, less than about 20 kDa, less than about 15 kDa, less than about 10 kDa, or less than about 5 kDa.

[0288] In some embodiments, the payload comprises a nucleic acid molecule (e.g., mRNA) encoding an antigen described herein. In some embodiments, the payload comprises nucleic acid molecule encoding a tumor-associated antigen (TAA) or tumor-specific antigen characteristic of lung cancer, or an antigenic fragment or epitope thereof. In some embodiments, the payload comprises nucleic acid molecule encoding an antigen of a lung metastasis. The payload, upon administration to a subject, allows for expression of the encoded TAA, tumor-specific antigen, or an antigen of a lung metastasis (or the antigenic fragment or epitope thereof), thereby eliciting immunity in the subject against the neoplastic cells expressing the TAA, tumor-specific antigen, or an antigen of a lung metastasis.

[0289] A polynucleotide to be delivered comprises a sequence encoding an antigenic peptide or protein. Particles (e.g., nanoparticles) containing these polynucleotides can be delivered to an individual to induce an immunologic response sufficient to decrease the chance of a subsequent infection and / or lessen the symptoms associated with such an infection. The polynucleotide of these vaccines may be combined with interleukins, interferon, cytokines, and adjuvants such as cholera toxin, alum, Freund's adjuvant, etc. A polynucleotide encoding an antigen described herein or an antigen described herein may be combined with adjuvants such as cholera toxin, alum, Freund's adjuvant, etc. A large number of adjuvant compounds are known; a usefulcompendium of many such compounds is prepared by the National Institutes of Health ( see Allison Dev. Biol. Stand.92:3-11, 1998; Unkeless et al., Annu. Rev. Immunol.6:251-281, 1998; and Phillips et al., Vaccine 10:151-158, 1992; each of which is incorporated herein by reference).

[0290] The antigenic protein or peptide encoded by the polynucleotide may be derived from a bacterial organism, a virus, a fungal organism, a protozoan, or parasitic organism. 7.6 Nanoparticles

[0291] In one embodiment, the particles described herein are nanoparticles. In one embodiment, the nanoparticles described herein can include at least one lipid component and one or more additional components, such as an agent (e.g., a prophylactic and / or therapeutic agent). A nanoparticle may be designed for one or more specific applications or targets. The elements of a nanoparticle may be selected based on a particular application or target, and / or based on the efficacy, toxicity, expense, ease of use, availability, or other feature of one or more elements. Similarly, the particular formulation of a nanoparticle may be selected for a particular application or target according to, for example, the efficacy and toxicity of particular combinations of elements.

[0292] The lipid component of a nanoparticle composition may include, for example, a lipid according to one of formula (I) described herein and a phospholipid (such as a phospholipid-PEG conjugate).

[0293] In one embodiment, provided herein is a nanoparticle comprising a cationic or ionizable lipid compound provided herein, an agent (e.g., a prophylactic or therapeutic agent), and one or more excipients. In one embodiment, the cationic or ionizable lipid compound comprises a compound according to Formula (I) as described herein, and optionally one or more additional lipid compounds. In one embodiment, the one or more excipients are selected from neutral lipids, steroids, and polymer conjugated lipids. In one embodiment, the one or more excipients is a polymer conjugated lipid. In one embodiment, the one or more excipients is a lipid poly(ethylene glycol). In one embodiment, the agent is encapsulated within or associated with the lipid nanoparticle. In one embodiment, the nanoparticle does not comprise cholesterol or a phospholipid other than a polymer conjugated phospholipid. In one embodiment, the nanoparticle comprises a cationic or ionizable lipid compound provided herein, an agent (e.g., a prophylactic or therapeutic agent), and a polymer conjugated lipid. In one embodiment, thenanoparticle consists of a cationic or ionizable lipid compound provided herein, an agent (e.g., a prophylactic or therapeutic agent), and a polymer conjugated lipid. In one embodiment, the nanoparticle comprises a compound according to Formula (I) as described herein, an agent (e.g., a prophylactic or therapeutic agent), and a lipid poly(ethylene glycol). In one embodiment, the nanoparticle consists of a compound according to Formula (I) as described herein, an agent (e.g., a prophylactic or therapeutic agent), and a lipid poly(ethylene glycol). In one embodiment, the nanoparticle comprises a compound according to Formula (I) as described herein, an agent (e.g., a prophylactic or therapeutic agent), and DMPE-PEG2000. In one embodiment, the nanoparticle comprises a compound set forth in Table 3, an agent (e.g., a prophylactic or therapeutic agent), and DMPE-PEG2000. In one embodiment, the nanoparticle consists of a compound according to Formula (I) as described herein, an agent (e.g., a prophylactic or therapeutic agent), and DMPE-PEG2000. In one embodiment, the nanoparticle consists of a compound set forth in Table 3, an agent (e.g., a prophylactic or therapeutic agent), and DMPE- PEG2000. In some embodiments, the compound is Compound 1. In some embodiments, the compound is Compound 9. In some embodiments, the compound is Compound 8. In some embodiments, the compound is Compound 7. In some embodiments, the compound is Compound 6. In some embodiments, the compound is Compound 5. In one embodiment, the nanoparticle comprises Compound 1, an agent (e.g., a prophylactic or therapeutic agent), and DMPE-PEG2000. In one embodiment, the nanoparticle consists of Compound 1, an agent (e.g., a prophylactic or therapeutic agent), and DMPE-PEG2000.

[0294] In one embodiment, provided herein is a nanoparticle comprising: i) between 0.5 to 3 mg / ml of a compound according to Formula (I); ii) a polymer conjugated lipid; and iii) an agent (e.g., a prophylactic or therapeutic agent).

[0295] In one embodiment, the nitrogen:phosphate ratio (i.e., the ratio between the amino groups present in the lipomer, and the phosphate groups present in the polynucleotide) is between about 10: 1 to about 50: 1. In certain embodiments, the nitrogen phosphate ratio is between about 10:1 to about 45:1, between about 15:1 to about 45:1, or between about 20: 1 to about 40: 1. Increasing nitrogen:phosphate ratios have been shown to positively influencedelivery of genetic material by increasing nucleic acid binding and negatively influence delivery by increasing toxicity (see, e.g., Incani et al., Soft Matter (2010) 6:2124-2138).

[0296] In one embodiment, the agent (e.g., prophylactic or therapeutic agent) to lipid ratio in the LNP (i.e., N / P, were N represents the moles of cationic lipid and P represents the moles of phosphate present as part of the nucleic acid backbone) range from 2:1 to 30:1, for example 3:1 to 22:1. In one embodiment, N / P ranges from 2.5:1 to 20:1 or 2:1 to 15:1. In one embodiment, N / P ranges from 3:1 to 10:1. Exemplary N / P ranges include about 2.5:1, about 3:1, about 5:1, about 10:1 and about 15:1.

[0297] In one embodiment, the weight ratio of the compound of Formula (I) to the polymer conjugated lipid ranges from about 10:1 to about 1:5. In one embodiment, the weight ratio of the compound of Formula (I) to the polymer conjugated lipid ranges from about 6:1 to about 1:2. In one embodiment, the weight ratio of the compound of Formula (I) to polymer conjugated lipid is about 10:1, about 9:1, about 8:1, about 7:1, about 6:1, about 5:1, about 4:1, about 3:1, about 2:1, about 1:1, or about 1:2. In one embodiment, the weight ratio of the compound of Formula (I) to polymer conjugated lipid is about 6:1. In one embodiment, the weight ratio of the compound of Formula (I) to polymer conjugated lipid is about 7:1.2.

[0298] In one embodiment, the cationic lipid can be any of a number of lipid species which carry a net positive charge at a selected pH, such as physiological pH. Exemplary cationic lipids are described herein below. In one embodiment, the cationic lipid has a pKa greater than 5.0. In one embodiment, the cationic lipid has a pKa greater than 5.25. In one embodiment, the cationic lipid has a pKa greater than 5.3. In one embodiment, the cationic lipid has a pKa greater than 6.0. In one embodiment, the cationic lipid has a pKa greater than 6.25. In one embodiment, the cationic lipid has a pKa greater than 6.5. In one embodiment, the cationic lipid has a pKa greater than 6.1, greater than 6.2, greater than 6.3, greater than 6.35, greater than 6.4, greater than 6.45, greater than 6.55, greater than 6.6, greater than 6.65, or greater than 6.7.

[0299] In one embodiment, the polymer conjugated lipid is a lipid poly(ethylene glycol). In one specific embodiment, the lipid poly(ethylene glycol) is DMPE-PEG. In one specific embodiment, the lipid poly(ethylene glycol) is DMPE-PEG2000.

[0300] In one embodiment, the compound in the nanoparticle formulation is about 0.5-7 mg / ml and the lipid poly(ethylene glycol) is about 0.05-2.0 mg / ml. In one embodiment, theRNA in the nanoparticle formulation is about 0.01-0.5 mg / mL. In one specific embodiment, the compound in the nanoparticle formulation is about 1.75 mg / ml, the lipid poly(ethylene glycol) is about 0.3 mg / ml and the RNA is about 0.375 mg / mL. In one such embodiment the lipid poly(ethylene glycol) is DMPE-PEG2000. In one such embodiment the RNA is a siRNA.

[0301] In some embodiments, the lipid nanoparticle has a mean diameter ranging from 10 to 100 nm, 35 nm to 100 nm, or from 30 nm to 65 nm. In some embodiments, the lipid nanoparticle has a mean diameter of about 10 nm, about 20 nm, about 30 nm, about 40 nm or about 50 nm. In some embodiments, the lipid nanoparticle has a mean diameter of about 60 nm, about 70 nm, about 80 nm, about 90 nm, or about 100 nm. In some embodiments, the lipid nanoparticle has a mean diameter of about 110 nm, about 120 nm, about 130 nm, about 140 nm, or about 150 nm.

[0302] Nanoparticles can be designed for one or more specific applications or targets. For example, a nanoparticle can be designed to deliver an agent (e.g., a prophylactic and / or therapeutic agent) such as an RNA to a particular cell, tissue, organ, or system or group thereof in a mammal’s body. Physiochemical properties of nanoparticles can be altered in order to increase selectivity for particular bodily targets. For instance, particle sizes can be adjusted based on the fenestration sizes of different organs. The route of delivery of nanoparticles can be selected to deliver an agent (e.g., a prophylactic and / or therapeutic agent) such as an RNA to a particular cell, tissue, organ, or system or group thereof in a mammal’s body. For example, nanoparticles described herein can be administered to a subject intravenously to target endothelial cells and tissues or organs comprising endothelial cells. The agent included in a nanoparticle can also be selected based on the desired delivery target or targets. For example, an agent (e.g., a prophylactic and / or therapeutic agent) can be selected for treating atherosclerosis, a cardiovascular disease, pulmonary hypertension (e.g., pulmonary arterial hypertension or secondary pulmonary hypertension), a lung cancer, a lung metastasis, chronic obstructive pulmonary disease (COPD), bronchiolitis obliterans, bronchiolitis obliterans organizing pneumonia (BOOP), pulmonary fibrosis, or a fibrotic lung disease and / or for delivery to a particular cell, tissue, organ, or system or group thereof (e.g., localized or specific delivery). In certain embodiments, a nanoparticle can include an mRNA encoding a polypeptide of interest capable of being translated within a cell to produce the polypeptide of interest. Such a nanoparticle can be designed to be specifically delivered to a particular organ. In someembodiments, a nanoparticle can be designed to be specifically to a mammalian lung. In some embodiments, a nanoparticle can be designed to be specifically to a mammalian heart. In certain embodiments, a nanoparticle can be designed to be specifically delivered to a mammalian liver.

[0303] The amount of an agent (e.g., a therapeutic and / or prophylactic agent) in a nanoparticle can depend on the size, composition, desired target and / or application, or other properties of the nanoparticle as well as on the properties of the agent. For example, the amount of an RNA useful in a nanoparticle can depend on the size, sequence, and other characteristics of the RNA. The relative amounts of an agent (e.g., a therapeutic and / or prophylactic agent) and other elements (e.g., lipids) in a nanoparticle can also vary. In some embodiments, the wt / wt ratio of the lipid component to an agent (e.g., a prophylactic and / or therapeutic agent) in a nanoparticle composition can be from about 2:1 to about 60:1, such as 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, 20:1, 25:1, 30:1, 35:1, 40:1, 45:1, 50:1, and 60:1. For example, the wt / wt ratio of the lipid component to an agent (e.g., a therapeutic and / or prophylactic agent) can be from about 10:1 to about 40:1. In certain embodiments, the wt / wt ratio is about 20:1. In certain embodiments, the wt / wt ratio is about 3:1. In certain embodiments, the wt / wt ratio is about 4:1. In certain embodiments, the wt / wt ratio is about 4.7:1. In certain embodiments, the wt / wt ratio is about 5:1. The amount of an agent (e.g., a prophylactic and / or therapeutic agent) in a nanoparticle can, for example, be measured using absorption spectroscopy (e.g., ultraviolet-visible spectroscopy).

[0304] In some embodiments, a nanoparticle includes one or more RNAs, and the one or more RNAs, lipids, and amounts thereof can be selected to provide a specific N:P ratio. The N:P ratio of the composition refers to the molar ratio of nitrogen atoms in one or more lipids to the number of phosphate groups in an RNA. In some embodiments, a lower N:P ratio is selected. The one or more RNA, lipids, and amounts thereof can be selected to provide an N:P ratio from about 2:1 to about 30:1, such as 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 12:1, 14:1, 16:1, 18:1, 20:1, 22:1, 24:1, 26:1, 28:1, or 30:1. In certain embodiments, the N:P ratio can be from about 2:1 to about 8:1. In other embodiments, the N:P ratio is from about 5:1 to about 8:1. For example, the N:P ratio may be about 3.0:1, about 3.4:1, about 3.47: 1, about 3.5:1, about 6.0:1, about 6.5:1, or about 7.0:1.

[0305] In some embodiments, provided herein is a nanoparticle described in Example 2 or Example 8.

[0306] In some embodiments, also provided herein is a method of making nanoparticles comprising contacting a solution comprising a compound described herein (see, e.g. Section 7.3), or a salt thereof, with a solution comprising a lipid poly(ethylene glycol), to provide a lipid mix solution. In some embodiments, also provided herein is a method of making nanoparticles comprising (i) contacting a solution comprising a compound described herein (see, e.g. Section 7.3), or a salt thereof, with a solution comprising a lipid poly(ethylene glycol), to provide a lipid mix solution and (ii) contacting the lipid mix solution with a solution comprising an agent. In some embodiments, the lipid poly(ethylene glycol) is a lipid poly(ethylene glycol) described herein (see, e.g., Section 7.5.1) or a salt thereof. In some embodiments, the lipid poly(ethylene glycol) is DMPE-PEG2000 or a salt thereof. In some embodiments, the lipid poly(ethylene glycol) is an ammonium salt of DMPE-PEG2000. In some embodiments, the lipid mix solution has a mass ratio of the compound : lipid poly(ethylene glycol) corresponding to a mass ratio of the compound : lipid poly(ethylene glycol) of a nanoparticle described in this Section 7.6. In some embodiments, the lipid mix solution has a mass ratio of the compound : lipid poly(ethylene glycol) of about 7: 1.2. In some embodiments, the agent is an agent described herein (see, e.g., Section 7.5.2). In some embodiments, the agent is: (i) an antibody or antigen-binding fragment thereof that binds to transforming growth factor beta receptor 1 (TGFβR1) or transforming growth factor beta receptor 2 (TGFβR2), (ii) a polynucleotide encoding an antibody or antigen- binding fragment thereof that binds to TGFβR1 or TGFβR2, (iii) a TGFβR1 decoy; (iv) a TGFβR2 decoy, (v) a polynucleotide encoding a TGFβR1 decoy; (vi) a polynucleotide encoding a TGFβR2 decoy, (vii) an siRNA or another inhibitory RNA that targets TGFβR1 or TGFβR2, or (viii) a TGFβR1 or TGFβR2 antigen. In some embodiments, the agent comprises TGFβR1 siRNA comprising the nucleotide sequences set forth in SEQ ID NOs: 7 and 8. In some embodiments, the method is a method of making nanoparticles as described in the Examples, for example in Example 2 or Example 8. 7.7 Compositions

[0307] In one aspect, a compound disclosed herein may be a component of a composition which may be useful in a variety of medical and non-medical applications. For example,pharmaceutical compositions comprising a compound disclosed herein may be useful in the delivery of an effective amount of an agent described herein to a subject in need thereof. Nutraceutical compositions comprising a compound disclosed herein may be useful in the delivery of an effective amount of a nutraceutical, e.g., a dietary supplement, to a subject in need thereof. Cosmetic compositions comprising a compound disclosed herein may be formulated as a cream, ointment, balm, paste, film, or liquid, etc., and may be useful in the application of make- up, hair products, and materials useful for personal hygiene, etc. Compositions comprising a compound disclosed herein may be useful for non-medical applications, e.g., such as an emulsion or emulsifier, useful, for example, as a food component, for extinguishing fires, for disinfecting surfaces, for oil cleanup, etc.

[0308] In another aspect, a compound disclosed herein may be a component of a composition for treating an endothelial-dependent disorder. For example, pharmaceutical compositions comprising a compound disclosed herein may be useful in the delivery of an effective amount of an agent described herein to a subject diagnosed with an endothelial-dependent disorder.

[0309] In another aspect, a compound disclosed herein may be a component of a composition for treating atherosclerosis, a cardiovascular disease, pulmonary hypertension (e.g., pulmonary arterial hypertension or secondary pulmonary hypertension), a lung cancer, a lung metastasis, chronic obstructive pulmonary disease (COPD), bronchiolitis obliterans, bronchiolitis obliterans organizing pneumonia (BOOP), pulmonary fibrosis, or a fibrotic lung disease. For example, pharmaceutical compositions comprising a compound disclosed herein may be useful in the delivery of an effective amount of an agent described herein to a subject diagnosed with atherosclerosis, a cardiovascular disease, pulmonary hypertension (e.g., pulmonary arterial hypertension or secondary pulmonary hypertension), a lung cancer, a lung metastasis, chronic obstructive pulmonary disease (COPD), bronchiolitis obliterans, bronchiolitis obliterans organizing pneumonia (BOOP), pulmonary fibrosis, or a fibrotic lung disease.

[0310] In some embodiments, the compounds disclosed herein are useful as compositions, either for delivery of an effective amount of an agent described herein to a subject in need thereof (e.g., a pharmaceutical composition or a cosmetic composition) or for use as an excipient. For example, cosmetic compositions may further use the compounds disclosed herein as excipients rather than as a delivery system encapsulating an agent to be delivered. In someembodiments, the composition is a pharmaceutical composition. In some embodiments, the composition is a cosmetic composition. In one embodiment, a pharmaceutical composition is provided comprising a compound of Formula (I), and a pharmaceutically acceptable excipient.

[0311] In some embodiments, the composition further comprises an agent described herein. In some embodiments, the agent comprises a small molecule, an organometallic compound, a nucleic acid, a protein, a peptide, a polynucleotide, a metal, a targeting agent, an isotopically labeled chemical compound, a drug, a vaccine, or an immunological agent. In some embodiments, the agent comprises a protein, a peptide, or a polynucleotide. In some embodiments, the agent comprises a polynucleotide. In some embodiments, the polynucleotide is DNA or RNA. In some embodiments, the RNA is ssRNA, dsRNA, siRNA, shRNA, miRNA, mRNA, or antisense RNA. In some embodiments, the agent has a mass of about 10 kilodaltons (kDa) to about 50 kDa. In some embodiments, the agent has a mass of about 15 kDa to about 50 kDa. In some embodiments, the agent has a mass of about 20 kDa to about 50 kDa. In some embodiments, the agent has a mass of about 25 kDa to about 50 kDa. In some embodiments, the agent has a mass of about 30 kDa to about 50 kDa. In some embodiments, the agent has a mass of about 40 kDa to about 50 kDa. In some embodiments, the agent has a mass of about 10 kDa to about 25 kDa. In some embodiments, an agent has a mass of about 10 kDa, about 20 kDa, about 30 kDa, about 40 kDa, or about 50 kDa. In some embodiments, the agent has a mass of less than about 50 kDa. In some embodiments, the agent has a mass of less than about 45 kDa, less than about 40 kDa, less than about 35 kDa, less than about 30 kDa, less than about 25 kDa, less than about 20 kDa, or less than about 15 kDa. In some embodiments, the agent is negatively supercharged. In some embodiments, the agent has a mass of less than about 50 kDa and is negatively supercharged. In some embodiments, the agent has a mass of about 10 kDa to about 50 kDa and is negatively supercharged.

[0312] In some embodiments, a polynucleotide and a compound disclosed herein (e.g., a compound of Formula (I)) are not covalently attached.

[0313] In some embodiments, the compounds disclosed herein (e.g., a compound of Formula (I)) are in the form of a particle. In some embodiments, the particle is a nanoparticle. In some embodiments, the compounds disclosed herein (e.g., a compound of Formula (I)) are in the form of liposomes or micelles. It is understood that, in certain embodiments, these compounds self-assemble to provide a particle, micelle or liposome. In some embodiments, the particle, liposome, or micelle encapsulates an agent. The agent to be delivered by the particles, liposomes, or micelles may be in the form of a gas, liquid, or solid. The compounds disclosed herein may be combined with polymers (synthetic or natural), surfactants, cholesterol, carbohydrates, proteins, lipids etc. to form the particles. These particles may be combined with an excipient to form pharmaceutical and cosmetic compositions. These particles may be combined with an excipient to form pharmaceutical compositions.

[0314] Once the complexes, micelles, liposomes, or particles have been prepared, they may be combined with one or more excipients to form a composition that is suitable to administer to animals including humans.

[0315] As would be appreciated by one of skill in this art, the excipients may be chosen based on the route of administration as described below, the agent being delivered, time course of delivery of the agent, etc.

[0316] As used herein, the term “excipient” means a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. Some examples of materials which can serve as excipients include, but are not limited to, sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil; sesame oil; olive oil; com oil and soybean oil; glycols such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; detergents such as Tween 80; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator. The compositions described herein can be administered to humans and / or to animals, orally, rectally, parenterally, intracistemally, intravaginally, intranasally, intraperitoneally, topically (as by powders, creams, ointments, ordrops), buccally, or as an oral or nasal spray. In specific embodiments, the compositions described herein are administered to humans and / or to animals intravenously.

[0317] In some embodiments, the pharmaceutical composition comprises a compound disclosed herein. In some embodiments, the pharmaceutical composition comprises about 20 weight percent, about 25 weight percent, about 30 weight percent, about 35 weight percent, about 40 weight percent, about 45 weight percent, about 50 weight percent, about 55 weight percent, about 60 weight percent, about 65 weight percent, about 70 weight percent, about 75 weight percent, about 80 weight percent of a compound disclosed herein.

[0318] Nanoparticles and / or pharmaceutical compositions including one or more nanoparticles can be administered to any subject, including those subjects that can benefit from a therapeutic effect provided by the delivery of an agent described herein to one or more particular cells, tissues, organs, or systems or groups thereof, such as endothelial cells of the tissues described in Example 8 (e.g., heart or lung endothelial cells). Although the descriptions provided herein of nanoparticles and pharmaceutical compositions are principally directed to compositions which are suitable for administration to humans, it will be understood by the skilled artisan that such compositions are generally suitable for administration to any other mammal. Modification of compositions suitable for administration to humans in order to render the compositions suitable for administration to various animals is well understood, and the ordinarily skilled veterinary pharmacologist can design and / or perform such modification with merely ordinary, if any, experimentation. Subjects to which administration of the compositions is contemplated include, but are not limited to, humans, other primates, and other mammals, including commercially relevant mammals such as cattle, pigs, horses, sheep, cats, dogs, mice, and / or rats.

[0319] A pharmaceutical composition can be prepared by any method known or hereafter developed in the art of pharmacology. In general, such preparatory methods include bringing the active ingredient into association with an excipient and / or one or more other accessory ingredients, and then, if desirable or necessary, dividing, shaping, and / or packaging the product into a desired single- or multi-dose unit.

[0320] A pharmaceutical composition in accordance with the present disclosure can be prepared, packaged, and / or sold in bulk, as a single unit dose, and / or as a plurality of single unitdoses. As used herein, a “unit dose” is discrete amount of the pharmaceutical composition comprising a predetermined amount of the active ingredient. The amount of the active ingredient is generally equal to the dosage of the active ingredient which would be administered to a subject and / or a convenient fraction of such a dosage such as, for example, one-half or one-third of such a dosage.

[0321] Pharmaceutical compositions can be prepared in a variety of forms suitable for a variety of routes and methods of administration. For example, pharmaceutical compositions can be prepared in liquid dosage forms (e.g., emulsions, microemulsions, nanoemulsions, solutions, suspensions, syrups, and elixirs), injectable forms, solid dosage forms (e.g., capsules, tablets, pills, powders, and granules), dosage forms for topical and / or transdermal administration (e.g., ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, and patches), suspensions, powders, and other forms. In specific embodiments, the pharmaceutical compositions are prepared for intravenous administration.

[0322] In some embodiments for parenteral administration, compositions are mixed with solubilizing agents such as CremophorTM, alcohols, oils, modified oils, glycols, polysorbates, cyclodextrins, polymers, and / or combinations thereof.

[0323] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions can be formulated according to the known art using suitable dispersing agents, wetting agents, and / or suspending agents. Sterile injectable preparations can be sterile injectable solutions, suspensions, and / or emulsions in nontoxic parenterally acceptable diluents and / or solvents, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that can be employed are water, Ringer’s solution, U.S.P., and isotonic sodium chloride solution. Sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil can be employed including synthetic mono- or diglycerides. Fatty acids such as oleic acid can be used in the preparation of injectables.

[0324] Injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, and / or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.

[0325] Dosage forms for topical or transdermal administration of a pharmaceutical composition include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, or patches. The particles are admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulation, ear drops, and eye drops are also contemplated as being within the scope of this disclosure.

[0326] The ointments, pastes, creams, and gels may contain, in addition to the particles described herein, excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc, and zinc oxide, or mixtures thereof.

[0327] Powders and sprays can contain, in addition to the particles described herein, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates, and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons.

[0328] Transdermal patches have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms can be made by dissolving or dispensing the particles (e.g., nanoparticles) in a proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the particles in a polymer matrix or gel. 7.8 Methods of Use

[0329] In another aspect, provided herein are methods of using the compounds disclosed herein (e.g., a compound of Formula (I)), e.g., for delivering an agent to a cell (e.g., an endothelial cell), tissue, or organ of a subject. In some embodiments, provided herein is a method for delivering an agent to a cell, tissue, or organ of a subject comprising contacting a population of cells (e.g., a population of endothelial cells), tissue, or organ of the subject with a composition disclosed herein or particle (e.g., nanoparticle) disclosed herein which includes the agent. In some embodiments, provided herein is a method for delivering an agent to a population of cells of a subject comprising contacting the population of cells of the subject with a composition disclosed herein, or particle (e.g., nanoparticle) disclosed herein which includes the agent. The contact of the agent, composition or particle (e.g., nanoparticle) with the cell(s),tissue, or organ may be conducted in vitro or ex vivo. Alternatively, the contact of the agent, composition, or particle (e.g., nanoparticle) with the cell(s), tissue, or organ may be conducted in vivo.

[0330] In some embodiments, provided herein is a method of delivering an agent to a cell (e.g., an endothelial cell) or organ of a subject (e.g., a human or non-human mammalian subject), comprising administering to the subject a composition disclosed herein or a particle (e.g., nanoparticle) disclosed herein which includes the agent. The delivery of the agent may be used to study a disease, disorder, or condition and / or understand a biological pathway(s). In some embodiments, the agent delivered has a beneficial (e.g., prophylactic and / or therapeutic) effect.

[0331] In some embodiments, provided herein is a method for delivering a drug to a cell (e.g., an endothelial cell), tissue, or organ of a subject comprising contacting the population of cells, tissue, or organ of the subject with a composition described herein, or particle (e.g., nanoparticle) described herein which includes the drug. In some embodiments, provided herein is a method for delivering a drug to a population of cells (e.g., population of endothelial cells) of a subject comprising contacting the population of cells of the subject with a composition described herein, or particle (e.g., nanoparticle) described herein which includes the drug. The contact of the composition or particle (e.g., nanoparticle) with the cell(s), tissue, or organ may be conducted in vitro or ex vivo. Alternatively, the contact of the composition or particle (e.g., nanoparticle) with the cell(s), tissue, or organ may be conducted in vivo. In some embodiments, provided herein is a method of delivering a drug to a cell or organ of a subject (e.g., a human or non-human mammalian subject) comprising administering to the subject a composition described herein or a particle (e.g., nanoparticle) described herein which includes the drug. The delivery of the drug may be used to study a disease, disorder, or condition and / or understand a biological pathway(s). In some embodiments, the drug delivered has a beneficial (e.g., prophylactic and / or therapeutic) effect.

[0332] In some embodiments, provided herein is a method for delivering a diagnostic agent or other detectable agent to a cell (e.g., an endothelial cell), tissue, or organ of a subject for imaging or detection purposes, comprising contacting the population of cells, tissue, or organ of the subject with a composition described herein, or particle (e.g., nanoparticle) described herein which includes the diagnostic agent or other detectable agent. In some embodiments, providedherein is a method for delivering a diagnostic agent or other detectable agent to a population of cells (e.g., a population of endothelial cells) of a subject for imaging or detection purposes comprising contacting the population of cells of the subject with a composition described herein, or particle (e.g., nanoparticle) described herein which includes the diagnostic agent or other detectable agent. The contact of the composition or particle (e.g., nanoparticle) with the cell(s), tissue, or organ may be conducted in vitro or ex vivo. Alternatively, the contact of the composition or particle (e.g., nanoparticle) with the cell(s), tissue, or organ may be conducted in vivo. In some embodiments, provided herein is a method of delivering a diagnostic agent or other detectable agent to a cell or organ of a subject (e.g., a human or non-human mammalian subject) for imaging or detection purposes, comprising administering to the subject a composition described herein or a particle (e.g., nanoparticle) described herein which includes the diagnostic agent or other detectable agent. In some embodiments, the composition or particle is delivered intravenously.

[0333] In some embodiments, provided herein is a method for delivering an agent to an endothelial cell of a subject comprising contacting the endothelial cell, or a tissue or organ of the subject comprising endothelial cells (e.g., the lung and / or heart) with a composition described herein, or particle (e.g., nanoparticle) described herein which includes the agent. In some embodiments, provided herein is a method for delivering an agent to a population of endothelial cells of a subject comprising contacting the population of endothelial cells of the subject with a composition described herein, or particle (e.g., nanoparticle) described herein which includes the agent. The endothelial cells may be from one or more, or all of the liver, lung, heart, aorta, spleen, pancreas, kidney, intestine, and the brain. In some embodiments, the endothelial cells are from the lung, heart, and / or aorta. The contact of the composition or particle (e.g., nanoparticle) with the cell(s), tissue, or organ may be conducted in vitro or ex vivo. Alternatively, the contact of the composition or particle (e.g., nanoparticle) with the cell(s), tissue, or organ may be conducted in vivo.

[0334] In some embodiments, provided herein is a method for delivering an agent described herein (e.g., a nucleic acid) to an endothelial cell in a subject, comprising administering to the subject a composition described herein or a particle (e.g., nanoparticle) described herein which includes the agent. In some embodiments, provided herein is a method for delivering an agent described herein (e.g., a nucleic acid) to a population of endothelial cells in a subject, comprisingadministering to the subject a composition described herein or a particle (e.g., nanoparticle) described herein which includes the agent. In some embodiments, provided herein is a method for delivering an agent described herein (e.g., a nucleic acid) to a tissue or organ comprising endothelial cells (e.g., heart and / or lung) of a subject, comprising administering to the subject a composition described herein or a particle (e.g., nanoparticle) described herein which includes the agent. In some embodiments, the endothelial cells are in one or more, or all of the liver, lung, heart, and aorta. In some embodiments, the endothelial cells are in the liver, lung, heart, and aorta. In some embodiments, the endothelial cells are from the lung, heart, and / or aorta. In some embodiments, the endothelial cells are in one or more, or all of the spleen, liver, lung, and aorta endothelium, and the heart. In some embodiments, the endothelial cells are in the spleen, liver, lung, and aorta endothelium, and the heart. In some embodiments, the endothelial cells are in one or more, or all of the pancreas, kidney, intestine, and the brain. In specific embodiments, the composition or particle is administered intravenously to the subject.

[0335] In some embodiments, provided herein is a method for delivering an antigen to a subject to induce an immune response (e.g., a cellular and / or humoral response) to the antigen, comprising administering to the subject a composition described herein or a particle (e.g., nanoparticle) described herein which includes the antigen. In some embodiments, the delivery of the antigen to the subject induces antibodies, which may be used in vitro, ex vivo, or in vivo to, e.g., detect the antigen. In some embodiments, the composition or particle is administered intravenously to the subject.

[0336] In some embodiments, provided herein is a method for delivering a vaccine to a subject comprising administering to the subject a composition described herein or a particle (e.g., nanoparticle) described herein which includes the vaccine. In some embodiments, the composition or particle is administered intravenously to the subject.

[0337] In some embodiments, provided herein is a method for delivering a peptide or protein to a cell, tissue, or organ of a subject to increase the amount of the peptide or protein in the cell (e.g., an endothelial cell), tissue (e.g., endothelial cells of one or more, or all of the liver, lung, heart, aorta, spleen, pancreas, kidney, intestine, and the brain), or organ (e.g., on...

Claims

WHAT IS CLAIMED IS:

1. A compound of Formula (I):(I), or a salt thereof, wherein: each R1is independently hydrogen or a group of formula (i):(i); each R2is independently hydrogen or a group of formula (i); and R3is independently substituted or unsubstituted alkyl; substituted or unsubstituted alkenyl; substituted or unsubstituted alkynyl; substituted or unsubstituted heteroalkyl; substituted or unsubstituted heteroalkenyl; substituted or unsubstituted heteroalkynyl; substituted or unsubstituted carbocyclyl; substituted or unsubstituted heterocyclyl; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; or a hydrophilic polymer; provided that at least one R1or at least one R2is a group of formula (i).

2. The compound of claim 1, wherein 4 to 12 of R1and R2are a group of formula (i).

3. The compound of claim 2, wherein 9 of R1and R2are a group of formula (i).

4. The compound of claim 3, wherein 6 of R1and 3 of R2are a group of formula (i).

5. The compound of claim 2, wherein 8 of R1and R2are a group of formula (i).

6. The compound of claim 5, wherein 6 of R1and 2 of R2are a group of formula (i).

7. The compound of claim 2, wherein 7 of R1and R2are a group of formula (i).

8. The compound of claim 7, wherein 6 of R1and 1 of R2are a group of formula (i).

9. The compound of claim 2, wherein 6 of R1and R2are a group of formula (i).

10. The compound of claim 9, wherein 6 of R1are a group of formula (i).

11. The compound of claim 2, wherein 5 of R1and R2are a group of formula (i).

12. The compound of claim 11, wherein 5 of R1a group of formula (i).

13. The compound of claim 2, wherein 4 of R1and R2are a group of formula (i).

14. The compound of claim 13, wherein 4 of R1are a group of formula (i).

15. The compound of any one of claims 1 to 14, wherein the group of formula (i) is a group of formula (i-a):(i-a).

16. The compound of any one of claims 1 to 15, wherein each instance of R3is independently substituted or unsubstituted alkyl; substituted or unsubstituted alkenyl; substituted or unsubstituted heteroalkyl.

17. The compound of claim 16, wherein each instance of R3is independently substituted or unsubstituted alkyl.

18. The compound of claim 17, wherein each instance of R3is independently substituted or unsubstituted C8-C50 alkyl.

19. The compound of claim 18, wherein each instance of R3is independently substituted or unsubstituted C10-C18alkyl.

20. The compound of claim 19, wherein each instance of R3is independently substituted or unsubstituted C13alkyl.

21. The compound of any one of claims 1 to 20, wherein each instance of R3is unsubstituted.

22. The compound of claim 21, wherein each instance of R3is independently -(CH2)nCH3, and n is an integer from 10 to 18.

23. The compound of claim 22, wherein each instance of R3is independently -(CH2)12CH3.

24. The compound of claim 1, wherein the compound is a compound in Table 3.

25. The compound of claim 24, wherein the compound is:.

26. The compound of claim 24, wherein the compound is:.

27. The compound of claim 24, wherein the compound is:.

28. The compound of any one of claims 1 to 27, wherein the compound has a purity of about 99%, about 95%, about 90%, about 85%, about 80%, about 75%, about 70%, about 65%, about 60%, about 55%, or about 50%.

29. A pharmaceutical composition comprising a compound of any one of claims 1 to 28, and a pharmaceutically acceptable excipient.

30. The pharmaceutical composition of claim 29, comprising about 20 weight percent, about 25 weight percent, about 30 weight percent, about 35 weight percent, about 40 weight percent, about 45 weight percent, about 50 weight percent, about 55 weight percent, about 60 weight percent, about 65 weight percent, about 70 weight percent, about 75 weight percent, about 80 weight percent, of a compound of any one of claims 1 to 28.

31. The pharmaceutical composition of claim 29 or 30, wherein the composition further comprises an agent.

32. The pharmaceutical composition of claim 31, wherein the agent is an organic molecule, an inorganic molecule, a nucleic acid, a protein, a polypeptide, a polynucleotide, a targeting agent, an isotopically labeled chemical compound, a vaccine, or an immunological agent.

33. The pharmaceutical composition of claim 32, wherein the agent is a polynucleotide, comprising DNA or RNA.

34. The pharmaceutical composition of claim 33, wherein the RNA is a coding RNA.

35. The pharmaceutical composition of claim 33, wherein the RNA is a non-coding RNA.

36. The pharmaceutical composition of claim 33, wherein the RNA is mRNA, RNAi, dsRNA, siRNA, shRNA, miRNA, or antisense RNA.

37. The pharmaceutical composition of any one of claims 33 to 36, wherein the polynucleotide and the compound are not covalently attached.

38. The pharmaceutical composition of any one of claims 29 to 37, wherein the compound is in the form of a particle.

39. The pharmaceutical composition of claim 38, wherein the particle is a nanoparticle.

40. The pharmaceutical composition of claim 39, wherein the nanoparticle further comprises a lipid poly(ethylene glycol).

41. The pharmaceutical composition of claim 40, wherein the lipid poly(ethylene glycol) comprises DMPE-PEG2000.

42. The pharmaceutical composition of claim 40 or 41, wherein mass ratio of the compound : lipid poly(ethylene glycol) : nucleic acid is about 7: 1.2 : 1.

5.

43. The pharmaceutical composition of claim 38, wherein the particle is a micelle, liposome, or lipoplex.

44. The pharmaceutical composition of any one of claims 38 to 43, wherein the particle encapsulates an agent.

45. A nanoparticle comprising a compound of any one of claims 1 to 28, and a nucleic acid, a protein, or polypeptide.

46. The nanoparticle of claim 45, further comprising a lipid poly(ethylene glycol).

47. The nanoparticle of claim 46, wherein the lipid poly(ethylene glycol) comprises DMPE- PEG2000.

48. The nanoparticle of claim 46 or 47, wherein mass ratio of the compound : lipid poly(ethylene glycol) : nucleic acid is about 7: 1.2 : 1.

5.

49. The nanoparticle of any one of claims 45 to 48, wherein the nucleic acid is DNA or RNA.

50. The nanoparticle of claim 49, wherein the RNA is mRNA, RNAi, dsRNA, siRNA, shRNA, miRNA, or antisense RNA.

51. The nanoparticle of claim 50, wherein the siRNA comprises transforming growth factor beta receptor 1 (“TGFβR1") siRNA.

52. The nanoparticle of claim 51, wherein the TGFβR1 siRNA comprises the nucleotide sequences of SEQ ID NOs:7 and 8.

53. A pharmaceutical composition comprising the nanoparticle of claim 51 or 52, and a pharmaceutically acceptable diluent or excipient.

54. A method for delivering an agent to a cell, a tissue, or an organ of a subject comprising contacting the population of cells, tissue, or organ of the subject with the pharmaceutical composition of any one of claims 29 to 44, or the nanoparticle of any one of claims 45 to 52.

55. The method of claim 54, wherein the cell is an endothelial cell.

56. The method of claim 54, wherein the tissue or organ comprises endothelial cells.

57. A method for delivering an agent to an endothelial cell, or a tissue or an organ comprising endothelial cells, the method comprising intraveneously administering to a subject the pharmaceutical composition of any one of claims 29 to 44, or the nanoparticle of any one of claims 45 to 52.

58. A method for delivering TGFβR1 siRNA to an endothelial cell, or a tissue or an organ comprising endothelial cells, the method comprising intravenously administering to a subject the nanoparticle of claim 51 or 52, or the pharmaceutical composition of claim 53.

59. A method of preparing the compound of any one of claims 1 to 28, comprising reacting a compound of Formula (II):with an epoxide of formula (III):in the presence of a solvent.

60. A method for treating pulmonary hypertension comprising intravenously administering to a subject in need thereof (i) a pharmaceutical composition comprising a compound of any one of claims 1 to 28, or a salt thereof, an agent, and a pharmaceutically acceptable excipient, or (ii) a nanoparticle comprising a compound of any one of claims 1 to 28, or a salt thereof, and an agent, wherein the agent comprises: (i) an antibody or antigen-binding fragment thereof that binds to transforming growth factor beta receptor 1 (TGFβR1) or transforming growth factor beta receptor 2 (TGFβR2), (ii) a polynucleotide encoding an antibody or antigen-binding fragment thereof that binds to TGFβR1 or TGFβR2, (iii) a TGFβR1 decoy; (iv) a TGFβR2 decoy, (v) a polynucleotide encoding a TGFβR1 decoy; (vi) a polynucleotide encoding a TGFβR2 decoy, (vii) an siRNA or another inhibitory RNA that targets TGFβR1 or TGFβR2, or (viii) a TGFβR1 or TGFβR2 antigen.

61. A method for treating atherosclerosis or a cardiovascular disease comprising intravenously administering to a subject in need thereof (i) a pharmaceutical composition comprising a compound of any one of claims 1 to 28, or a salt thereof, an agent, and a pharmaceutically acceptable excipient, or (ii) a nanoparticle comprising a compound of any one of claims 1 to 28, or a salt thereof, and an agent, wherein the agent comprises: (i) an antibody or antigen-binding fragment thereof that binds to transforming growth factor beta receptor 1 (TGFβR1) or transforming growth factor beta receptor 2 (TGFβR2), (ii) a polynucleotide encoding an antibody or antigen-binding fragment thereof that binds to TGFβR1 or TGFβR2, (iii) a TGFβR1 decoy; (iv) a TGFβR2 decoy, (v) a polynucleotide encoding a TGFβR1 decoy; (vi) a polynucleotide encoding a TGFβR2 decoy, (vii) an siRNA or another inhibitory RNA that targets TGFβR1 or TGFβR2, or (viii) a TGFβR1 or TGFβR2 antigen.

62. The method of claim 60, wherein the pulmonary hypertension is pulmonary arterial hypertension.

63. The method of claim 60, wherein the pulmonary hypertension is secondary pulmonary hypertension.

64. The method of claim 61, wherein the cardiovascular disease is coronary artery disease, stroke, heart failure, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, abnormal heart rhythm, congenital heart disease, valvular heart disease, carditis, aortic aneurysm, peripheral artery disease, thromboembolic disease, or venous thrombosis.

65. The method of any one of claims 60 to 64, wherein the pharmaceutical composition comprises about 20 weight percent, about 25 weight percent, about 30 weight percent, about 35 weight percent, about 40 weight percent, about 45 weight percent, about 50 weight percent, about 55 weight percent, about 60 weight percent, about 65 weight percent, about 70 weight percent, about 75 weight percent, about 80 weight percent, of a compound of any one of claims 1 to 27.

66. The method of any one of claims 60 to 65, wherein the compound is in the form of a particle.

67. The method of claim 66, wherein the particle is a nanoparticle or a microparticle.

68. The method of claim 66, wherein the particle is a micelle, liposome, or lipoplex.

69. The method of any one of claims 60 to 65, or 67, wherein the nanoparticle further comprises a lipid poly(ethylene glycol).

70. The method of claim 69, wherein mass ratio of the compound : lipid poly(ethylene glycol) : nucleic acid is about 7: 1.2 : 1.

5.

71. The method of claim 69 or 70, wherein the lipid poly(ethylene glycol) comprises DMPE- PEG2000.

72. The method of any one of claims 66 to 71, wherein the particle encapsulates the agent.

73. The method of any one of claims 60 to 72, wherein the agent comprises an siRNA or another inhibitory RNA targeting TGFβR1 or TGFβR2.

74. The method of claim 73, wherein the siRNA is a transforming growth factor beta receptor 1 (“TGFβR1") siRNA.

75. The method of claim 74, wherein the TGFβR1 siRNA comprises the nucleotide sequences of SEQ ID NOs: 7 and 8.

76. The method of claim 73, wherein the inhibitory RNA is mRNA, RNAi, shRNA, or antisense RNA.

77. The method of any one of claims 60 to 72, wherein the polynucleotide comprises DNA or RNA.

78. The method of any one of claims 60 to 76, wherein the polynucleotide, siRNA, or another inhibitory RNA and the compound are not covalently attached.

79. The method of any one of claims 60 to 78, wherein the subject is a human.

80. Use of the pharmaceutical composition of any one of claims 29 to 44, or 53, or the nanoparticle of any one of claims 45 to 52 in the manufacture of a medicament for delivering an agent to a cell, a tissue, or an organ of a subject.

81. The use of claim 80, wherein the cell is an endothelial cell.

82. The use of claim 80, wherein the tissue or organ comprises endothelial cells.

83. The pharmaceutical composition of any one of claims 29 to 44 or 53, or the nanoparticle of any one of claims 45 to 52 for use in delivering an agent to a cell, a tissue, or an organ of a subject.

84. The pharmaceutical composition or the nanoparticle of claim 83, wherein the cell is an endothelial cell.

85. The pharmaceutical composition or the nanoparticle of claim 83, wherein the tissue or organ comprises endothelial cells.

86. Use of the nanoparticle of claim 51 or 52, or the pharmaceutical composition of claim 53 in the manufacture of a medicament for use in the treatment of pulmonary hypertension, atherosclerosis, or a cardiovascular disease.

87. The nanoparticle of claim 51 or 52, or the pharmaceutical composition of claim 53 for use in a method for treating pulmonary hypertension, atherosclerosis, or a cardiovascular disease, the method comprising intravenously administering the nanoparticle or the pharmaceutical composition to a subject.

88. The nanoparticle or the pharmaceutical composition of claim 87, wherein the subject is human.

89. A TGFβR1 siRNA comprising the nucleotide sequences set forth in SEQ ID NOs: 7 and 8.

90. A pharmaceutical composition comprising the TGFβR1 siRNA of claim 89, and a pharmaceutically acceptable carrier, diluent or excipient.

91. A method for reducing TGFβR1 RNA in a cell, comprising contacting the cell with the TGFβR1 siRNA of claim 89, or the pharmaceutical composition of claim 90.

92. The method of claim 91, wherein the cell is an endothelial cell.

93. A method for reducing TGFβR1 RNA in cells, a tissue, or an organ in a subject, the method comprising administering to the subject the TGFβR1 siRNA of claim 89, or the pharmaceutical composition of claim 90.

94. The method of claim 93, wherein the subject is a human.

95. Use of the TGFβR1 siRNA of claim 89, or the pharmaceutical composition of claim 90, in the manufacture of a medicament for reducing TGFβR1 RNA in cells, a tissue or an organ.

96. The TGFβR1 siRNA of claim 89, or the pharmaceutical composition of claim 90, for use in a method for reducing TGFβR1 RNA in cells, a tissue or an organ, the method comprising administering to a subject the TGFβR1 siRNA or the pharmaceutical composition to a subject.

97. The TGFβR1 siRNA or the pharmaceutical composition of claim 96, wherein the subject is a human.

98. A method of making nanoparticles comprising contacting a solution comprising a compound of any one of claims 1 to 28, or a salt thereof, with a solution comprising a lipid poly(ethylene glycol), to provide a lipid mix solution.

99. A method of making nanoparticles comprising (i) contacting a solution comprising a compound of any one of claims 1 to 28, or a salt thereof, with a solution comprising a lipid poly(ethylene glycol), to provide a lipid mix solution and (ii) contacting the lipid mix solution with a solution comprising an agent.

100. The method of claim 98 or 99, wherein the lipid poly(ethylene glycol) is DMPE- PEG2000 or a salt thereof.

101. The method of claim 100, wherein the lipid poly(ethylene glycol) is an ammonium salt of DMPE-PEG2000.

102. The method of any one of claims 98 to 101, wherein the lipid mix solution has a mass ratio of the compound : lipid poly(ethylene glycol) of about 7: 1.

2.

103. The method of any one of claims 98 to 102, wherein the agent is: (i) an antibody or antigen-binding fragment thereof that binds to transforming growth factor beta receptor 1 (TGFβR1) or transforming growth factor beta receptor 2 (TGFβR2), (ii) a polynucleotide encoding an antibody or antigen-binding fragment thereof that binds to TGFβR1 or TGFβR2, (iii) a TGFβR1 decoy; (iv) a TGFβR2 decoy, (v) a polynucleotide encoding a TGFβR1 decoy; (vi) a polynucleotide encoding a TGFβR2 decoy, (vii) an siRNA or another inhibitory RNA that targets TGFβR1 or TGFβR2, or (viii) a TGFβR1 or TGFβR2 antigen.

104. The method of any one of claims 98 to 102, wherein the agent comprises TGFβR1 siRNA comprising the nucleotide sequences set forth in SEQ ID NOs: 7 and 8.

Citation Information

Cited By

  • Substituted tertiary amine (STA) motifs for the membrane transport of biomolecular cargo

    WO2026050397A1